{"title": "PDF", "author": "PDF", "url": "https://minerva.usc.es/xmlui/bitstream/10347/10004/1/rep_610.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "cleaned_text": "DEPARTAMENTO DE FISIOLOX\u00cdA ROLE OF THE EFFECTOR AND REGULATORY ARMS OF PATHOPHYSIOLOGY OF EXPERIMENTAL ASTHMA PhD THESIS Tesis Doctoral Oscar Amor Carro 2013 El Prof. Dr. FERNANDO DOMINGUEZ PUENTE, Catedr\u00e1tico del Departamento de Fisiolog\u00eda de la Facultad de Medicina en la Universidad de Santiago de Compostela, CERTIFICA Que el presente trabajo titulado \" ROLE OF THE EFFECTOR AND REGULATORY ARMS OF THE ADAPTIVE IMMUNE RESPONSE IN THE PATHOPHYSIOLOGY OF EXPERIMENTAL ASTHMA \", ha sido realizado bajo su tutor\u00eda por el licenciado en Biolog\u00eda D. Oscar Amor Carro, y lo autoriza a ser presentado como trabajo de Tesis Doctoral ante el tribunal correspondiente en la Universidad de Santiago de Compostela. Santiago de Compostela, julio de 2013 Prof. Dr. Fernando Dom\u00ednguez Puente El Dr. DAVID RAMOS BARB\u00d3N (MD, PhD), director del grupo de Pneumologia Experimental en el Institut de Recerca Biomedica del Hospital de la Santa Creu i Sant Pau en Barcelona, y profesor asociado al Medicine Department de McGill University en Montreal, CERTIFICA Que el presente trabajo original de investigaci\u00f3n titutlado \" ROLE OF THE EFFECTOR AND REGULATORY ARMS OF ADAPTIVE IMMUNE RESPONSE IN THE PATHOPHYSIOLOGY OF EXPERIMENTAL ASTHMA \" ha sido realizado bajo su direcci \u00f3n, por el licenci ado en Biolog\u00eda D. Oscar Amor Carro en la Unidad de Investigaci\u00f3n Respiratoria del Complexo Hospitalario Universitario de A Coru\u00f1a y en el Institut de Recerca del Hospital de la Santa Creu i Sant Pau en Barcelona; estimando adem\u00e1s que este trabajo se encuentra concluido y en condiciones de ser presentado y defendido como Tesis Doctoral ante el tribunal correspondiente en la Universidad de Santiago de Compostela. Barcelona, junio de 2013 Dr. David Ramos Barb\u00f3n ROLE OF THE EFFECTOR AND REGULATORY ARMS OF IMMUNE RESPONSE IN THE PATHOPHYSIOLOGY OF EXPERIMENTAL ASTHMA Memoria para optar al grado de Doctor en Biolog\u00eda por la Universidad de Santiago de Compostela presentada por: Oscar Amor Carro Santiago de Compostela, julio de 2013 UNIVERSIDADE DE SANTIAGO DE COMPOSTELA Facultade de Medicina Departamento de Fisiolox\u00eda INSTITUTO DE INVESTIGACI\u00d3N BIOM\u00c9DICA DE A CORU\u00d1A (INIBIC) Unidad de Investigaci\u00f3n Respiratoria INSTITUT DE RECERCA HOSPITAL DE LA SANTA CREU I SANT PAU Pneumologia Experimental Este trabajo ha sido financiado con subvenciones concedidas por el Instituto de Salud Carlos III del Ministerio de Ciencia en Innovaci\u00f3n (bec as operativas FIS PI08/1822 y PI11/01001, y Ayuda Predoctoral de Formaci\u00f3n en Investigaci\u00f3n FI07/00399); y la Xunta de Galicia (bolsa predoutoral 2006/000177). This work has been supported with grants from Instituto de Salud Carlos II,I Ministerio de Ciencia en Innovaci\u00f3n, (becas operativas FIS PI08/1822 and PI11/01001, and Ayuda Predoctoral de Formaci\u00f3n en Investigaci\u00f3n FI07/00399); and Xunta de Galicia, Conseller\u00eda de Educaci\u00f3n en Ordenaci\u00f3n Universitaria (bolsa predoutoral 2006/000177). AGRADECIMIENTOS ACKNOWLEDGEMENTS AGRADECIMIENTOS Hacia el final de una etapa profesional como es la defensa de una tesis doctoral, es inevitable echar la vista atr\u00e1s para analizar el camino reco rrido. A lo largo de estos a\u00f1os he compartido innumerables momentos con much\u00edsimas personas, y de todas y cada una de ellas siempre he extra\u00eddo algo que ha marcado mi desarrollo person al y/o profesional, y que me gustar\u00eda reflejar aqu\u00ed: Gracias a mis padres, sin los cuales nunca hubiese tenido la oportunidad de recorrer este camino; gracias por el apoyo incond icional y los sacrificios realizados para que yo est\u00e9 ahora en este punto. Este trabajo es m\u00e1s suyo que m\u00edo. Gr acias, a Ana, incansable compa\u00f1era de viaje desde el principio de este proyecto, que ha confiado siempre en m\u00ed m\u00e1s que yo mismo, anteponiendo muchas veces mi persona a la suya propia. Tengo mucho que aprender de ella y tambi\u00e9n mucho que devolverle. Gracias a toda mi familia en general: a los \"Mansos\" porque dura nte estos \u00faltimos a\u00f1os, nuestra presencia en casa es motivo de celebraci \u00f3n y han sido muchos los momentos compartidos; a Cristina, que ha sido perfecta anfitriona y nos ha ayudado a sentirnos como en casa; a Antonia, Roberto y los cu\u00f1ad@s, que me han alentado en los tramos \"cuesta arriba\". Gracias tambi\u00e9n a Esther, que desde muy temprano y casi sin darme cu enta, me ha encaminado hacia la investigaci\u00f3n biom\u00e9dica. Y como no, a mis amigos, por las quedadas, las salidas, las celebraciones... y sobre todo la comprensi\u00f3n en mis largas ausencias. Gracias tambi\u00e9n a mis compa\u00f1eros del Locomotiv Chill, que me han hecho uno m\u00e1s desde el principio, Forza Chill! Quiero tambi\u00e9n expresar mi gratitud a las personas con las que he coincidido en mi etapa en la \"Respiratory Research Unit \" del INIBIC, recuerdo con cari\u00f1o esos casi cuatro a\u00f1os. Gracias a Bea por ayudarme codo con codo en tantas \"horas de campana\" y su apoyo y positividad en todo momento; a Nadia por su ayuda con la morfometr\u00eda y su paciencia; a Laura por ser mi maestra de la ingenier\u00eda gen\u00e9tica (un hacha en el \"cortar&pegar\"); a Luis por contagiarme el gusanillo de las c\u00e9lulas madre; a Katie, por su forma de trabajar y su ayuda en el dise\u00f1o de la hibridaci\u00f3n in situ ; y a Rebe, por tantos y tantos trabajos, momentos y viajes compartidos, casi, casi hasta el d\u00eda de hoy. Gracias Bea, Luis, Laura y Rebe por formar equipo esos d\u00edas agotadores de \"Flexi\" \u00a1rozando la extenuaci\u00f3n! Gracias tambi\u00e9n a tod@s los compa\u00f1er os del INIBIC; en especial a Dolo, Mar\u00eda, Mariajo y Nati por tantas risas en lo s caf\u00e9s (y fuera de ellos) y a Ang\u00e9 lica por su tutela en mi primer Western y por lo mucho que me ha ense\u00f1ado. A la Unidad de Cirug\u00eda Experimental: Alberto, Eduardo, Sole, Guti, Luis y Mariano, por las facilid ades para que el trabajo con los animales aqu\u00ed presentado se realizase de la mejor forma posible. Siempre ocupar\u00e1n tambi\u00e9n un lugar especial para m\u00ed los compa\u00f1er@s del Servei de Pneumologia del Hospital de la Santa Creu i Sant Pau , todos ellos grandes personas y AGRADECIMIENTOS profesionales. Gracias por hacerme sentir parte de esta gran familia desde que he \"aterrizado\" y ayudarme a comprender por qu\u00e9 Sant Pau es m\u00e9s que un hospital . Agradecer en especial a la Sala de Treball : Teresa, Vicky, Txell, Anna, Rebe... por hacerme encajar en un equipo de un valor humano y profesional enorme y por tantos buenos momentos, hab\u00e9is hecho de Sant Pau mi segunda casa. Gracias a todos los facultativos neumol\u00f3gicos que han contribu\u00eddo estos \u00faltimos a\u00f1os a enriquecer el Biobanco multic\u00e9ntrico de Biopsia s Bronquiales: Dr. Vicente Plaza Moral y Dr. Alfons Torrego Fern\u00e1ndez del Hospital de la Santa Creu i Sant Pau, Barcelona; Dr. Carlos Mart\u00ednez Rivera del Hospital Universitario Germans Trias i Pujol, Badalona-Barcelona; Dr. Antol\u00edn L\u00f3pez Vi\u00f1a del Hospital Universitario Puerta de Hierro, Madrid; Dr. Santiago Bardag\u00ed Fons del Hospital de Matar\u00f3, Matar\u00f3-Barcelona; Dr. Francisco Javi er Gonz\u00e1lez Barcala del Complexo Hospitalario de Pontevedra, Pontevedra; Dra. Teresa Baz\u00fas Gonz\u00e1lez del Hospital Universitario Central de Asturias, Oviedo; Dr. Patrick Berger de la Univer sit\u00e9 Bordeaux, Burdeos, Francia; y Dr. James G. Martin de McGill University, Montreal, Canad\u00e1. E llos han hecho posible el Biobanco y, por tanto, mi trabajo sobre las biopsias bronquiales humanas. Quisiera mencionar y agradecer tambi\u00e9n el gesto que ha tenido el Prof. Shimon Sakaguchi, del Institute for Physical and Chemical Research (Yokohama, Jap\u00f3n) al cedernos desinteresadamente el cDNA de Foxp3 murino que ha sido generado en su laboratorio (ver referencia 411). Gracias a mi tutor de la USC, el Dr. Fern\u00e1ndo Dom\u00ednguez, por su apoyo tras los cambios de direcci\u00f3n que han surgido al inicio de este camino. Y por supuesto, gracias a David, mi director de tesis, por darme la oportunidad de iniciarme en el camino de la investigaci\u00f3n en su grupo y por su apoyo y confianza desde el inicio. Sobra decir que este trayecto no lo habr\u00eda podido realizar sin su orientaci\u00f3n; he aprendido mucho a lo largo de estos a\u00f1os (y lo sigo haciendo). Gracias a todos. \"The most exciting phrase to hear in science, the one that heralds new discoveries, is not 'Eureka!', but 'That's funny...'\" Isaac Asimov INDEX INDEX 3 INDEX ABSTRACT....................................................................................................................... .............. ABBREVIATIONS.................................................................................................................. ....... 15 INTRODUCTION................................................................................................................... ........ 21 1. ASTHMA......................................................................................................................... aspects.......................................................................................................... 3 1.2. The asthma burden .................................................................................................... 26 1.3. Asthma path ophysiology........................................................................................... 26 1.4. Animal models of experimental asthma.................................................................... 34 2. ALLERGIC RHINITIS.................................................................................................... 42 2.1. General aspects.......................................................................................................... 4 2 2.2. Rhinitis an imal models.............................................................................................. 44 2.3. The murine nasal cavity ............................................................................................ 45 3. THE IMMUNE SYSTEM................................................................................................ 49 3.1. Immune cells ............................................................................................................. 4 9 3.2. infiltrates 2. Study design ................................................................................................................... ... 83 3. Sensitization d challenge Genetic cell 86 effector and adaptive immune reseponse in pathophysiology of airw ay hyperresponsiveness ........................................................... 92 6.2. Preparation of 92 6.3. Measurement pulmona 106 9. Quantitative ysis............................................................................................................... ........................................................................................................................ 109 1. Pathophysiology with airway hyperresponsiveness in the lung bu t not in the upper airway. ............................................... 114 1.3. mucoid response and lower airways.................................................................................................................. ....... 114 1.4. Subepithelial collagen deposition and greater i.n. allergen ex posure in the lung............................................................................... but not in the IP model................................................................. 121 2. Role of effector and regulatory T cells in experimental asthma: effector versus arms. ............................................................................................................... ........ 123 2.1. Generation CD4+T cells............................................................ 123 2.2. Adoptive transfer of antigen-specific lls af ter HDM-indu ced experimental thma model.......................... 130 3. FOXP3+ cells infiltrate the 216 and adaptive immune reseponse in the pathophysiology of experimental e nasal cavity in the rat............................................................. 46 Figure 3. The nasal epith elium in the mouse............................................................................ 47 Figure 4. Frontal histological ons of the murine nasal cavity. .......................................... 48 Figure 5. General view of blood ce ll lineage. .......................................................................... 51 Figure 6. Development of T cells............................................................................................. 54 Figure 7. TCR:MH C interact ion. ............................................................................................. 56 T into iTreg cells in a TGFB rich environment .......................................................................................................... 73 Figure 11. OVA models. ......................................................................................................... . 84 models........................................................................................ for ventilatory mechanics........................................................ 94 Figure 16. Nasal cav ity in mouse............................................................................................. 99 Figure 17. Especimen collection and analysis 1 Figure staining lung munofluorescence and M CT quantification..................................... 120 27. adoptive antigen-specific cells....................................................................................................... 7 Figrue 30. counts after adoptive transf effector T analysis of tissue sections, adop adoptively T on Airway contractile tissue mass in adaptive immune reseponse in pathophysiology of experimental Table copy in contro l subjects....................................................... 135 ABSTRACT ABSTRACT 13 Classic murine models of experimental asthma based on intraperitoneal sensitization followed airway with the allergens may essential for the triggering of the subsequent immune response. In the present in the upper and lower airways. We detected in this model a high number of Foxp3 mRNA + cells in production, and was found as an early prior to the development of any adaptive immune suggests the over the intraperitoneal model, moderate numbers of Foxp3 mRNA-expressing the allergen instillations, and in the intraperitoneal sensitization model may have been non-functional. In all, these results suggest that classic animal models of experimental asthma based on intraperitoneal sens itization but fail to operated by Treg subpopulations. The data are also consistent with the hypothesis that primary contact of the antigen with the respiratory mucosa is crucial to determine the profile of the subsequent immune response in terms of attack versus tolerance, and that the in nate immune system plays a central role in such decisions. that FOXP3-expressing T drive immune regulation in an experimental asthma setting, versus the induction asthma features by effector CD4+ T cells, we of adoptive transfer experiments employing genetically modified T cells, by Role arms of the to elicit migration airways translational Treg cells in human asthma, we studied the of FOXP3+ cells (in year of our Lord) ADAM: A disintegrin and metalloproteinase activated B NK: natural killer T TNFA: tumor necrosis factor alpha factor receptor TSDR: T regulatory specific demethylated Tr1: type cells endothelial growth consensus for not italicized, Greek transforming growth beta). - Gene symbols are italicized with all letters are in upper case never used (eg: but not italized (eg: TGFB). Guidelines for transforming growth factor beta). - Gene symbols are italicized with first letter upper case and all the rest lower case and no hyphens. - Greek symbols are never used (eg: mRNA level). - Proteins designations the same as the gene symbol, but not italicized and all upper case (eg: TGFB). 1 23 disease inly by inflammation (1). aazein , meaning to pant, to exhale to clinically describe asthma is documented in a Chinese medical book, approximately in the year 2600 BC (2, 3). However, the earliest text where th e word asthma was coined as a medical period, a hospital facility was built in Damascus in 706 by Al-walid, the Ummayad Caliph. This hospital may be considered the most ancient precedent of modern hospitals. In the 17th century, Jean Baptiste Van Helmont (157 9 - 1644), a Belgian physician, chemist and physiologist who in the \"pipes\" of the lungs and pointed out that the contraction of the lungs is a pathophysiological mechanism of asthma (2). Later in the same century, Bernardino Ramazzini (1633 - 1714) detected a link between asthma and organic dust and also recognized exercise-induced asthma. By described hereditary component. In Willis that asthma was by defaults in nervous fibers pertaining to the breathing parts. From this we can conclude that as thma first depicted as a disease rather than a symptom by Thomas Willis and John Floyer in the 17th century. The asthma concept was refined in the later part of the 19th century with the publication of a treatise by Henry Hyde Salter, where he diseases like asthma or hay fever were considered as an \"aristocratic dis ease\" due to asthma being more prev alent in England in aristocratic people than in farm workers. This was later in terpreted as a sign of superiority in the British population by the British physician Morell Macken zie (1837 - 1892). Also, the French writer Marcel Proust (1871 - 1922) described in detail his asthmatic disease in letters to his mother, where he wrote about symptoms and feelings he felt during his asthma attacks. Asthma 24Advances in Medicine at the beginning of the 20th century were to a great extent contributed by Sir William Osler, inflammation (5). clini cal observation with physiology and pathology. In 1903, Dixon documented physiological of bronchial narrowing from In 1906, experimental exposure to purified allergens was found to reproduce the symptoms of hay fever (7), which led to the characterization of asthma as an allergic hypersensitivity to foreign antigens. In 1921 the discovery of a serum substance that could passively transfer \"allergy\" to a specific allergen (8) led to the identification of IgE (9) and provided a crucial link to characterize asthma as an allergic disorder. In the first part of 20 th century, Ehrlich described aniline stains for eosinophils to a clearer understanding of how allergen exposure triggers the release of chemical mediators from airway mast cells (early reaction), and this in leads to the recruitment of eosinophils, basophils and mononuclear cells (late reaction) (12, The la te response in asthma was linked with was increasing the role of T lymphocytes in allergic responses (15), which led to the identification of a special subset of T ce secreting and eosinophils, and were responsible for the recruitment, priming and survival of the primary effector cells asthma in 1990' are esp ecially prominent as takes on a more severe and chronic phenotype (17, 18) and are described in detail below. early 2000's, inflammation (local production of cytokines and growth In the last decade, th ere have also been considerable advances in the knowledge of dendritic cell biology and function that have highlighted in asthmatic disease (23). Significant improvements in asthma care have been achieved from the early 90's upon the introduction of the Global Initiative for Asthma (GINA), which issued re ference guidelines for a \"chro nic inflammatory disorder of the airways in which many cells and cellular elements play a ro le. The chronic coughing, at night or in the early morning. These episodes are usually associated with widespread but variable airflow is often variable in asthma, and can be association with triggers infections, leading in the latter case to an irreversible deterioration of lung function (25). the basic and clinical knowledge on asthma has considerably evolved in the recent y ears, a greater complexity of the disease is also being perceived. There is no current explanation fo r the increasing prevalence of asthma as per the data presented on next section. Furthermore, a the each year, and is estimated to account for 1 every 250 deaths (24, 29). Many of these deaths, otherwise preventable, are due to suboptim al asthma attacks health another standpoint, industrialized have seen a sustained increase the 60's, and taken a lead in asthma research as a priority in the health systems of the European Union and North America. It is un clear whether the increasing prevalen ce in these areas (30). industrialization Occidental lifestyle (31), a nd this trend is paralleled by an also growing prevalence of autoimmune diseases that the overall asthma prevalence is increasing by 50% per decade in the world, and has doubled within a decade in the European Union (29, 32). Another reason to establish asthma as a research priority is the fact that, despite current treatments and their positive impact in the management of most about 10% of asthmatics still develop severe, refractory and, in a percentage of the latter, asthma may turn fatal (34). In Spain, the prevalence of asthma ranges from 5.1 to 7.5% in the general population, (24, 32) and 9 to 13% in children aged 13-14 (35). Ac ute asthma attacks are a frequent cause of hospitalization, the most common cause of hospital admissions among children of all ages (37). Noteworthily, patients that suffer asthma exacerbations cost three times more, in terms of health care resources, than th ose who do not exacerbat (36). Therefore, asthma exacerbations imply a great cost for in all countries. Additionally, the productivity losses caused to account for \u20ac9.8 billion h bifurcates into the left and right main bronchi. From this point, the intrapulmonary airways continue to branch respiratory the respiratory epithelium openings). This structure of conducting airways ends into the lung parenchyma, which is the area of gas exchange, made of respiratory bronchioles, alveolar ducts, sacs and alveoli. At the histological the airways consist of several tissue layers that differ in composition from the trachea to small bronchioles. The function of this branching is to carry inspired air to the alveoli, and expired air to the outside. In this route, conducting airways: trachea, bronchi and bronchioles. The in so-called respiratory epithelium, a epithelium, cells are anchored to the basal membrane, bu t not all of them reach the lumen. This epithelium is composed by several lamina propia conjunctive tissu e rich in elastin fibers, which provides a space for the distribution of blood and lymphatic vessels and nervous fibers. Both layers, the respiratory eptithelium and the lamina propia , are called mucosa. Immediately beneath the mucosa, and depending on the level of the ai rways, we can find a layer called submucosa. The tracheal find tracheal cartilage, the trach eal muscle and the adventicia, a layer of loose connective tissue and adipose cells that surrounds the trachea. standpoint mainly innervated by and systems, which determine the bronchial airway tone sustaining balance bronchial smooth cells be and obstruction (39), and may start in an early phase of the disease prior to the onset of symptoms changes airway In the respiratory epithelium, ciliated cel ls are predominant, and goblet and basa l cells and goblet cells intercalate. The lamina propria , rich as an artifact resulting from ssue processing (41). A role for the airway epithelium in pathogenesis of asthma studies highlighting the presence of epithelial dysfunctio of the epithelial epithelial cell activati on and the release of a inflammatory and airway remodeling Another where they are normally absent, and can make up a higher proportion of the submucosa in fatal asthma compared plugs in airways of all sizes, from second generation airways to bronchioles (51), and lead to atelectases. As such, it has been reported that over 50% of the airways can be occluded by muc ous during a fatal asthma attack hyperplasia. The basement membrane of the airway epithelium formed by the basal (the \"true\" as defined by electron microscopy) and the lamina reticularis (a net of reticular fibrils, of type VII co llagen mainly, and microfibrils of fibrilin), both synthesized matrix is in the subepithelial region and is mainly constituted type I and III collagen fibers, fibronectin and proteoglycans (26, dysfunction (44). in angiogenesis, such the vascular endothelia l hyperplasia and Clinical and experimental ggest the increased smooth muscle mass plays a central role in the asthma airway rs through a combination of immune cells such as mast cells (62) and T cells (38, 63, 64), which will be described further on. The increased airway smooth muscle may in the of the Airway smooth muscle cells are able to secrete mediators can alter tissue homeostasis and thus modify the function of other cell types. In in asthmatic may play a relevant role in the disease (57, 65). Also, Ma et al. observed in increase (66). However, these results remain controversial, because Woodruff et al, in a similar study, found no difference in MLCK expression levels between smooth muscle cells from asthmatics versus controls (67). Apart from the feature, defined usually determined by measuring volume in the first expiration on airway test output is the MCh concentration that causes a 20% or greater fall in FEV 1 (provocative concentration 20 or PC 20), and the test is generally considered positive if such value is ozone, infections, etc. The MCh challenge test is very sensitive and has a high negative predictor value (69). The relation between airway Airway hyperresponsiveness is considered a risk factor for the development of asthma in children (70). Recently, associations between disintegrin and metalloproteinase domain 33 (ADAM33 ) gene has been and catalytic fragment, which is a powerful angiogenesis factor involved in smooth muscle development (72). surface of mast cells, leading to the immediate of histamine, which causes an early within 10 minutes and Asthma 32lasting IgE has been linked to allergic responses in humans for almost 50 years (73, 74). Histamine acts on of the 3-8 hours of mediators including cytokines and leukotrienes (75). 1.3.4. is inferred that asth ma existed priorly to the times of the Egyptian Empire, 3000 years BC, although the disease has only identified as an asthma since the 17th century. The George Egypt in 1870s, mixture herbs so that the sufferer could inhale their fumes). In the Galen treated asthma symptoms with owl's blood in wine. In the Middle Age, Moses Maimonides (1135-1204 AD), a physician in the court of Sultan Saladin of Egypt and Syria, diagnosed asthma months when would begin as a common cold. He also note d that the dry months of sufferers moderation of sexual activity, and chicken soup. At the end of the 19th were unrealistic (76). One hundred years ago in China, it was common to give a person with asthma herbs containing ephedrine, of such agents block cholinergic signalling to some extent sympathetic tone and airway smooth muscle relaxation (77). The first pharmacological aim for the treatment of asthma, before the relevance chronic airway inflammation to achieve After the first studies on the use of nebulizers to produce a fine spray in the 1870's, James Burnett, an Edinburgh physician, reported in a bronchodilator therapy for asthma when inhalation therapy was revolutionized with the INTRODUCTION 33 of the first pressurized metered-dose inhaler (pMDI) (79). By the early asthma deaths is still widely used, nowadays as rescue medication, due to its quick an d more selective action on airway smooth muscle and minimal side effects (82). The use of salbutamol and the introduction of systemic steroids for the management a large reduction of asthma deaths possible in the late 1970s (79). The isolation of cortisone by Tadeus Reichstein in 1936, and its posterior identification by Kendall and Hench (79), favoured its first applicatio n in asthma in 1950 (83), which in turn led to the confirmation of its beneficial e ffects by clinical trials a few year s (84). subsequent years, prednisone and hydrocortisone were developed and introduced in diabetes and obesity, to on a safer administration of steroids. dipropionate (BDP) steroids is treatment identification of the role of mast cells (12, Although the efficacy management of 1980s, inhaled clinical practice (90-93). LABAs have a bronchodilator action for up to twelve hours, and appear to also have a side anti-inflammatory moderate persistent asthma beyond allergen exposure in specific settings was a key step in the pathophysiology of asthma, led in the 1990s to the idea of blocking the primary mast cells signaling cascade by the IgE site that binds its high affinity receptor (Fc R1) on the mast cell. This approach was successful or their r eceptors, with a growing development pipeline and important hopes for severe asthma and other diseases. In the case of omalizumab, still the only approved therapy of this type for asthma, the treatme nt effectiveness is variable and concerns on its cost and potential side effects have been raised (100-107). Presently there cure intended of However, evidence consists in delivering a radio frequency energy to the airways by flexible bronchoscopy with the aim of reducing airway smooth muscle mass and responsiveness (108-111). However, enough evidence th at this technique ameliorates all asthma types (112) and its high complexity and cost make this a pproach not valid for routine treatment. In all, we can conclude that current asthma treatment is suboptimum and not sufficient control severe asthma (38). of new therapeutic targets and treatments. 1.4. Animal models of experimental asthma Animal models have contributed significant knowledge to the the asthmatic immunological response. It is probable that the first recording of bronchoconstriction in an animal model of allergic disease was reported by Auer et al. in 1910 using guinea pigs during anaphylactic shock (113). In this work, to by The cause of asphyxia was defined by the authors as \"a titanic contraction of the smooth muscles of the bronchioles; which occludes their lumen gradually, so that finally no air enters or leaves the lung [...] the animal was INTRODUCTION 35 strangulated\". Since this first animal model in which a bronchoconstriction was described, extensive effort has been done to an imal model that mimics human asthma. 1.4.1. Different animal models of experimental asthma No laboratory known asthma, with lung inflammation and bronchoconstriction (114, 115). Current research work in cats is being conducted to elucidate mechanisms that asthma been used to model allergic due to their natural clinical implication have been achiev ed through selectively breeding dogs with high IgE levels at baseline (119). The high IgE levels with the predisposition to develop the which levels and ai rway hyperresponsiveness (121) (122). This fact has made sheep a potential and attractive model moderating lung allergic responses in sheep (124, 125), did not translate to humans (126). This highlights the care that must be taken when comparing animal models with human disease. In the case of sheep, one also has to take into account the high costs for housing and mani pulation that these large animals require. Guinea-pigs have been used as animal models for pulmonary hypersensitivity for more than 80 years (127). In these animals, the major bene fit is the lung as the target organ for the hypersensitivity response, which allows species-specific discrepancy in response to leukotrienes with humans (131), must be taken into account when employing the guinea pig for experimental purposes beyond the histological study of (132). Rats are widely animal ls for human diseases (133-140) as they are relatively cheap, large in size, and stable under an aesthesia. In the respiratory field, the rat eases a broad range of antigens (133, used (145). The rat represents a useful asthma allowed us to understand of mainly applied to the mouse, have displaced rat as a \"second option\" for asthma has in recent years together with the advent of transgenic technology, which balancing the usage 1.4.2. to (148), which reflects the murine to human diseases. Thus, murine models are considered an important basic research tool to understand the mo and cellular bases of asthma some differences be taken in to account when working with disease animal models, and the mouse is not an exception. Differe nces in the tracheo-brochial tree between humans be considered (152), us: the size, where total lung capacity in humans is about 5 L and only 1 mL in the mouse; the alveoli of the murine lung are smaller mean linear intercept (MLI)) those of m); the thickness of the blood-gas barrier is about 0,38 m in the mouse and 0,62 m in 37 components of the infla mmatory infiltrates in Mice also have other advantages compared with othe r animal models (rat, ho rse, sheep...): they are cheap, small, and have a rapid biological cycle, with a gestational period of approximately 20 days, a lactation period about 4 weeks, an d they reach sexual maturity at 5 weeks. Pros and cons in the usage of mice as models for human asthma have been reviewed (156-163). An important issue to take into account in the development of mouse asthma models is the choice of mouse strain, because the used to sensitize animals in asthma models, from the most traditionally used ovalbumin (OVA) to a number of on toxicity were performed more than 100 years ago on dogs, guinea-pigs, and rabbits, where violent or fatal reactions to repeated injections of to so-called \"toxalbumins\" (166). Already in the 20th century, the first animal models of experimental asthma were described in guinea pig (1926) (167), dog (1970) (168) and even the monkey (1972) (169, 170). These models were based on sensitizing animals to an allergen in of called tolerance\". In the duce allergic Th2 responses in these animals. In the 1970s, Church reported a rat model of \"anaphylactic bronchoconstriciton\" and the inhibitory of Two years later, Stotland et al. immunized rats with OVA plus aluminium hydroxide gel as a coadjuvant with Asthma 38or without B. vaccine, and reported \"anaphylactic bronchoconstriciton\" 14 days after sensitization (173). At the same time, Chang et al. established a mouse model of sensitization to ragweed al. studied the kinetics and localization of IgE production in a F 1/J mouse model of allergic sensitization to several sensitization subcutaneous immunization. They showed that the site for IgE production is the bronchial lymph node s in both cases and that the correlation serum IgE levels. In Carswell et al. established an experimental asthma m odel that became \"classical\", in which Lister rats were subcutaneously sensitized with OVA and aluminum or B. pertussis as coadjuvants, followed by aerosol airway challe nge reported incr ease in IgE levels the respiratory response (177). In the 80s, approximately 10% of the U.K. po pulation suffered from allergies to HDM (178) and the association between HDM and asthma became an intense focus of research. as flakes or human skin shedding and grow in contain major mite component is Dermatophagoides spp (D. pteronyssinus in Europe and D. farinae in America). The major allergen from D. pteronyssinus , especially for asthma, the mite faecal particle s. This allergen, called Der p 1 has been first isolated by Chapman et al. in 1980 (181) and molecularl y characterized by Simpson et al. (182). In the following years, a wide range of allergens with similar patterns was described allergic diseases, including asthma, with the aim of reproducing the human disease as closely as possible. This led in the early 90s to encompass clinical experimental research with HDM in atopic people (184-186) with animal models (187, 188). Since then, HDM has become an extensivel y asthma in and its use in animal models is an advantage in these terms (191-193). However, an inconvenien ce of this approach is that HDM is a complex mixture of antigens and it is difficult to standardize for experimental purposes. Taking all this together, the allergen choice must be in agreemen t with the aims each study, taking into account the advantages and limitations and arching for a balance in each case. 1.4.4. Sensitization and challenge protocol Since the first murine asthma model over 40 years ago (172), a broad range of protocols have been used to induce experimental allergic disease in animal models. The majority of murine been injecting an adjuvant, either a dose of T and B cells, and the release of a myriad of mediators, which results in the manifestatios of allergic disease in the upper and lower airways. These models the sensitization, in the way it occurs in human disease. The division between the sensitization and challenge phases is artificial in these models, and sensitization is induced by a parenteral antigen \"vacci ne\" primary airway exposure leading to IgE production was performed by van Hout et al. (194), who used aerosolized OVA to challenge rats, which led to IgE synthesis. In the 80s, Holt et al . highlighted the \"need of models which more closely approximate triggering of responses under the antigenic stimulus is accompanied by and po of entry antigen normal\" (195). Despite the obvious importance of the respirator y tract as a portal of entry for antigens which act as allergens, the interest in antigen inhalation as a mode of induction for specific IgE responses has not been reflected by the classical i.p. sensitization models. This line was followed by others. McCaskill et al. developed an animal model of grass was still used as an adjuvant (196). Also, Sedgwick et al. reported in 1984 of same this model, spleen and respiratory tract lymph node cells, but not course and natural disease history. However, there are few works on allergic airway disease that do not distinguish between sensitization and challenge periods (192, 193). Animal models of allergic disease where the first exposure to antigen was not the with first antigen exposure in the respiratory tract did show dependence IL10 to generate tolerance (199). Moreover, the to context, cells the development or attenuation of allergic disease may depend on the nature of the allergen and the local microenvironment in which the allergen is delivered. There are also different ways to challenge anim als with an allergen. McCusker et al have reported that the route and site of challenge influence the final result of the model (200). Allergen administration can be done via intra-tracheal instillation, a route used in rat asthma models, but difficult in the mouse due to the small size of the animal. Another method is to challenge the animals with aerosols or nebulilzed antigen in a closed box not controlled and the antigen can be deposited on the skin and hair of the animals, and reach the intestine after test in humans (207). I.n. performed on animals has been reported to achieve antigen deposition in the nasal cavity and less than 3% in the digestive tract (55, 200, 208). Alternatively, i.n. challenge can be done under light anesthesia (e.g. with inhaled sevoflurane), which is less involve swallowing of rodents as animal models for lung diseases demanded the development of techniques and equipment for pulmonary function testing in mice and rats. The small size of the airways was an important challenge to overcome from early studies on pulmonary resistance in mouse, in the late 1980s (210). Two main options exist for pulmoanry function testing in rodents: invasive and noninvasive approaches (211). Each type of technique has its own pros and cons, and factors such as and reliability for each particular experimental INTRODUCTION 41 pulmonary mechanics, and are applicable to the of function and peripheral pulmonary mechanics parameters through complex usually terminal in the same animals. Noninvasive pulmonary function testing is quick and simple in terms of animal instrumentation, since no anesthesia nor intubation are of pulmonary mechanics, has been questioned. invasive testing, used in humans for the induction and maintenance of general anaesthes ia. It produces denso-dependent central nervous system, cardiovascular, and respiratory depressant effects (213) and is one of the preferred agents for mask induction due to its lesser put under For this a the Once paralysed, the animal is subjected to mechanical ventilation that is usually set at 150-250 breaths/min and 6-10 mL/Kg for the mouse (211, 215). This is achieved by means of a rodent mechanical ventilator such as the FlexiVent \u00ae (SciReq, (216). The Flexivent is fitted and washer trap to cleanse the gas output. Since ra ts and mice have small airways and the functional residual capacity (FRC) largely maintained by inspiratory which is minimal or null in the anesthetized animal s, it is important to use PEEP to avoid small airway collapse at the end of expiration. The inspiratory and expiratory arms of the ventilator tracheal cannule through a Y-tube adapte r provided with valves that work together in each respiratory cycle, and pressure transducers. The main a piston Asthma 42driven by a high-precision linear motor. The exact position of the piston at any given time and its movements, as well as the ventilation settings and able to infer the inspiratory volume and flow from the movements of breathing support and forces simple or complex waves, called perturbations, on the transducers with the inferred volumes introduced. From these data sets, the software then calculates pulmonary function variables by applying mathematical models. The models (i) the linear first-order single compartment model, which airways and pulmonary structures as a unique compartment; mechanics parameters from peripheral structures compartment model, based on a simple-wave perturbation called function purposes. The main variable obtained is lung resistance L), which reflects the global lung resistance comprising airway (R aw) and tissue (R ti) resistance (210, 219). R L measurements upon airway challenge with creasing MCh rhinitis is an that affects mucosa and is caused by an IgE-mediated which is episode itching an d sneezing begins within seconds and wanes 5 to 30 minutes later (221). This early phase is driven by basophils and and obstruction begins minutes later and can last for hours. This late phase is mainly driven by prostaglandins, interleukins the recruitment of eosinophils into nasal tissue. The diagnosis is further supported by a positive variable and all these symptoms are not necessarily present in the same patient. has allergic although the data many do not recognize rhinitis as a (30). It has increased more rapidly than asthma in the last is not a severe disease, it alters the social life of the patien t (222, 223) and affects work productivity (224). The direct cost of treatments costs derived from loss in considerable socio- economic impact. A study on the prevalence of allergic rhinitis in Europe showed evaluate of allergen-specific nasal in patients with rhinoconjunctivitis (207). Like in traffic through regional nodes after antigen exposure (227, 228). rhinitis asthma and (232). Moreover, sube pithelial fibrosis was found in the nasal mucosa of patients with perennial rhinitis (233, 234), therefore patterns (237). Rhinitis and asthma have been suggested to be two manifestation of one syndrome within two sections of the respirator y tract, an idea that has led to an ongoing debate on an \"airway system integration\" theory such airway unity concept is not from a phy siopathology standpoint, epidemio logical data have shown an asthma. Approximately between allergic rhinitis and asthma led to the development of a series of workshops on Allergic Rhinitis and its Impact on Asthma joint diagnostic and therapeutic strategies (243). 2.1.2. Relationship between the upper intrapulmonary airways There are several physiologic and anatomical communication systems between the upper airways (235, 238): -Naso-bronchial interaction. An allergen deposited in the nares can induce bronchospasm. It has been proposed that this phenomenon is driven by a nervous network between the nasal cavity and the lower airways, in which the trigeminal nerve (cranial par V that collects the sensitivity of the nasal mucosa) is the afferent pathway, and pneumogastric nerve -Respiratory Inflammatory mediators from nasal may be aspirated into the lower airways, especially during identified as a \"communicator\" between th e upper and lower pathway. dissemination of the propagation of inflam mation between the upper and lower airways. It has been proposed that allergic inflammatory responses (244-246). 2.2. Rhinitis animal models Mizuno et al. established in 1991 one of the first animal models of experimental allergic rhinitis in guinea pigs (247). They studied and using i.n. sensitization chemical mediators involved in allergic rhinitis, and Zhao et al. studied in this model its similarities with human symptoms (249). A lthough the model did not reproduce all human allergic rhinitis symptoms, it achieved Suleimani et al. studied the relationship between nasal airway pressure and lung inflation pressure in OVA sensitized and challenged guinea pigs and found no correlation (250), although this negative finding may have been due to an excessively short duration of the model. Studies on dogs have also been performed. The anatomy established (254-257). Models in larg e animals such as dogs may better represent the human disease and have an advantage as the size of the animal allows for invasive that implies a high cost of maintenan ce and breeding, and the long life cycle is disadvantage to rodents. Rodents represent a valid 258, 2.3. The murine nasal cavity There are some studies of the cavity in murine asthma models (55, 150, 200, 263). Sampling procedures in the murine nasal cavity, quantitative morphometry, are technically difficult (151), but some sets achieved. murine models based on i.n. instillation, deposition in the nasal has been reported (151, 200). In asthmatics, eosinophilic inflammation and basal membrane concomitant with alterations found in bronchial biopsies (233). These data encourage the analysis of the upper airway in murine models of experimental asthma. However, there are few allergic rhinitis murine models (221, 261, 262, 264, 265), and the even less studies that have considered the upper and lower airways together (200, 263). In the 1980s, John T. Young established a protocol for the histopathological study of the nasal cavity in the rat (266), where four frontal sections were studied, from the upper incisor teeth to the last molar (Figure 2). Meticulous anatomical diagrams of the rat and mouse nasal cavity were also done (267) to serve as a guide for comparative stud ies. Based on the similarities between the rat and mouse nasal cavity (268), Farraj et al. adapted the study of the rat nasal cavity to a mouse model of Allergic rhinitis 46allergic airway disease (263). In this work, only three sections were set for analysis because of the smaller size of the mouse skull: section to the incisor teeth, comprising the nasal turbinates); a middle section (at the level of the incisive papilla in the hard palate, comprising the paranasal sinuses); and a distal section (at the level of the second palatal ridge, comprising the etmoidal sinus and nasopharynx). The rodent and human nose cavities have similar types of epithelia, but with different thickness and distribution (221). Interspecies variability in the gross anatomy also exist (269). The human nose has three nasoturbinates middle and inferior), wheras evolutionary to cavity in rodents and humans (Figure 3), their distribution is quite different. Approximately 50% of the nasal cavity is covered by olfactory epithelium in rodents, as opposed to only 3% in humans (268). In the mouse, as for humans, an important function of the nasal cavity is to condition the air, as it is inspired before entering the lower airways. Such cavity in mucous and all mucous substances that wet the air as it passes Regarding temperature control, the nasal cavity is profusely irrigated by superficial blood vessels which, together with abundant venous sinuses, draw a large blood flow in the proximity of the nasal epithelium and work as a heating system. Similarly to humans, murine nasal protuberances nasoturbinates and Figure 2. of the nasal cavity in the rat . Ventral view of the rat hard palate, with the lower jaw removed. The distribution of four tissue sampling blocks (I-IV, stippled areas) to be processed for analysis is indicated. The numbers on the right indica te the location of the seven cuts necessary to produce the four slices. A, upper incisor teeth; B, in cisive papilla; C, first palatal ridge; D, second palatal ridge; E, first upper molar allowing time to condition the air before it enters the lower airways. An anterior section section of the main nare The inciso r teeth roots, which are curved backwards in the mouse, are symmetrically placed besi des the nasal cavity and can be seen as compact de ntin matrix structures. Laterally, there are two pairs of turbinates, the naso-turbinates and maxilo-turbinates, from top to bottom respectively. Near the bottom of the cavity, adjacent to both si des of the septum, there is the vomeronasal organ, typical organ is covered by a specialized tissue connected to ne urons particular cavity varies depending on the non-keratinized squamous epithelium (Figure 3-A). (Figure 4-B) a narrowing of the air this section, the can as lateral communicating with the nares. Figure 3. The nasal epithelium in the mouse. Different types of epithelium can be found in the murine nose depending on its location. In the non-stratified, not keratinized squamous epithelium ( A). Deeper cylindrical respiratory epithelium ( B), comprising arrows), goblet cells (black arrows) and cylindrical ciliated cells (hollow arrows). Finally, the most formed by serous and mucous glands. In this mid region of the nasal cavity, there is respiratory epithelium covering the bottom and middle part of the cavity and sinuses. In th e upper part there HE stained. Anterior A), mid ( and posterior ( C) sections are shown. The panels s how the surface of the ( ( f). posterior of the (Figure 4-C) shows to the nasopharynx in humans). The upper part of the posterior nasal section is composed of a labyrinth by epithelium. this is an area of slow airflow, this provides enough time to allow for epithelium of structure. 3. THE IMMUNE SYSTEM The human immune system is a complex and fascinating network of cells, tissues, and organs that work in coordination to maintain molecules, been acquired and improved for over millions of years of evolution and have made the immune system essential for the survival of Virtually all particles that reach any part of the body interact with some component of the immune system. First of all, the innate immune system includes all surface, mechanical, and mucosal barriers that cover all the surfaces that ar e in contact with the exte cells. Monocytes originate in bone marrow from monoblasts (which in turn derive from a myeloid progenitor) and circulate in the bloodstream throughout the 24h, monocytes migrate from the tissues where into resident macrophages. The main monocyte/macrophage (such as microorganisms), whole cells or cell detritus (fro m self or non-self origin ), and substances. For instance, particulate inflammatory (274-277). act as antigen presenting cells, and participate in hemost asis through the production of substances that participate in coagulation (278) and on the granulocyte. Neutrophilic granules, which define the neutrophils, serve as a reservoir for digestive and hydrolytic enzymes, prior to their delivery into the phagosome (274). The main role of neutrophils in immunity is to take up blood but not normally in healthy tissues. They are short lived against parasites, which are too large to be ingested by macrophages or neutrophils. in their granules. They have two functions. upon activation they release granules containing highly in the basophilic granules. present at the site of inflammation, require growth factors similar to eosinophils, and exert an d are involved in the response against parasitic worms. They underlay the body surfaces and alert the immune system of local invasion by reactions. Even context, mast cells can a dual role level of low leads to the contrary, a high a llergen concentration can induce the production immunoregulatory All blood cells arise from pluripotent hematopoietic stem in the bone marrow. pluripontent cells differentiate into two and myeloid. The common lymphoid progenitor differentiates into T cells, B cells and NK cells, which all enter the bloodstream. B cells ultimately locate in the B zones of lymphoid tissues upon activation, they mature as cells . T cells migrate to the thymus, where they mature into naive T cells, wh ich are then the bloodstream and scan the secondary lymphoid tissues search of antigen-presenting cells. The common myeloid progenitor divides to produce the granuloc yte, platelet and er ythroc yte linea ges. Dendritic arise from both myeloid lymphoid progenitors within th e marrow. They migrate via the blood to tissues throughout the body. These cells mature after they have encountered a potential pathogen and mi to the antigen presenting The vertebrates, when a provides specific antigen recognition and memory, and therefore takes be achieved. th faster ective. The adaptive Dendritic cells, discovered and initially described in 1973 by Nobel Price awardee Ralph M. Steinman (284), represent the link between the inna te and adaptive responses of the immune system (285, 286). For this reason, dendritic cells are a current research hot topic. Functionally, two types of dendritic cells have are present in the lungs and seem in the maintenance of participate and localization in tissues, dendritic cells comprise a wide variety of cells from different haematopoietic origins (288, 289), with the co mmon characteristic of working as antigen presenting cells. and There, th ey antigen-specific their activation effector T cells (primary im Dendritic nd peptide to effector immune cells a process called trogocytosis, which may be a mechanism of amplification of the immune response (290). The marrow lymphoid progenitor gives rise to two lineages: natural killer (NK) cells and lymphocytes. The NK cells circulate in the blood and have cytoplasmic granules and invariant membrane receptors (which make NK innate immune and harmful to distinguish self versus non-self antigens and cells (291). When a NK cell INTRODUCTION a cell Lymphocytes lineages. Both are antigen specific responders, and are the core of the adaptive immune response. B cells originate in bone marrow, where they begin their maturation process the results (BCR) onto th e cell surface. All of identical d, cells are released into th e blood as immature B cells and are recruited by secondary lymphoid organs. The production of and the cells become mature naive B cells. When a naive B cells meets its specific antigen through the BCR, it interacts with a helper T cell and b ecomes an activated B cell. Clonal expansion and immunoglobulin class switch ensue, which then leads to the development of plasma cells that produce a particular immunoglobulin class and the resulting soluble antibodies (295, 296). Since the research work presented in this thesis was mostly focused on T cells, a more in-depth account of T cell development and function is presented on the following section. 3.1.1. Development of cells in the microenvironment B and cell lineages the common lymphoid progenitor. These signals are mainly provided by stromal cells, which is proliferation and maturation of B lymphocytes. The most important factor for T cell survival and development in the bone marrow is the produced by the stromal IL7 progenitors, promoting the rearrangement of (TCR, analogue to the BCR) nor other rkers of T cell maturation with the thymic stroma. DN cells are divided into four stages depending on the expression of Kit factor st age, thymocytes still express Kit and CD44. In these early maturation steps, as for B cell developm ent and early T cell stages in the bone marrow, IL7 is essential cell survival. Kit signalli is also important for DN lymphocytes. As thymocytes mature and progress DN3 stage, they reduce CD44 and If is successful, thymocytes cell their CD25 expression and begin Figure 6. Development of T cells. T lymphocytes originate in the the bone marrow from a common lymphoid progenitor. They subse quently migrate to the thymus, where undergo antigen, it becomes both thymocyte cease proliferation, the -light and are unique among T- lineage cells in that they do not express IL7R (they are refractory to IL7) nor most receptors by process \"positive selection \". After the positive selection, such thymocytes will again express IL7R an presently explained TCR- mediated positive the CD8+T (310), and Parallel to the positive selection process in the Although versus foreign antigens completely turning the thymocyte into an while results apoptosis, the between TCR survival and maturation. A in the marrow through antigen presenting cells (313). Negative selection taking place in the bone marrow or thymus is termed central self tolerance processed A). The T All cells in tissues are susceptible to be killed by cytotoxic extracellular domain stabilizes the interac tion tolerance status against self antigens, and were demonstrated in the 1980s and 1990s (314-316). However, a question arises on how cells in secondary lymphoid seems by (AIRE) (317), enabling the majority of T cells bear : TCRs, there is a minor population of T cells bearing : TCRs that differ in the types of antigens that are able to T cells delivered to the periphery and usually reside within epithelia. T cells with : or : TCRs share a common progenitor; in fact, TCR T TCR T at the DN1 stage. The compromise between both subsets is not yet fully understood, but it seems that the strength of the TCR signal, together with Notch signaling, is itical in pluricellular organisms (319) and implicated in lymphocyte development (320, 321). in In contrast T cells, TCR cells display repertoire of limited diversity : lead : TCRs, and therefore TCR T cells are considered cells of the adaptive immune system by definition. Another subset of ILLs is the NKT cells (324). These cells derive from immature DN thymocytes (325), bear : TCRs of limited diversity, and usually express an NK1.1 receptor (326), commonly found on NK cells (327). There is a subs et of NKT cells that also express the CD4 receptor (328). The NKT cells play an important role cytokines like IL4, IL10 and IFNG (329). NKT cells are to in and cells activation of a naive T cell by an antigen is a complex process that needs participation of the innate immune tigens reach the body through a mucosal surface or a cut in an epithelium. Microorganisms pathogens typically which of and cytokines. These in turn stimulate the activation of T cells and induce their differentiation in to different types of effector cells. Antigens or pathogens that pass take up antigens and activated. This indu ces their migration to lymphoi d naive the antigen presenting cells (335). A lternatively, if antig ens blood, antigen processing and presentation by antigen presenting cells is in cell maturation occurs in the thymus, naive T cells are T cells leave the lymphoid tissues and go back into the bloodstream to a naive with identical , interaction, cells nodes. Naive cells express the B7 counter T cells different types effector T cells, as discussed later. Once proliferation occurre d, T cells differentiate into effector T cells and do not require any other co-stimulatory signal to act (341). Activated effector T cells leave lymph of inflammation. there point infection, As mentioned above, naive T cells fall into two large groups. The first bears CD8 co-receptor on their surface and the other cells such antigens, by direct contact or by releasing cytokines (343) like IFNG, which can block viral replication or even lead to the el imination of viruses from infected cells without killing them (344). When effector CT cells recognize an antigen cytoplasm are released into the cy toplasm of the target ce ll by a calcium that trigger apoptosis of target cells (343). CD4 T cells differentiate into helper T cells and regulatory T cells , cells to differentiate and produce antibodies, particularly of the IgE class, which is involved in the response against parasites. A more recently defined the is involved in the immune response against extracellular bacteria and some parasitic worms by cells under be in asthma pathogenesis through IL9 production (349). The immune system 60Treg cells are a heterogeneous group of cells with different developmental origins but with a common immunosuppressor role. They act through cell contact response. the main goal of Treg cells is immunological tolerance. There are different types of Treg cells depending on their origin. Natural Tregs (nTregs) are generated in the thymus and play by self-reactive effector T ce lls that escape negative selection in the thymus (350). Another type, adaptive Tregs different subsets, secreted Examples of T cells differentiation of naive CD4+ T into different subsets of during the response The differentiation and Th2 subsets was first described by Mosmann et in (352). The accompanied by extensive 354). other intracellular pathogens (such as mycobacteria some other bacterial and protozoa genera), and also activate B cells to produce IgG, to opsonize infected (357, and IFNG (362). INTRODUCTION 61 There is the regulation of Th1/Th2 differentiation signals because CD4+ T cell-driven immune response to be defined, and and its regulation fully T cells and, together with IL13, induces B cells to switch to IgE production ( 363, 364). IL5 is a potent of Th2 responses are research, and As alternative has been proposed that, if an infection is caused by pathogens that not TNFA), small amounts immune compromising naive T cells with the Th2 lineage (370, 371). In f act, GATA3 expression is key to induce Th2 differentiation (370), cells a chromatin remodeling mechanism shown to be essential for thymocyte maturation at DN3 (374) and SP (375) stages. GATA3 the controls IL5 (377) and IL13 (378) in committed Th2 cells, but it is not essential for IL4 (3 75). which in GATA3- independent manner (376, 379). STAT5 expression GATA3 its expressi naive CD4 T cells (376). Once effector CD4 + T cells are committed towards a Th2 phe notype, clonal expansion is driven by an IL4 dependent mechanism. a induces proliferation of mature Th2 cells by growth of a an both and inhibit Th1 and Th2 differentiation. In the mid 1990s, Yao et al. described and characterized IL17 as a novel cytokine produced by T cells in response to particular pathogens (386, 387). IL6 and TGFB activat e a transcription factor called signal Stat3 in mice, which in turn induces the expression of orphan nuclear receptor ROR INTRODUCTION 63 in developing Th17 cells (388, 389). ROR induces the transcription of the gene encoding IL17, and is a key transcription factor for the differentiation of naive CD4+ T cells into effector effector subset the defe such may play a role in the recruitment of neutrophils, and the differentiation of local monocytes into macrophages. GCSF is drawn back to the bone marrow to increase the production of ne utrophils and macrophages. Work done with knock-out animal models, and research on human immunological disorders, has allowed to link the failure with Regulatory cells Already in the 1970s, Gershon et al. realised that there T cell cell T subs et clear definition and hampered the study of suppressor stage ssor\" in general avoided (406). In the early 1990s Sakaguchi et al. T a CD4+CD25+ cell subpopulation healthy 64Hori et al. , Fontenot et al. and Khattri et al. demonstrated by work (410-412) that the forkhead box transcription to T self-antigens. These cells appeared to maintain a tolerogenic state of the body to self-antigens. In fact, defects in the FOXP3 gene, chromosome, the human X-linked cells (414). defect in the markers such as low IL7 receptor expression (CD127 LOW) (425) and tumor necrosis factor receptor 2 (TNFR2) (426) have been recently described to identify human Treg a key Treg development and as a counterbalance to common effector- memory T cells (427). Also, depending on different MHC-II expression, a spectrum Treg populati defects in function may result in different autoimmune diseases (351, 429, 430). The transcription FOXP3 seems to be centr al to immune expected is an demethylation FOXP3 in T the first attempts to describe \"suppresso r\" cells, there is still a lack of a molecular marker to identify immunoregulatory cells. In fact, it is presently from experimental approaches that immunoregulatory cell subsets do exist, and this field has just a Possibly, regulatory not a characteristic of just one defined cell type, but an atribute of vari ous cell subsets that can ex ert a regulatory function in a particular tissue environment. Moreover, Tr eg cells seem to be involved, not only in the tolerance to self-antigens or the attenuation of late immune responses, also early infections (434). Conversely, the involvement of Treg cells in the of infection has also been proposed (435). Defects in Treg cells have been to anti-tumour growth in the survival growth (440, IL2 it is not necessary for the regulatory the of downregulate to activate effector T ce lls (449) (Figure 9). A third factor that seems important for nTreg development is the nature of the interaction between the TCR on lymphocytes and the immune system 66transduction pathway has been linked to the generation of nTreg cells (451, 452). Isomura et al. identified the NFKB pathway transcription factor c-Rel as critical to generate normal amounts of T reg cells (453), and this finding was further supported by Visekruna et al. and Deenick et al. (454, 455). FOXP3 also associat es with the nuclear fact or of activated T cells (NFAT) to induce a Treg phenotype (447), interacts transcription factor such as FOXP3 would stimulate not just a member the IL12 family that ma y be a downstream target for FOXP3, has been recently observed in FOXP3+ T reg cells (459). EBI3 (461), and may attenuate effector T cells in ac ute and tissue environment, to control infections or inflammatory diseases not all human nTreg cells (464), and the exact and contained rforines. Surprisingly, ac tivated human Treg granzymes A and B (465), which would theoretically provide them with a cytotoxic expression in Treg cells and makes them able to kill B cells, resulting in the of B cell T from cells (471). mech the Treg cells use to T Treg cells expre CD4 that binds MHC-II (473). interact with through CTLA4 induce the production of immunosuppressive molecules that suppress effector T cells (474, 475). From the mechanisms by which Treg cell subsets can act, it is difficult to elucidate whether there is a key common pathway, or multiple by integrating all such mechanisms into a model by which regulatory T cells use one or another inhibitory pathway depending on the environmental context (463). However, no experimental demonstration has been achieved for this theory to date, and further research is warranted. The immune system 68Other were nTregs, (Table 1). et al. described a CD4+ T cell Latter, r findings a regulatory cell subset that called 1 T (Tr1). This subset was able to suppress the proliferation of T through secretion cells (477). The stimulation of CD4+T cells in the presence capacities over naive CD4+ T cells in 69 response against foreign work in the absence of FOXP3 expression (480, 481), it must currently \"master for all cells with ector T cells transiently in this case is unknown (481). Th3 regulatory cells In 2003, contemporarily with the demonstration of the role of FOXP3 in nTregs, Chen et showed that CD4+CD25- T cells may become iTreg immunoregulatory phenotype, was TGFB induces FOXP3 expression in Th3 cells, TSDR and intestinal epithelial cells (483, 484). Tolerance induction is the default immune pathway in the gut, and the 486). Double negative regulatory T cells Double negative regulatory T cells (DN Treg) were first described in 2000 by Zhang et al. , who reported a novel TCR specificity a TCR+CD3+CD4-CD8-CD25+CD28-CD30+CD44-) IL2, IL4 or IL13 nor FOXP3 (488). These cells induce apoptosis on CD8+ T cells of the same TCR specificity requiring dir ect intercellular contact (489, 490). DN T cells account for 1-5% of peripheral TCR+CD3+ T cells (491, 492). Contrary to nTregs and similar to iTregs, DN Treg cells have extrathymic development. Early thymectomy does development required need stimulation immune system 70DN homing to transplanted (496). DN Treg CD4+ T cells through inhibition of IL2 production (497), and have the ability to k ill allogeneic lymphoma cells (498), inhibit autoimmune (499) (490). There is therefore current interest on the potential use of DN Treg cells to inhibit clonal expansion of allo- an d xenograft T cells after transplantation (500-502), and other potential applications in the field of immune-mediated diseases. CD8+ regulatory T cells In the early pointed to CD8+ T cells as experimental allergic CD8+ Treg cells are involved in oral (505) and neonatal tolerance (506-508), and have been implicated in mechanism is similar to seen is inhibition of Th1, the tolerogeni c dendritic cells became anergic (512). A wide spectrum of CD8+ Treg subsets has been reported (512), but their study is hampered by the lack of a specific marker. The existence CD8+ Treg undisputed (514), although they represent a minor subset of the CD8+ T cells. It is very difficult to isolate CD8+ Treg cells from total CD8+ T are can secrete IL10 and inhibit to they downregulate IL2R chain expression on target T INTRODUCTION 71 cells through CTLA4 and TGFB1, and make the target cells become unresponsive A and cytotoxic T cells (522, 523). Mathematical models applied to in vivo experiments (524, 525) suggested that CD4+CD25+FOXP3+ T cells depend on to the proliferation of effector T cells (525). NKT regulatory cells NKT cells have been regarded as effector cells in immune-related diseases such as to provide (527). An in teraction between donor Tregs an d NKT cells to protect against graft versus host disease has been described (528), and a reciprocal regulation has been documented where NKT cells modulate cont act (529). role NKT experimental autoimmune encep halomyelitis has also been +iNKT population described (532), which derive presence of TGFB. Such (532). of iNKT cells into FOXP3+iNKT cells, and their participation in oral to lerance, was also described in the TGFB-rich gut mucosa (532). All together these data lead to the thought that NKT regulatory cells participating in oral tolerance may have been misidentified as Th3 cells, in the absence of NKT cell marker verification (437, 477). T regulatory cells T cells have been linked to epithelial regeneration and seem in bowel inflammatory disease models (535, 536). K\u00fchl al. found T cells with in vitro regulatory capacities similar to those of CD4+CD25+FOXP3+ T cells from human peripheral blood (537). This T regulatory subset secretes IL10 cells upon activation the presen ce of TGFB (532). Therefore, T cells The immune 72other T cells produce TGFB (538), which adds to the TGFB secreted by the and A recent recently found in mice and humans (540). In this case, their development seemed to be TGFB and IL2 dependent (541). B regulatory in effector T cell (542, T cell responses (545, 546) IL10. protein been lymphocytes (548). Bregs studies have pointed out that Breg cells may be a cause of deterioration in diseases such as type 1 diabetes, the notion of regulatory T cells as static regulatory activity is getting obsolete. Even nTregs are now seen as a dynamic population that depends on tissue environment for its regulatory function (430). Di fferent Treg and T effector switch capacities in in vitro depending on the cytokine environment. Regulatory FOXP3+ explained by the Treg cells may express, together through stimulation in of TGFB and absence of IL6 and IL21 (384), or in the presence of IL4 and IL13 (557). The best understood T TGFB asthma The lungs, as the organs for gas exchange, play a vital role in the maintenance of homeostatic balances. This includes the regulation of pH and CO 2 partial pressure, and the supply of O 2 for tissue oxygenation and aerobic metabolism. enclose larg est surface in contact w ith the outside (75 m2 approximately) and ventilate about 15,000 L of air a daily. Moreover, it is estimated that they are exposed to more that 7 kg of pollution through the year. The study of asthma necessarily CD4+CD25- T cells into production by negative feed-back. But in a TGFB rich environment, S M A D 7 i s n o t a b l e t o downregulate paracrine TGFB production, and cells, form underlying the basement respiratory 75 cells/mm2 in most peripheral airways (562). Macromolecules not cross the tight-junction formed epithelial cells then antigens CD4 with Th2 phenotype (563). these Th2 pro- inflammatory cytokines map to the long arm of chromosome 5 in humans (566), and polymorphisms in this region are linked to the development of atopy and airway hyperresponsiveness (567). are asthma (569) in experimental asthma (570). This cytokine is also implicated in the development of pulmonary In turn, neutrophils may attract eosinophils to the focus of inflammation and cause their degranulation (5 76). Recently, a new helper T (577). It 75 suggested, in mouse models of allergic asthma, that lung recruitment Th1 cells is BAL eosinophilia, of (579), results have also asthma Th1 cells in asthma is not clear cells play a role in asthma, thought to be relevant but still uncertain. iNKT cells were shown to be essential for the responses, airway asthmatic patients (585, 586). After the identification of FOXP3 as the first Treg cell marker in are involv ed in the mechanisms of tolerance induction (590, 591) and, in and cells, asthma. by antigen be essential for the innate immune system to operate, and interactions determine the addition, the upper red studies. According the current system integration theory, the upper airway as the primary si te of antigen exposure may play an important role in the development of lower airway disease and should be considered in the models. Therefore, in the work presented in this thesis we aimed immunoregulatory mechanisms and the plausible involvement of Treg cells in the disease mechanisms. Furthermore, to attempt some translation of the experimental data to human asthma, we involved clinical on allergens through primary exposure in the airways. experimental models based on primary airway antigen exposure, and the integrated analysis of the upper and intrapulmonary airways in such models, may unveil model. a. To analyze hyperresponsiveness as a primary in vivo outcome, and profile its development and evolution through a time series of experiments. b. To analyze other experimental contractile mass. c. To analyze the presence and f unction of Treg cells as Foxp3 To develop an allergic rhinitis model for the integrated analysis of events in the upper and intrapulmonary airways. 2. To generate antigen-specific Treg Foxp3 gene transfer vector suitable for the retroviral transduction minimum effective number of T cells, induce experimental asthma on adoptive transfer. 3. To obtain evidence on the presence of Treg cells in the airway wall of human asthmatics, by means of bronchial biopsy analysis. METHODS METHODS 83 1. Animals All study protocols were approved by the Comit\u00e9 \u00c9tico de Experimentaci\u00f3n Animal, Xunta de Galicia , in accordance with European Uni on Ib\u00e9rica, S.L. (Barcelona, Spain) and maintained at the Unidad de Cirug\u00eda Experimental (UCEX) of the Instituto de Investigaci\u00f3n Biom\u00e9dica de A Coru\u00f1a (INIBIC). Animals were transported in approved supply by means of gelatinous wet packs. Upon arrival, the animals were inspected and then distributed in groups of 2-3 animals into cages made of poly carbonate macrolon. The cages had a cleft for a 400- mL water feeding bottle and had top covers provid ed with polycarbonate filte rs (Ebeco, E. Becker & Co. GmbH, Germany). The cages were placed in a ventilate d stainless with a double positive/negative-pressure filtration system (Ebeco, E. Becker & Co. GmbH). The housed controlled adaptation period after arrival, the animals were redistributed into groups of 4 to 5 mice and were fed ad libitum with water and Teklad Global maintenance feed, egg protein-free (Harlan Interfauna Ib\u00e9rica, S.L., Barcelona). The mice were aged 6 to 12 weeks when entered in the experiments. 2. Study design We the through i.n. challenge, wi th the aim of establishing experimental asthma that would us to unoregulatory pathways. These models stemmed from prior reports (150, 164, 200, 595) and previous own experiece on Brown Norway rats (133). as allergens. model consisted of two groups: a control group challenged with PBS and an active disease group challenged with allergen. The immune response was induced by active sensitization or by adoptive transfer of T cells from donor animals. Mouse batches were assigned to the experimental groups through consecutive random sampling. Four models of active sensitization, using OVA as an allergen, were developed with n=10 animals per experimental condition (Figure 11). Thr ee of these models were based on direct primary allergen exposure in the airways: (i) short IN model (referred to as 3IN model here forth) consisting Role of effector and arms of experimental (ii) odel) consisting of 10 i.n. instillations; and (iii) extended IN model (30IN model), with 30 i.n. instillations. The fourth model involved sensitization as per classical asthma modeling (IP m odel), where the animals were all i.p. sensitized to OVA and then challenged with PBS (control gr oup) or OVA. In this latter model, sensitization was achieved by means of two i.p. injections separated by one week (days 0 and 7), and the animals were then submitted to i.n. challenge starting one week after the second i.p. injection (day 14). For all models, i.n. instillations (PBS or OVA) were administered three times per week (Monday, Wednesday, and Friday) for a period according to each specific model. For experiments on adoptive transfer of effector CD4+ T cells, OVA airway of recipients. The following groups were included: (i) naive cells from (ii) ad optive transfer of OVA- Figure 11. OVA models. Four murine models of experimental asthma were developed, with their respective controls challenged with arrows : i.p. sensitization. Black arrows: i.n. exposure to OVA (or PBS in control groups). METHODS 85 stimulated CD4+ T cells plus 3 PBS i.n. challenges (n=12) ; and (iii, iv, v) adoptive (n=6), 50,000 (n=8) or 100,000 antigen recruitment of the transferred CD4+ T cells to the airways, two i.n. instillations we re administered to the recipients prior to cell transfer, on the day before and just before cell injection (Figure 12). Adoptive transfer pilot experiment on Treg cells, on HDM-challenged animals. In this case, two groups of mice were subm itted to i.n. instillations (28 instillations in total, daily administered Monday through Friday for a 37-day peri od), and adoptive cell transfer was performed on groups consisted of HDM-challenged animals 75,000 CD4+ (Figure 12). 3. Sensitization and challenge For i.p. sensitization to OVA, the animals were lightly anesthetized with 2% sevofluorane (Sevorane\u00ae, Abbot Laboratories, Madrid, Spain), inhaled in a Plexiglas chamber. On days 0 and 7, 10 g of OVA (Sigma-Aldrich, Sant Louis, USA) adsorbed in 50 mg of aluminum hydroxide (Imject\u00ae Alum, Pierce Laboratories, Rockford, USA) were i.p. in jected in a 100- L PBS volume. For all experimets using HDM, the allergen was standardized as previously Figure 12. Adoptive transfer models. Two adoptive transfer models re designed, to evaluate the involvement of effector CD4+ T cells (Teff) and regulatory cells of effector and regulatory T cells, respectively. Role of pathophysiology of experimental et al. (596). i.p. the animals were lightly anesthetized as described above for OVA, and 0.12 g of Der p 1 allergen (1.2 L of HDM stok) adsorbed in 50 mg of aluminium hydroxide (Pie rce Laboratories) was i.p. injected in a 100 L PBS volume. Intranasal instillations were started on day 14 afte r first i.p. sensitization (day 0 in non i.p. sensitized models) and under light anesthesia as For each instillation, 12.5 L of a 6.66 g/mL OVA solution in PBS, or PBS alone for controls, was deposited per nostril using a micropipette. For HDM instillations, 12.5 L of PBS containing 1 g of HDM Der p 1 allergen (HDM extract, Greer In c., USA) was administered nare. 4. Genetic cell engineering T cells to induce expression and/or GFP for in vivo tracking, as appropriate. The choi ce of gene transfer vector was determined by the need of achieving expression in cells as target cells. Since activated T cells undergo very fast cel genes encoding the viral envelope and capsid proteins, and the retro-transcriptase, but preserve the n ecessary sequences for viral RNA encapsidation and for retro-transcribed DNA repeats (LTRs), the packaging signal for RNA encapsidation and the tRNA binding site. Th ese retrovectors with a multiple site containi ng a variety of restriction sites, which allows the user to insert the complementary DNA sequen ce (cDNA) encoding -lactamase) the selection of transformed bacteria, for vector DNA amplification; and a puromyci ne resistance gene that allows to select transfected cells for the preparation of packaging cell lines in eukaryotes. To produce virion particles for transfer to th e target cells, packaging cell lines expressing the env, gag and pol structural genes were generated. The separate introduction and integration of the structural genes into the pack aging cell minimizes the ces indu ce permanent expression of the gene of interest, but they cannot replicate within these cells due to the absence of viral structural genes. The retroviruses employed are RNA viruses that require targ et cells to be under active proliferation in order to transduce the cells, that is , to integrate into cell (metaphase and anaphase) to integrate the retro-transcribed viral DNA into the host DNA. This mechanism can be us ed to selectively transd uce proliferating cells within a cell population. In this retrovirus to pr infection, only cells transduced green encoding amplified sticky end primers (Table 2, primers 01 and 02) and subcloned of pMSCV between XhoI GmbH, Erlangen, Germany) using Expand High Fidelity PLUS System (Roche Diagnostics, reseponse pathophysiology of experimental asthma 2. Primers Primer Name (5\u00b4 We commercial bicistronic vector pRetroX-IRES-ZsGreen1 (Clontech) to obtain was upstream the IRES, and GFP signal. ZsGreen was not 03 04 in Table 2 (with sticky ends for XhoI). We called the resulting vector, provided MCS upstream the the site. orientation was checked by PCR (Table 2, primers an d 5' ends respectively. These expression presen t at the selected with Madrid, Spain) expanded. stored for (Gibco, use. assays performed in NIH3T3 cells of pMSCV-GFP and pRetroFOXP3-IRES-GFP Role described (see section 3 on sensitization and challenge). One week after sensitization, the mice were euthanized and the with collagenase 60 a CO 2 incubator (37\u00baC). Tissue was disrupted using a the resulting was passed through m Biosciences) and collected in non essential aminoacids (Invitrogen) -mercaptoetanol (Merck, Madrid, Spain). To stimulate antigen-specific CD4+ T cells, 40 g/mL OVA experiments) or Der p 1 (for CD4+Foxp3+ T were added as appropriate. 4.4. T cell retroviral infection After 24 hours of with the cells a spin splenocyte \u00b5g/mL polybrene (Sigma -Aldrich), at of infection (MOI, ratio of infectious viral particles to cells) of 1. The cultures were then centrifuged at 455g for 1 hour at 37\u00baC. After incubator and maintained in for 7 and then sorted by FACS to separate the GFP-expressing cells for in vivo transfer. Cell sorting was done wi th BD For this purpose, were resuspended in buffer (see CD4, Rat cells. 5. T cell adoptive transfer experiments To study the role of effector CD4+ T cells Design). The were i.v. injected in the tail of the recipients in mice (PBS-instilled, n=5) received 105 stimulated GFP+/CD4+ T (control 1). One group of OVA-challenged animals (n=5) received 105 non-transduced, non-activated T cells (c and were subsequently challenged with OVA (Figure 13). To study the role of Treg cells in experiment al asthma, two groups of mice (n=4 per group) were i.n.-challenged with HDM as depicted (S ection 2, Study Design). One group of animals Figure 13. Adoptive transfer of T cells. CTRL1 group was instilled with PBS and received 1x105 activated GFP+ T received 1x105 non-activated, non- trasduced 0.25X105; EXP 0.5x105; on day 2 after the first i.n. instillation. Animals were euthanized on day 10 after first instillation. A B Role of the effector and regulatory arms of the the tail as described for effector for mechanical ventilation Figure 15 depicts the setup for Mice valu was introduced into the FlexiVent software for automatic adjustment of total lung capacity (TLC) tidal volume. Figure 14. Adoptive instillations with HDM GFP+ Treg cells day of instillation 24, to evaluate the immunoregulatory properties of these cells 25 *: Dose D5 was administ ered in limited experiments where indicated. For induction of anaesthesia, 2% sevoflurane was first administered into a plexiglass chamber as described for i.n. instillations, and then delivered through a nasal mask, leaving the neck of the mouse exposed. Deep anaesthesia was reached by increasing sevoflurane to 3%, and silk Neuromuscular blockade and connection to the mechanical ventilator A 0.15 mL volume of 0.5 mg/mL weight-adjus ted for each individual animal) and a PEEP of 2 cm H 2O. Optimal settings for mouse mechanical ventilation are 4. Role of of adaptive immune reseponse in the pathophysiology of experimental asthma 94 mouse mechanical ventilation module of the FlexiVent is provided preset air volumes through the arm to the tracheal cannula PEEP released through the exhaut. The FlexiVent equipment comprises a computer with proprietary software (a) that controls the mechanical ventilation module (b), collects the signals pig). The animals are usually connected to the ventilator through tracheostomy, such as the mouse shown inside the orange square. The panels at the bottom show the a b c d e f The trachea is separated from surrounding tissues, and the cannula is and fixed with surgical silk. a b An incision is made in the upper third of the neck Once the cannula is fixed, the animal is quickly connected to the Figure pressure 6-7 cm H 2O Peak inspiratory About issued the FlexiVent software (FlexiVent 5.2). For data collection, tidal-volume mechanical ventilation was transiently interrupted and pressure prime R L due to airway plugging, and for overall data quality. Once the anaesthetized animal was connected to stable (this would usually take 1-2 minutes). Then a R L baseline value was averaged from a series of several prime waves. After R L baseline reading, the MCh nebulization protocol was performed starting with PBS and finishing the maximum MCh (see MCh concentrations on Table 3). For each 25 L of PBS or MCh solution was deposited into the nebulizer cup and passed through 20 seconds to the tidal volume- ventilated animal. After each nebulization was finished, prime waves and data collection were performed every 10 seconds for 3-4 minutes. A valid peak R L value was taken as the response R L to Role of the effector and regulatory arms of the corresponding MCh baseline R earlier, and significantly higher than control for the same MCh dose. To avoid artifact data due to the during ventilation, a a 300 which usually uncollapses the lung parenchyma (597). 7. Euthanasia specimen collection procedures 7.1. Euthanasia Once the lung function data collection protocol was completed, a bolus heparin (Sodium injected to avoid post-mortem blood clotting. Then, 0.3 mL of chloride to deeply anaesthetized animal. 7.2. Bronchoalveolar lavage was collected for and differential leukoc counts, and to store samples of its fluid fraction for further analysis. For this purpose, 1 mL of PBS was introduced into the lungs using a syringe connected then retrieved, which allowed for a approximate 0.7 mL fluid BAL fraction was introduced in a conic polypropylene tube (Falcon) and plunged on until fraction using PBS-filled syringe, and a collection syringe. Four mL of PBS was introduced into the lungs in 1-mL steps, and tube. The first BAL fraction was centrifuged at 458 g for 5 minutes, and The cell pellet was resuspended and pooled into the second BAL fraction, which was then centrifuged. The supernatant was discarded and the cell pellet, comprising the to tal cells from the first and second BAL fractions, was resuspended in 1 mL of PBS. From this suspension, total cell counts were done under the microscope using Neubauer (ZUZI Co rp., cells per mL, and cytocentr ifuged specimens 60 follows: Germany), for 6 minutes in the proprietary \"cytospin\"centrifuge. The slides were then allowed to dry at room temperature for 20 minutes, and were fixed in methanol (Panreac, Barcelona, Spain) for 10 minutes. After fixation, the slides were again dried at room temperature for 20 minutes, and stored for later staining. 7.3. Lungs A mid-sagittal incision was done in the abdomen through the skin, subcutaneous tissue, muscular plane, and parietal peritoneum, using a scalpel. Once the abdominal cavity was exposed, the bowels were separated to expo se the inferior vena cava and abdominal aorta on the posterior abdominal wall. Then, the diaphragm muscle was cut using blunt scissors, diaphragmatic incision, the chest to the neck tracheotomy. The abdominal cava-aorta bundle was cut and the right ventricle was punctured with a syringe and needle to perfuse the pulmonary vascular circuit with PBS before lung extraction. After perf usion, the lungs were excised in bloc the thoracic cavity, along with the can nulated tracheobronchial tree and heart. The lungs were then inflated cmH 2O connecting recirculation pump with 4% formaldehyde (Panreac) in PBS for 20 hours, for normalized quantitative morphology. After fixation, into usel tissue processor (STP 120 Spin Tissue Processor, Thermo Scientific, Madrid, Spain) over night, with a paraffin inclusion program detailed on Table 5. Once processed, the blocked in paraffin and cut with a microtome (RM2155, Leica reseponse pathophysiology experimental Skulls Heads were sectioned at cerebellomedullary cister n level to separate the skull from the spine, and the skin, eyes, brain and lower jaw were excised. The skulls were immersed in formalin and the air contained in the nose was purged by introducing formalin blunt needle. This procedure elim inated the trapped in the upper ai rway to ensure correct fixation of the nasal cavity structures (266). The skulls were fixed for 20 hours and then immersed into a decalcifying solution (SHANDON TBD-1 TM, Thermo Fisher Scientific) for 5 hours. After decalcification, frontal slices of the nasal cavity were cut with a scalpel in standardized anatomic locations, according to the (266) and later adapted for mice by Farraj et al. (263). We processed the samples as per Farraj with minor modifications. A proximal cut was done behind the incisisor t eeth, middle cut at the first palatal ridge, and distal cut at the 3rd palatal ridge (Figure 16). METHODS 99 8. nucleic for was first defrosted at room temperature for 30 minutes and introduced into acid alcohol (37% hydrochloric acid in 96\u00ba ethanol, Panreac). They were then staine d with Wright solution (Gurr\u00ae, VWR, Barcelona, Spain) for 10 Figure 16. Nasal cavity in mouse. We analyzed the at three frontal sections: proximal at incisisor teeth level, middle at first palatal ridge, and distal at third palatal ridge. Role of the effector and regulatory arms of the adaptive immune reseponse in the pathophysiology of experimental asthma 100 minutes and washed with distilled water until a cha nge in color was appreciated. After filtration to discard precipitates, the samples were stained with commercial Giemsa solution (Merck) for 30 minutes, and then differentiated into glacial acetic acid (Panreac) to get a regular samples were passed through using FelxiVent ventilator total and/or differentia l cell counts. Upper oxylin It is basic or cationic and therefore is used to to remain in the and must be combined with metallic ions (iron salts or aluminum) an acidic fluores cein derivative that pink used to stain basic cellu lar components, by placing them into heater at 60\u00baC for minutes immediately with HCl (Merck); the iron contained in tap water favo urs haematoxylin fixation to the were immersed into for 5 minutes and then washed several times in tap water to attenuate the excess colorant. The samples were then immersed into an eosin solution (see appendix) for 5 minutes and then dehydrated immunofluorescence for a-sma (D) GFP and Il10 mRNA. Scale B, C 50 \u00b5m; D, 100 \u00b5m; E, 10 \u00b5m; and F, 25 \u00b5m. Role of the effector and regulatory arms of the adaptive immune reseponse experimental asthma acid-Schiff (PAS) Mucopolysaccharides are the main components rich staining technique is based on its ability to break the links of the hexose ring and expose aldehyde groups, which are then bound by the Schiff reactive. This reactive is a fuchsine derivate that produces acid, colorless that becomes purple-violet when it binds the and rehydr ated as described, except for the use of tap water. The samples were then immersed in peri odic acid solution (see appendix) for 10 minutes, washed in tap water, and placed in Schiff reactive (M erck) in the dark for 30 minutes. After that, the slides were immersed in sodium bisulfite (Sig ma-Aldrich) for 10 minutes, and washed with tap water again. The sections were then placed in Ha rrys' haematoxylin for 10 minutes and washed in tap water. Finally, the samples is to provide resistance and physical su pport to tissue structures. There are several types of collagen, being I and IV the types mostly found in subep ithelial fibrosis technique slides were then immersed in ferric aluminum aqueous solution (Merck) washing the slides in tap then stained with Weigert's ferric haematoxylin (Sigma-Aldrich) for minutes again in tap water until getting a dark- grey tissue color. Next step was incubation in picr ic acid (Panreac) for about 6 minutes (time varied on incubation, the slides were washed in tap water un til they became yellow, a co lor shift attributed to the picric acid. The samples were then i mmersed in Ponceau's fuchsine (Certistain\u00ae, Merck) for 8 minutes and washed twice with 1% phosphomolybdic acid (Merck) solution in distilled water for 5 minutes. Collagen was then stained with with aniline blue (Merck) for 12 minutes. The slides were finally washed several 0.2 % Triton X-100 (Sigma-Aldrich) in PBS for 20 minutes and then blocked with a universal blocking solution (Image-iTTM Signal Enhancer; Molecular Probes, Invitrogen) for 30 minutes with the aim as detection system as per manufacturer's instructions, in PBS with 20% goat serum (Vector Labs, Peterborough, UK) and 0,1% Tween-20 (Sigma-Aldrich) as diluent. Nuclear counterstaining was Molecular Probes, Invitrogen). were then appropriate for flow cytometry, is phosphatase complex, and development Vector Red chromogen (all from Vector Labs). Cell nuclei were counterstained with green solution R NA strands, complementary to a specific DNA or RNA squence to be localized in tissue sections. In this work, FISH was performed lung reseponse pathophysiology of experimental asthma 104 Table 6. Probes for FISH Probe Name Sequence the theoretical fo Information resources (available on-line at www.ncbi.nlm.nih.gov) and TIB (598). No other mRNA homologues were found in mouse or rat using a Basic Local Alignment Search Tool (BLAST software, provided METHODS 105 online by the National Institutes of Health, USA) . One, two and three probes, complementary to was used as a positive control (Table 6, probe 11) and probes without an annealing sequence were used as negative controls (Table 6, probes 18 - 26). 8.7.2. Fluorescence in situ hybridization protocol Lung sections of ethanol minute and dried at 37\u00ba C for 10 minutes. Proteina se K (Enzo Life Sciemces, Farmingdale, USA) pretreatment was applied at 1:30 dilution for 15 min at 37\u00ba C, and the slides were then washed twice with using gentle PBS. Afte r acetylation treatment, the tissues dehydrated from water through 50\u00ba, 70\u00ba and 100\u00ba ethanol (1 min each), and then allowed to dry at room temperature for 10 min. The samples were then prehybridized with hy bridization buffer (Enzo Life Science) at 37\u00ba C for 20 min and then washed in preheated PBS. The specimens were then immediately hybridization (Sigma-Aldrich) and were incubated at 37\u00ba C for hour. After the hybridization min, twice with PBS at room temperature. For the detection step, a permeabilizing treatment using 0.2% Triton (Sigma-Aldrich) in PBS for 20 min was applied, followed by two PBS washes (5 min each). A bovine albumin (Sigma-Aldrich) goat anti-biotin (Sigma- incubation, the slides were twice in PBS at room temper ature and incubated for 30 min with donkey anti- sheep and anti-goat fluorescently-labeled second ary antibodies (Alexa 647 and 594 respectively, Invitrogen) at 5 g/L, in 5% mouse serum (Sigma-Aldrich) and 0,2% Tween-20 in PBS. Two PBS washes were done at room temperature followed by a with DAPI (1:300). The samples were then washed three times in PBS, fixed in 4% paraformaldehyde solution (Sigma) for 15 min and mounted with ProLong\u00ae Gold mounting media (Molecular Probes, Invitrogen). reseponse biopsies a following groups of subjects: (i) severe (n=29); bronchial or investigation of hemoptysis; n=5). The protocol was approved by the Ethics Review Board of the Vicente Plaza Moral and Dr. Alfons Torrego Fern\u00e1ndez (Hospital de la Santa Creu i Sant Pau, Barcelona); Dr. Carlos Mart\u00ednez Rivera (Hospital Universitario Germans Trias i Pujol, Badalona-Barcelona); Dr. Antol\u00edn L\u00f3pez Vi\u00f1a (Hospital Universitario Puerta de Hierro, Madrid); Dr. Santiago Bardag\u00ed Fons (Hospital de Matar\u00f3, Matar\u00f3-Barcelona); Dr. Francisco Javier Gonz\u00e1lez Barcala (Complexo Hospitalario de Pontevedra, Pontevedra); Dra. Teresa Baz\u00fas Gon z\u00e1lez (Hospital Universitario Central de Asturias, Oviedo); Dr. Patrick Berger (Universit\u00e9 Bordeaux 2, Burdeos, France); and Dr. James G. Martin (McGill University, Montreal, Canada). The biopsi es were fixed in 4% formaldehyde DAB st aining kit (all from for detection. The tissue fluorescence microscope Tokyo, sampling unts surface matrix and membrane in the upper airway were based on prior methods (263, 266). Nasal samples in OVA-challenged mice and controls were examined to determine the area most sensitive to changes in the amount of PAS-positive epithelial substances, which nasal cavity, whereas no differences were observed in the middle and distal nasal sections. Within the proximal nasal section, the main differences were found in the mid septum, maxiloturbinates, and do rsal wall, which were the areas consequently selected for quantitative data acquisition from PAS color extraction. Eosinophils and PAS + cells were counted through the entire length of the the Cell counts (eosinophils quantitative morphology was with AnalySISD\u00a9 (Soft Imaging System, Olympus) and ImageJ (v.1.43m, National In stitutes of Health, USA) software. The images acquired from micrometric ruler slide (Leica Microsystems). A digital scroll tablet (Trust, Dordrecht, Holland) was used to outline the basement membrane for its measurement in intrapulmonary airways and upper airway sections, and to define regions of interest and boundaries 10. Statistical analysis was performed using SPSS (version 16.0) software, and graphics were gererated using SigmaPlot (version 2000). Data are presented as mean standard error of the mean (SEM) otherwise specified. Group comparis ons of Role of effector and arms of the adaptive Dunnett test (multiple ays after antigen challenge, and airway remodeling upon the to the airways, (IP model) w ith primary allergen in the and with hyperresponsiveness, cantly increased R L (p<0,05 versus control group) on the 2.5, 5 and 10 mg/mL MCh doses (Figure 19-C and Table S1 the 10IN model, where the time span from the first exposure of the immune system to the allergen was similar to the IP model, the OVA- challenged animals developed and attenuated analyzed the 3IN and 30IN models. In the 3IN model, the R L curve of the OVA- challenged animals largely Table S1 in appendix). In the R L curve was flattened in closeness to th e reached L response tested completion ols. animals ( B) a bordelline model, as established were significantly increased after the OVA instillations in all models, with a progressive ramp in the models. Differential distribution strongly IP mode l, lymphocytes were the predominant infiltrating population in the IN models. In these OVA-challenged animals showed an P<0.01 their P<0.05 3IN and 10IN control groups. consistent trend with airway hyperresponsiveness in the lung but not in the upper airway. Total BAL cell counts were significantly increas ed in the OVA-challenged mice in all models, with a progressive gradient in the IN models (Figure 20-A). Among the control groups, a small but significant increase was observed in the numbers in the OVA-challenged animals showed a trend consistent with the airway responsiveness da ta. In the IP model, the OVA-challenged animals showed strong eosinophilic inflammation in the showed attenuated eo conversely, increased lymphocytic infiltration in the BAL, compared with IP model. In lung tissue sections, the OVA-challenged anim als showed the airway inflam mation in the 3IN model, as were control animals in all models (Figure 21). Eosinophil numbers in th e showed a consistent OVA-challenged model, where it reached an intensity similar to the IP model (Figure 22 and Table S5 in appendix). Control animals showed a baseline presence of eosinophils in the nose, in a ll models, where the 10IN control group showed a higher presence of eosinophils compared with the co groups mucoid response in the upper and lower airways. With the aim of studying the muco id secretory response and goblet rhinitis, PAS techniqu e. The number of PAS+ cells and the load in the respiratory epithelium were quantitatively assessed the upper and a airways, with the highest values a ttained in the IP model (Figure 23 and tables S6 and S7 in appendix). In the IN models, the 3IN OVA animals showed an early increase, limited but RESULTS 115 B C D E Figure 21. Lung inflammatory infiltrates. Tissue sections were stained with e airways, similarly to the control groups in all models. In the 10IN model, the insets. A Intranasal vs. intraperitoneal sensitization variables. increased mucous the 10IN model, although attenuated in comparison with the IP model, and declined in the 30IN model. Regarding the nasal cavity and as stated in the methods section, we found that the proximal zone, particularly the septum, was the most sensitive area to changes induced by allergen challenge. All OVA exposed groups showed a significant mucoid response in this area of stage in the 3IN model, showing a greater response than in the lungs. All control groups showed basal mucous mice in the 3IN model ( B). The OVA-challenged groups in the ( E) or versus the OVA challenged group in the IP model. *: P<0.01 versus CTRL. P<0.05 versus 3IN and 30IN control groups. Scale bars: 50 m. A B C D E RESULTS 117 1.4. Subepithelial collagen deposition and allergen ex posure in the and S10 in appendix). In the IN models, the extracellular matrix mass peaked in the 10IN OVA-challenged Figure 23. staining in lung sections. Lung were stained load. 3IN (B), ( C) and 30IN load (mucoid mass) ( comparable lungs, while OVA- strong The 3IN showed a that in the model, and declined in 30IN *: 30IN. bars: D F B C Intranasal vs. intraperitoneal sensitization model 118 animals, and was significantly increased in bo th the 10IN and 30IN models. There were no significant increases in the IP nor 3IN OVA-challenged OVA-challenged animals showed increased amounts of both goblet cells the IP ( ( D) all other OVA-challenged groups. Scale bars: 100 m. BC D E F G A RESULTS 119 Airway contractile tissue mass was quantified on the basis of -SMA immunofluorescence and digital signal extraction and processing (Figure 26). No differences between controls and OVA- challenged animals were found in the 3IN and 10IN models. The airway contractile tissue mass showed its greatest increase in the OVA-challenged animals of the IP model, and was weakly but significantly increas ed in stained blue, ECM masss was calculated from digital color extraction. OVA-challenged animals in the IP ( A) and B) models showed challenged animals of the 10IN and 30IN models D). *: P<0.01 versus controls (CTRL). Scale bars: 100 m. A B C D E Intranasal vs. intraperitoneal sensitization model 120 Figure 26. Alpha- contractile a significant contractile tissue mass (M CT) versus control (CTRL) in the IP model ( A, E). Increased M CT was absent in the 3IN ( B) 10IN ( C) models, and was but significant in 30IN model bars: 100 m in A, B and D; 200 m in C. A B C D E RESULTS 121 bu t not in the IP model. Due to failure to detect FOXP3 protein by immunohistochemistry analyzed mRNA by FISH, the were the inflammatory and Table S12 in appendix). The the 3IN model, devoid of inflammatory infiltrates, were taken as controls for this purpose. The OVA-challenged animals in the IP model showed the greatest numbers of Foxp3 mRNA+ lymphocytes. In the IN models, there was a progressive increase in Foxp3 -transcribing cells that became significant in the 30IN group, but this maximum was 20.3% the IP model mean. Il10 and Tgfb mRNA-expressing cells were significantly increased through a joint gradient in the IN models, from the 3IN to the 30IN animals. The IP animals vs. intraperitoneal model 122 A B C D E F GHFigure 27. FISH in lung tissue for Foxp3 the inflammatory infiltrates in the OVA challenged animals of the IP model ( A, E). In the IP models, Foxp3+ cells increased progressively to reach significant but limited numbers the (B, ). For co-localized cytokine bars: m in A, B; 5 m in C, D; 2.5 m in F-H. RESULTS 123 2. Role of and in ex perimental effector regulatory play in it. models may by- pass T cell-driven regulatory asthma allergen exposure occurs in the airways. The results from models presented here show that primary, sustained antigen exposure in leads to an overall attenuation of asthma features and to a shift we aimed at demonstrating of effector this purpose, we performed T cell experiments in ex perimental asthma with sole antigen exposure in the airways. 2.1. Generation of an tigen-specific CD4+T cells To study the role of the effector T cells in experimental asthma we for subsequent tracking in obtain with forced GFP expression, gfp c commercial pMSCV asthma features. models 124 2.2. Adoptive T non- cells and were 0.5x105 OVA-specific cells did amplified from pAcGFP vector by PCR ( C, column G, 742 bp band) using XhoI and vector ( A and C, column X, 6295 band). To verify correct assembly, the the gfp insert ( D, column M, blue arrow, 742 bp band) from the plasmid ( D, column M, red arrow, 6283 bp band). Vector drafts were designed using the total animals with adoptiv e transfer of non- activated T cells versus the PBS- instilled group with adoptive transfer of activated a significant increase in total BAL leukocytes versus both control groups. No significant increase in total BAL cells was observed subepithelial Figure transfer of antige n-specific T cells. Three experimental groups we re respectively transfered 0.25, 0.5 or 1 x 105 GFP+ effector T cells (T eff), and were OVA-challenged. These groups were compared with two control groups: recipients of effector T cells, (control 1); and recipients of naive T cells, OVA-instilled (control 2). Only the group that received 1 x 105 specific GFP+ T cells showed R L increase on maximum MCh dose. *: P < 0.05 versus controls 1 and 2. Figure 30. BAL cell counts after adoptive transfer counts were in recipients of effector T cells (Teff) or naive T cells (N/A T cells), challenged with OVA or PBS, as indicated. *: P<0.05 versus control group 1 (recipients of 1x105 effector T cells, PBS-instilled); : P<0.05 versus of 1x105 naive T cells, OVA- challenged). 126 2.3. Generation of antige Treg cells To study the role of antigen-specifc Treg cells in a mouse disease, we tracking the animals. For this purpos es we used a bicistronic vector with two open reading frames separated by an IRES sequence, with one common promoter that drives co-expression of the two subcloned cDNAs. Due to our use of a construct that we term pRetroX-IRES-GFP A B C E Figure 31. Histopathological analysis of lung tissue sections, adop tive cell transfer experiments. Four-m lung stained w that received 105 non-activated T cells ( B), showed no inflammation or OVA i.n. instillations, respectively. The predominant leukocytes present in the were alveolar macrophages ( A and B insets). Animals that were recipients of of 2.5 x 104 (C), 5.0 x 104 (D) or 1 x 105 (E) activated, GFP expressing, T we checked GFP expression in Recipients of 0.25 x 105, 0.5 x 105 and 1 x 105 activated GFP+ T cells, OVA-challenged, respectively. The GFP signal is seen as a red cytoplasmic signal. A progressive presence of GFP+ in insets). Scale 500 m in main panels, 20 m in insets. A B C D E Adoptive transfer models 128 To generate Treg cells, primers X hoI sticky ends ( C, red arrow, 5252 bp band). using XhoI sticky end primers ( D, red arrow, 1855 bp band) and subcloned into the XhoI site . The resulting pRetroX-IRES-GFP vector ClaI sticky ( E, F, 1290 bp) and subcloned into pRetroX-IRES-GFP MCS. To Foxp3 insert ( F, blue arrow, 1290 bp band) from the plasmid (F, red arrow, 7107 bp of NIH3T3 cells after transduction with pRetroFOXP3-IRES-GFP viruses (sec ond and third gel columns). In the first column, a non-transduced pool of NIH3T3 cells was run. Al pha-tubulin was used as a positive control for all cellular flow cytometry histograms, blue tran sduced populations. B C DA experimental asthma model. To test the effect of Treg on ongoing di sease, we conducted p ilot adoptive transfer experiments experimental asthma induced by primary HDM exposure received i.n. HDM instillations under the same and the 30IN model. Upon HDM scatter of in R1 region, consistent with a FSC/SSC profile of activated were CD25+ (C) and, among cells there 5 and 10-mg/mL MCh doses, compared with the PBS-instilled animals of the 30IN model (n=10), which acted as a control group (figura 36 and Table S15 appendix). The day 31 of the i.n. instillation protocol and continued the protocol up to completion on day 37 (28 HDM instillations). These animals mass reduction was found versus the HDM-challenged animals that did not receive Treg cells (Figure 37 Table Treg instilled animals, in comparison with PBS-instilled animals (control group of the 30IN HDM- instilled animals that received of subjects with severe asthma. FOXP3+ were in from subjects and Tables inflammatory infiltrates. Figure 37. Airway contractile tissue mass CT) in adoptive transfer model. Animals instilled with ( increase in M CT compared with the control animals of the 30IN model (C) *: P<0.01 versus the PBS challenged group of the 30IN model. Scale bars: 100 m. BRESULTS 133 or the m in A, B; 200 m in C, D; 20 m in insets. A Bronchial biopsies 134 B C D E A F Figura 39. FOXP3+cells in human bronchial biopsies. Four-m to The tonsil was used where versus up (CTRL). Scale bars: 200 in ( A); 100 ( B, C); 50 m in ( D); 2.5 ( RESULTS 135 139 Animal the study of biological disease mechanisms patients can explored using experimental models, and the data from such models can often be translated to the human setting. Animal models play as well a crucial role in the preclinical development of new drugs by the ph armaceutical industry. There is a variety of publications in the literature where different animal species have been used to model asthma (55, 117, 133, 154, 164, 204, 208, 600). The animal most often employed is the mouse, due to its low cost and easy handling, but also due to the similarities seen between murine experimental asthma and actual human asthma. In fact, it is possible to reproduce human and is a cardinal human asthma feature (149, 160, 601, 602). However, animal models have limitations to be considered when interpreting the data in the human disease translation context. In most studies reported on animal the experimental disease was induced by allergic work the of prior subcutaneous or i.p. sensitization, to better both this purpose, the animals were airway-exposed to antigen or control through continued protocols, without a tween a sensitization and secondary exposure. Because OVA generally used as an allergen to model asthma in animals (55, 133, 164, 200-202, 263, 603-607), and with the purpose airway antigen to a classical i.p.-sensitization model (600), we adhered to the use of OVA in our i.n. Role of the effector and regulatory arms of reseponse despite the limitation and certain OVA actual human by i.n. in and ar e deposited into the lungs (151, 200). Other approaches for airway allergen exposure have been less used and present methods are controversial as a repeated procedure on the same animal due to the invasive intervention required. Another approach is the exposure of awake animals to allergen nebulized into a chamber, which results in poor deposition in the airways and facilita tes allergen exposure, partly indirectly tolerance. In fact, the inhalation of aerosolized OVA in an exposure chamber has been used as a model of antigen tolerance induction after primary exposure in the A/ J mouse (263). In order to profile the timeline of the immune response and associated the providing a minimum or no-response reference, within response l developed. It is widely accepted that the time elapsed from the first contact of the immune system with an immunizing antigen to the attainment of a primary adaptive is about 7 days (611). Therefore, response if any observed in the 3IN model be to immune system. The 10IN model cutoff was chosen as the time point where the time elapsed from the first contact with the antigen was equivalent to the time span of the comparator model, the IP model, from the first i.p. injection for sensitization to the last i.n. challenge. Finally, the results obtained in the in 10IN model led us to develop the 30IN model, to chose in vivo lung output airway hyperresponsiveness, as the primary outcome the experimental disease through 10IN muscle contraction, which in turn increases R L. In animals with experimental asthma, R L increases significantly through progressive MCh doses in comparison with control animals. Testing R L responsiveness to MCh under mechanical ventilation in experimantal animals serves spirometric of airway hyperresponsiveness in humans. In the experiments presented in this thesis, the OVA-challenged animals of the IP model showed a steep, significant R L increase versus the control i.e. frank airway hyperresponsiveness, consistent with the established features of this immunization-driven In the 3IN model, L response profile of the OVA-challenged mice closely followed that control group, the absence of an reduced R L increases in comparis on with the frank hyperresponsiveness seen in the IP model. The RL response was in this case limited to borderline statistical significance versus the control group. Thus we interpreted this result as an attenuation \"natural\" exposure airway inflammation and hyperresponsiveness, and were bypassed in the classical IP model. In view of the 10IN model data, we enquired was tested in the 30IN model where, conversely, the R L response in the OVA-challenged animals declined and closely approached the control group 3IN model. In summary, primary allergen exposure in nsiveness intra-group baseline R of lung tissue sections to determine the numbers of eosinophils the airway wall. All OVA-challenged groups had BAL total cell counts versus their re spective control groups. Control groups were homogeneous across the IP, 3IN and 10IN models, whereas control groups showed a modest but significant in total BAL cells, group was due to lymphocyte influx, as show n by the differential counts. Alth ough without an im pact on total BAL cells, the control group of the IP model show ed increased eosinophils compared with the IN control groups, attributable to background systemic Th2 activity. The nsistent and arms of the adaptive immune reseponse in the pathophysiology of experimental asthma in the BAL differential counts infiltration in the OVA-challenged animals, with a trend paralleling the R L response, best reflected in the airway wa ll counts as per quantitative morphology. It is noteworthy that the model showed a limited bu eosinophil response in the 3IN model (612). Contrary to the eosinophilic IN models in the ai L differential counts consistently observed on examination of lu sections. In su mmary, prim ary antigen exposure their spective groups. In the 3IN model, the OVA-challenged group showed a consid changes of in asthma and allergic rhinitis, 51, 54, 60, 613-615). The that induce these changes in asthma are understood, animal in OVA-challenged in the model suggest that this early response, which occurred ahead the necessary time to mount an adaptive may the process of induced goblet cell hyperplasia and increased mucoid mass, the greater the longer exposure in the IN models. The nasal septum region was the most sensitive to such changes. Overall, the data suggest that the idea that links the innate immune system with the early induction of one of the components of airway remodeling, as the overall a progressive upper airway the intrapulmonary is Conversely, there was no significant increase in the IP and 3IN models. In both cases, th e absence of subepithelial fibrosis is attributable to the short airway antigen exposur e, particularly in the IP model. Since of sensitized animals led to increased collagen depo sition in a prior IP model (600), the data suggest that subepithelial fibrosis is associated with chronicity and may be driven by the adaptive immune response. airway and hypertrophy, is considered central mechan ism of airway hyperresponsiveness and disease of the layer is the airway remodeling feature on which most attention has been focused, and for which the largest data body has been generated. Mechanisms proposed for the growth of airway smooth asthma include: (i) in situ proliferation, least in part induced by the proximity of mastocytes (62) or by direct T cell contact (133, 561); (ii) the migration and differentiation of fibroblasts or dedifferentiated muscle of a airway smooth muscle cells have the capacity to switch between a contractile and a secretory pheno and and granulocyte macrophage In work, we analysed airway smooth muscle remodeling in respons e to primary airway alle rgen exposure in the IN models, versus the IP model. We employed -SMA detection, the most extensively excellent performance on virtually any type of including an immune reseponse in the pathophysiology of experimental asthma 144 was coined (595) to refer to -SMA-based The analysis of airway contractile tissue mass in the IP model demonstrated a large increments of airway contractile tissue mass regardless the shortness of airway challenge period, whereas the IN models showed attenuated growth that reached statistical significance in the 30IN model only. In these models, there was therefore a dissociation between the trend of airway hyperresponsiveness and that of the airway contractile tissue growth. Another objective in the series of experiments presented here was to study an integrated rhinitis and asthma model. In human disease there is strong evidence for a connection between rhinitis and asthma. Allergic rhinitis is in fact considered factor asthma, and vice versa (622- 624). This y and in the immune responses. However, there are few or no works that have integrated the study of the upper and lower airways within the same experimental disease mode l. The establishment of an integrated model as described here may provide a useful tool for the study of the mechanisms of allergic sensitization and immune regulation, as the of new therapeutic preventive study the cavity and paranasal sinuses, of which only the nasal mucosa was sensitive to changes, particularly in the septal region. The OVA-exposed IP model showed strong eosinophilic inflammatory infiltration. In the IN m odels, was a gradient of eosinoph il infiltration from non-significant in the 3IN model to maximum in the 30IN model. Therefore, the of measure of allergic rhinitis in this increasing sharply eosinophilic inflammation and mucus load in the lungs, which were downregulated after plateauing in the lung. Interestingly, the nasal mucosa showed a baseline presence of eosinoph ils in all control groups, not seen in the intrapulmonary airways. Such eosinophil baseline fl uctuated and peaked at the 10IN control group, to return to bottom line in the 30IN model. Although there is no direct explanation for this, we speculate that the baseline presence of eosinophils in the nasal mucosa is relevant to its DISCUSSION 145 physiological functions, and is responsive to non-specific stimuli in a fashion. intense sampling of antigens and non-protein chemicals, and our data support that core immune system decisions on responsiveness or tolerance may occur at this level. The differences seen between the IP and IN models also strengthen the idea that the primary site of plays a into a body cavity definitely escapes immunoregulatory pathways that reside in the mucosal systems, yet the arising from primary exposure regionally regulated. The latter data by the different response patterns elicited in the nasal mucosa versus intrapulmonary airways, in the IN models. The 3IN, 10IN and 30IN model series may be interpreted y where data are therefore consiste nt with the epidemiologi cal association between allergic rhinitis and asthma, yet challenge the simplis tic theory that encloses both disorders together under the \"one airway, one disease\" concept (238, 241). The relationship between both disorders is in fact subjected to a variability the whole tract, with airways to attenuate experimental asthma in th e IN models, and the time sequence of the events observed, we hypothesized an involvement of Treg cells. We ongoing description, and absence marker or panel of markers such IL10 and TGFB cytokines, as best defined markers (397, 411, 433, 482) suitable for in situ detection on fixed Foxp3 , Il10 and Tgfb m R N A b y F I S H a n d w e l i m i t ed the technique to the OVA- challenged groups of the four models. The 3IN OVA group, devoid of signs of an established Role of the effector and regulatory arms of comparator 10IN and 30IN OVA groups, and we analyzed the presence of transcri pts in the lymphoid cells of the inflammatory infiltrates. We found that, in the lungs of the IN models, the numbers of and Tgfb features declined. That is, there was a progressive presence of lymphoid cells with signs of Treg activity that correlated with the development of a tolerant state. Interestingly, the OVA animals of the IP model, which showed the strongest airway hyperresponsiveness and Tgfb transcription. This suggests that, in the OVA animals of the IP model, there is a reactive induction of Foxp3+ cells although most of them may not be functional. a post-transcriptional impairment of FOXP3 translation features as in the IN models, remain open questions. In summary, the data from the IN model series versus the IP model show that primary antigen exposure in the airways asthma suggests the establishment of a immunoregulatory setting in the lungs. The diverging findings in the IP model suggest that the interaction of the antigen with the airway mucosa is essential for the development of an effective immunoregulatory arm. The activation of Treg cells may be driven by signals of the innate immune system and the effector arm of the adaptive immune response and, in the case of i.p. sensitization, failure to mount effective immune versus that, may both es overall immune response may be subjected to differential regulation in the nose and the lungs. The data are consistent with a biological basis for the epidemiological be an invalid on experimental asthma by primary antigen exposure in the airways are consistent with the presence of an immunoregulatory arm, operated by Treg subpopulations other than the effector arm the be necessary and sufficie and remodeling (133). To demonstrate that FOXP3-expressing may drive immune regulation in an experimental asthma setting, versus the induction asthma features by effector CD4+ T cells, we performed two series of adoptive transfer experiment s. In the first of such series, antigen-specific effector CD4+ T previously rat Coupling T activation cycle as a result of activation by antigen in the presence of antigen-presenting cells, and oncoretrovirus-derived gene transfer vectors can only transduce cells undergoing proliferation (625). This principle a to select effector, antigen-specific CD4+ T cells for adoptive transfer in the rat, on the basis of GFP gene transduction and subsequent cytometric sorting of cells In the experiments presented here, we aimed at titrating the mini mum necessary of were i.n.-challenged three times only within a short time window after cell transfer, to prevent any overlap of a host no effect on R L, eosinophil recruitment to the airways could be appreciated starting at 2.5 104 cell transfer, and the transferred cells could be tracked to the airways on the basis of cells, some of the cells are able to migrate to the airways upon antigen challenge and airway inflammation. It is unlikely readily observed presence in the lungs of such few transfer red cells is the result of random distribution in the entire organism. The data rather conditions, since T cells are a difficult-to-transduce population and the generation of autologous, viable engineered cells may not be feasible in large num bers. Our data suggest that quite limited numbers of engineered cells may successfully the diseas ed organ and induce clinically relevant effects. In the second series of adoptive transfer experiments we aimed at testing the effect of reseponse showed th in induction of tolerance during sensitization or prior to airway challenge on sensitized animals (592-594), but did not test to revert presented here are from asthma was first induced through animals instillations orne allergen, already tested in previous reports (596, 626, 627). Due to the exploratory nature of these pilot experiments, and in keeping with the \"3R\" principle Reduction, Refinement) we employed the PBS-instilled group of the 30IN model as a by others (192), at a time point where OVA-challenged animals showed a decline of experimental asthma features in the IN experiment series. Variability due to the molecular structure of each particular allergen, which may determine fact recognition receptors (630), may have contributed to the lack of data consistency between OVA and HDM as experimental inhaled allergens. The of such mismatch is nevertheless unclear in the absence of a line data set for HDM exposure, to demonstrate the CD4+ effector T cells, employing for this purpose a gene transfer vector encoding Foxp3 gfp. functional Treg cells (411). It is noteworthy that cells generated through this process are pecific. exploratory Treg cell transf to a modest reduction of the inflammatory infiltrates seen on tissue secti ons, without achieving impact by GFP detection. The soundness of the experiments may have been limited by the small group size, and an insufficiently strong experimental intervention. Viable the suggests if These adoptive experi 30IN model series were at least in part driven by the increasing numbers of mucosal be to human disease and asth ma field, data on Treg cell populations are limited blood in control subjects (633-635) and, in BAL fluid, Treg cells have been found to be either decreased no direct data have been contribu ted for asthma, but a report showing that Treg cells from peripheral of the studies on the role of Treg cells in asthma, evidence from direct lung sampling is lacking almost completely. Two studies on Treg a sampling procedure not necessarily representing the status of the airway wall, yielded inconsistent data (588, 636), and no work has been reported on tissue specimens. The difficulty and fo explain the lack of direct Treg cell data in the airway wall. To contribute data filling this gap, and to specialized biopsy for asthma research, that we have developed. We found that FOXP3 + cells were virtually data from the Role of the effector and regulatory arms of the adaptive immune reseponse in the pathophysiology of experimental asthma 150 animal models. Our experimental and clinical data ma y together turn the faulty Treg hypothesis into the possibility that competent or not remains unknown at this point. The failure to physiologically may play a physiological role in bridging the a of increased TGFB production. Classical the disease. Our findings on Foxp3 -expressing cells in the IN that mucosal contact during provide the joint analysis of effector and immunoregulatory pathways, and a closer representation of the overall immune response in human regulation, and highlights the importance of analyzing the upper and lower airways. Finally, our analysis on FOXP3-expressing cells on human bronchial biopsies suggests that, consistently experimental the nose and intrapulmonary airways, w ithin an early time window insufficient for the development of adaptive posure experimental asthma features, the progression of subepithelial fibrosis and the shift predominantly lymphocytic inf iltrates concomintant Scarce numbers of such cells are able to migrate to the airways in hyperresponsiveness on of such cells are able migrate airways and ammation and asthma. Mutat of J R Coll 1988;22:36-44. 3. Saavedra-Delgado AM, and Cohen SG. Huang-Ti, Yellow Emperor and & Company, 1882. 5. Osler W. The Principles and Practice of Medicine . 1st. New York: D. Appleton and Company, 1892. 6. Brodie MD, and Dixon TG. The pathology of asthma . Transactions of the Pathological of 1903;liv:17. Cooke RA, and Vander A. Huma Res and Krishnaswamy release of mediators of immediate hypersensitivity from human lung tissue. Fed Proc 1974;33:2256-62. 13. Durham SR, Lee TH, Cromwell O, Hamid Q, Ying S, Tsicopoulos A, Barkans J, Bentley SH, Seo JY, Choi DC, Yoon HJ, Cho YJ, Min KU et J, and Isogai S. Bronchial subepithelial SM, Lordan JL. s J, Del Mastro RG, Fa lls K, Simon J et al. Association of the ADAM33 gene with asthma and bronchial hy immunogenetics asthma and eczema: a new focus on the epithelium. Nat Rev Immunol 2004;4:978-88. 22. Cookson W, and Moffatt M. Making sense genes. Engl Hammad H. Bi ology the origin of asthma. Immunity 2009;31:412-24. 24. Masoli M, Fabian D, Holt S, and Beasley R. Th e global burden of asthma: M, and Vignola AM. As thma. From bronchoconstriction to airways inflammation and remodeling. Am J Respir Crit Care Med remode ling in asthma. Allergol Int 2007;56:341-8. 28. Plaza V, and Rodrigo GR. Asma Aguda. Madrid: Ergon, 2007. 29. Braman SS. The burden Chest DP, SK al. - a global perspective. 2007;62:213-5. 32. Ramos-Barbon D. Asma. Ar ch PJ. of asthma immune reseponse in pathophysiology of experimental asthma S, Hernandez GG, Guillen- Grima F, Diaz et and III) in 2004;59:1301-7. 36. y Eur Respir European lung Resp Society \u00bfPodemos Arch Bronconeumol 2005;41:3-9. 39. Bumbacea D, Campbell D, Nguyen L, Carr D, Barnes PJ, Robinson D et al. Parameters associated with persistent Care Med 41. Ordonez 42. Polosa MT, Tuck AB, et and r sheath Respir Cell Nakamura Y, Tate L, Ertl RF, Kawamoto M, Mio T, regulate fibroblast proliferation. Am J Physiol 1995;269:L377-87. 47. Carroll N, Elliot J, Morton A, and James A. The structure of large and small airways in nonfatal and fatal asthma. Am Rev Respir Dis 1993;147:405-10. 48. Cluroe A, Holloway Trounce JR. A clini cal and pathological study of fatal cases of status asthmaticus. Thorax 1953;8:207-13. 52. Saetta M, Di Am Mol Biol DA, Huang X, Koth LL, Chang GH, Dolganov GM, Zhu Z et al. Direct effects of interleukin- 13 on epithelial cells cause airway and mucus overproduction in Subepithelial fibrosis in the bronchi of asthmatics. Lancet 1989;1:520-4. 57. Herrero T. Remodelaci\u00f3n de la v\u00eda a\u00e9rea en el asma Fisiopaolog\u00eda de l matriz extracelular y funci\u00f3n de los glicosaminoglicanos. Archivos de Alergia e Inmunolog\u00eda Cl\u00ednica 2001;32. 58. Epithelial A, Riccio A, Pellegrino R, Ca nonica GW et al. On the functional Dis 61. P, and Hamid Q. Role N Engl J Med 2002;346:1699-705. 63. Ebina M, Takahashi T, Chiba T, and Motomiya 1993;148:720-6. 64. JL. Asthma--more muscle cells? Am Crit Care Med 2004;169:980- Madison JM. Migration ai rway cells. Am Cell Mol Biol 2003;29:8-11. 66. Ma X, Cheng Z, Kong H, Wang Y, Unruh H, Stephens NL et al. Cha nges in Hays OD J Care 2004;169:1001-6. 68. LW. Al ergia. 2\u00aa Madrid: El 1999;14:63-73. 71. Holgate ST, Yang Y, Haitchi HM, Powell RM, Hollowa y JW, Yoshisue H et al. The genetics of ADAM33 an example of Haitchi HM, Nichol as B, Yoshisue H et al. The soluble form reaginic with an gamma A- or J Allergy 1966;37:169-85. 75. Kosako H, Yoshida T, Matsumur a F, Ishizaki T, Narumiya S, and Inagaki M. Rho-kinase/ROCK is involved in cytokinesis through the phosphorylation of myosin proteins at cleavage furrow. Oncogene 2000;19:6059-64. nd exercise and muscle as a target asthma history new directions. Respir Res 2006;7:123. Adrenalin: a short account of its ther apeutic applications. The Medical Times and Hospital Gazette 1903:385-87. 79. Crompton G. A brief history of inhaled asthma apy the years. Prim Respir J 2006;15:326-31. 80. Speizer FE, Doll R, Heaf P, Strang LB. Inves into use Rise and fall of asthma mortality in England and Wales in relation to use of pressurised aerosols. Lancet 1969;2:279-85. 82. Dennis SM, Sharp SJ, Vickers MR, Frost CD, Crompton GK, Barnes PJ et al. Regular inhaled salbutamol and asthma control: the TRUST random ised trial. Therapy Working Group of the National Asthma Task Force and the MRC General Practice Rese arch Framework. Lancet 2000;355:1675-9. Role of the effector and arms of immune reseponse in pathophysiology experimental HM, Koelsche GA, Prickman LE, Maytum CK, Lake CF, Williams HL. The effect of cortisone of bronchial asthma and hay fever to pollen. J cortisone acetate in chronic asthma; report to the Medical Research Council by the subcommittee on clinical trials its modulation by therapy. Ann Allergy 1985;55:857-62. 88. Djukanovic R, Wilson JW, Britten KM , Wilson SJ, Walls AF, Roche WR al. an 1992;145:669-74. 89. Holgate ST. Med A:25-31. 90. Ullman Svedmyr N. Salmeterol, long acting inha led Finnerty Harri s Palmer compared Greening Northfield UK Group. Lancet 1994;344:219-24. 95. Woolcock A, Lundback B, Ringda l N, and LA. of addition of salmeterol to inhaled els O'Byrne PM. A long-term study of Med 97. Nelson HS. Long-acting beta-agonist s in adult asthma: Evidence that these drugs are safe. Prim Care Respir J 2006;15:271-7. 98. Corne J, Djukanovic R, Thomas L, Warner J, Botta L, Grandordy B et al. The effect Clin 1997;99:879-87. Holgate ST, J, Lotvall J, Persson GB, Chung KF et al. Efficacy and Busceti MT, Grembiale RD et al. Update on optimal use of omalizumab in management of asth ma. J Asthma Allergy 2011;4:49-59. 102. Tan R, and Corren J. Omalizumab in the treatm ent of asthma. Expert an anti-IgE. Prescrire Int 2007;16:179-82. 105. Omalizumab: Allergy Clin Immunol 2011;43:45-53. 107. Kim HL, Leigh R, and Becker A. Omalizumab: Practical cons iderations regarding the risk dogs. Appl Physiol 110. Brown RH, Wizeman Respir Niven RM , Corris PA, Siersted HC, Olivenstein R yet. Chest 2011;140:576-7; discussion 7. 113. Auer J, and Lewis PA. The Physiology Of The I mmediate Reaction Of Anaphylaxis In Padrid P. Chronic lower airway disease in the dog and Probl Vet Med 1992;4:320-44. 115. Padrid P. Feline asthma. Dia gnosis and treatment. Vet Clin No rth Anim Pract 2000;30:1279- JM, DeClue Herszberg 118. de Weck AL, Mayer P, Stumper B, Schiessl B, and Pickart L. Dog a llergy, model allergy genetics. Int Arch Allergy and Bice DE. Pulmonary immunity to ragweed a Beagle dog model of alle rgic asthma. Exp Lung Res 2001;27:433-51. 120. K, Aikawa response an tigen challenge in allergic sheep. N Engl J Med 1972;286:965-70. 123. Van der Velden J, Barker D, Barcham G, Koumoundouros E, asthma. PLoS One 2011;6:e28740. 124. Tomioka K, Garrido R, Ahmed A, Stevenson JS, and Abraham WM . YM461, Pharmacology bronchial asthma and death induced in the guinea-pig by the nasal inhalation of dry horse dander. Am J Dis Child 1927;34:23-52. 128. Pretolani M, BB. Ann N Y The late effect of sodium spir 1988;138:1157-63. AR, Larsson AK, Vollmer E, Dahlen SE, Uhlig S, and Mar Characterisation of guinea pig precision-cut lung slices: comparison Eur Respir mid Fixman ED, and Martin JG . c immune reseponse pathophysiology of experimental asthma 162 134. Dornas WC, and Silva ME. Animal models for the st udy of arterial hypertension. J Biosci 2011;36:731-7. 135. Dai T, Kharkwal GB, Tanaka M, Huang YY, B il de Arce VJ, and models for investigation. Physiol 139. Haller J, O, Wada K, and Rossa C, Jr. Anim al models to study host-bacteria T, Yanaura K. The contribution of mast Jahnsen FL, Turner DJ, as al. Bi directional interactions between antigen-bearing respiratory tract dendritic cel and T cells precede the late phase reaction in experimental asthma: DC activation occurs in the airway mucosa but not in the lung parenchyma. J Exp Med 2003;198:19-30. 145. Singh P, Daniels M, Winsett DW, Richards J, Doerfler D, of allergic responses to house dust Am J Physiol Lung Cell Mol Physiol 2003;284:L588-98. 146. Dietrich WF, Miller J, Steen R, Merchant MA, Damron-Boles D, Husain Z et al. A comprehensive genetic map of the mouse genome. Nature 1996;380:149-52. 147. Elias JA, Lee CG, Zheng T, Ma B, Homer RJ, and Z hu Z. New insights into the pathogenesis of asthma. J Clin GP, Fredberg U, Inman MD, Jordana M et al. Murine models of asthma. Eur Respir J 2003;22:374-82. 150. McCusker CT. Use of mouse models of allergic rhinitis to study the upper allergy: what learned and what should we do next? Allergy 2004;59:914-9. 152. Irvin CG, and Bates JH. Measuring the lung function in the mouse: the size. Respir Res 2003;4:4. 153. Wanner A. Utility of animal in the study of human airway disease. Chest 1990;98:211-7. 154. Humbles AA, SJ, Friend DS, Xanthou G, McKenna EE et al. A critical role for eosinophils in allergic airways re modeling. Science 2004;305:1776-9. 155. Lee JJ, Dimina D, Macias MP, Oc hkur SI, McGarry MP, O'Neill KR et al. Defining a link with asthma in mice congenitally deficient in eosinophils. Science 2004;305:1773-6. 156. Richards IM. Mouse models of allergic disease; how do they re late Trends Pharmacol Sci Biol 159. Pabst unsolved problems. Pathobiology 2002;70:252-4. REFERENCES JG. Airway remodeling: animal models . Clin Rev Allergy 2007;62:579-90. 164. Shinagawa K, and Kojima M. Mous e model of airway remodeling: stra in differences. Am J Respir Crit Care Med 2003;168:959-67. 165. Bulloch W. The history of Bacteriology. London: Oxford University Press, 1937. 166. caused by certain toxalbumins. Lea Bros, 167. Alexander HL, WG, and Holmes JA. Reactions cutaneous, J Lab Clin Med 1970;76:181-9. 169. Patterson R, and Talbot C. A diate-type J Allergy C lin Immunol 1972;49:292-300. 170. Patterson R, Talbot CH, and Robert s M. Reverse passive respiratory re actions Immunol 1972;10:267-74. 171. Mota rat. Can IC, sensitized rats to aerosol Inhibition of cell responses to house 180. ER, and Baldo BA. Standardization of allerg ens. Qualitative of mite Platts-Mills RL, and Stewart GA. Structural studies on the allergen Vandaele F, and Vis HL. Atopic dermatitis: role food house dust 185. Tupker RA, De PJ, A, and van der Meer JB. Induction of atopic dermatitis by immune reseponse in the pathophysiology of experimental asthma 164 187. Stewart GA, and Holt PG. Immunogeni city and tolerogenicity of a majo r house dust mite allergen, Der p I from Dermatophagoides pteronyssinus, in ts. Int Arch Allergy Immunol 1987;83:44-51. Allergy Appl Enssle K, Takatsu K, Schnoy N et al . The relevance of murine animal models to A, and Jordana Modeling a human- mouse chimera model IL-4 IL-5 dependent. R, Gajewska BU, Coyl AJ Van Hout CA, and Johnson HG. Synthesis of ra t IgE by aerosol immunization. J Immunol 1972;108:834- 6. 195. Holt PG, Batty JE, pollen hypersensitivity in Immunology 1982;46:745-50. 197. Sedgwick Ray A, A, Krishnamoorthy N, Qi Z, and Ray P. Regulatory T ce lls in many flavors control asthma. Mucosal Immunol 2010;3:216-29. 200. in a murine model of allergic rhinitis: role of the upper Allergy Clin Poul sen LK, 2004;114:28-38. 204. Kim JO, Kim DH, Chang WS, Hong C, Park SH, K im S et al. Asthma is induced by intranasal coadministration of allergen and natural killer T-cel a mouse model. J et al. Inducti on of airway remodeling of nasal mucosa by repetitive allergen challenge Larsen Sanchez Rondon C, Navarro A, Montoro J et al. Allergen-specific nasal provocation testing: review by the rhinoconj unctivitis Wang Y, and C. Neonatal exposure with L PS and/or and Drazen JM. Pulmonary responses bronchoconstrictor Taube 213. Patel SS, and Goa KL. Sevoflurane. A review of its pharmacodynamic and pharmacokinetic properties and its clinical use in general anaesthesia. Drugs 1996;51:658-700. 214. Sakai EM, Appl Physiol 1992;72:168-78. 219. Casan P, Garc\u00eda F, and Ge a J. Fisiolog\u00eda y biolog\u00eda resp iratorias. Madrid: Ergon, 2007. 220. Bousquet J, Jacot W, Vignola AM, Bachert C, and Van Cauwenberge P. Allerg ic rhinitis: 221. Wagner P, Valentin B, and Burtin B. Assessment life patients with perennial allergic rhinitis with the Fr ench allergic is and by treatment. Allergy 1996;51:893-906. 224. Cockburn IM, Bailit HL, Berndt ER, and Finkelstei n SN. Loss of work productivity due to illness and medical treatment. J Occup Environ Med 1999;41:948-53. 225. SL. rate of di agnosis of allergic rhinitis Eur Respir J 2004;24:758-64. 227. Shi HZ, Humbles A, Gerard C, n immune reseponse in the pathophysiology of experimental asthma 166 233. Chanez P, Vignola AM, Vic P, Guddo F, Bonsignore G, Godard P et al. Comparison between nasal and bronchial inflammation in asthmatic and control s ubjects. Am Crit Care Med 1999;159:588-95. Acta SE, Fokke ns W et al. Tissue remodelling in upper airways: where is the link with lower airway remodelling? Allergy atop ic patients: a lower Otolaryngol Neck Surg 2011;145:396-400. 2003;58:1235-43. 240. Bousquet J, AM, Links between rhinitis and asth ma. Allergy 2003;58:691-706. 241. Serrano C, Valero A, and Pica do C. Rinitis y asma: una via respiratoria, una enfermedad. Arch Bronconeumol 2005;41:569-78. 242. Leynaert B, Bousquet and Neukirch F. Perennial Allergy Clin Immunol 2001;107:469-76. 246. Togias A, Bienenman A, Bloom D, R. S, D. I, and A. H. Changes in H. Effects flutropium on experimental models of drug- in guin ea pigs. Jpn J Pharmacol 1991;55:321-8. 248. Yamasaki M, Matsumot o T, Fukuda S, Nakayama T, Nagaya H, and Ashida Y. Involvement Zhao Y, Woo JK, Leung PC, Chen GG, Wong YO, Li u SX et al. Symptomati c and pathophysiological observations 250. comprehe C ontrol of nasal vasculatur e and airflow resistance in the dog. J Physiol 1984;349:535-51. 252. Lung MA, and Widdicombe JG. Lung reflexes and nasal vascular resi stance in the anaesthetized dog. J Physiol 1987;386:465-74. 253. Lung MA, and Wang Increase and parasympathetic interaction in vascular and secretory control of the nasal mucosa in an aesthetized dogs. J Physiol 1997;505 (Pt 3):823-31. 255. Cardell LO, congestion and J Appl Physiol 2003;94:1821-8. Bice Hey JA, and McLeod RL. A model of allergic nasal congestion in to ragweed. Am J Rhinol 2003;17:227-32. 258. Pauluhn J, and Mohr U. Experimental approaches to evaluate re allergy in P, C. Pathophysi ology of nasal obstruction and meta- analysis vocetirizine. Exp Allergy J, Den burg A, Ellis R, Inman MD et Allergen-induced Kozutsum i D, Murakami R, Kimu ra S, and Kino K. Establishment of an allergic rhinitis model in mice for the evalua tion Life Dohi M, Okunishi K, Nakagome K, Tanaka R, Imamura M al. nasal allergic Pathol 2003;31:432-47. Hussain I, Randolph D, Brody SL, Song SK, Hsu A, Kahn AM et al. Induction, distribution and modulation of upper L, Ellis R, Inman MD et al . Pathogenesis of murine experimental 1981;1:309-12. 267. Mery S, Godo M, and Morg an KT. Nasal diagrams: a tool for recording the distribution of nasal lesions in rats and mice. Toxicol Pa thol 1994;22:353-72. 268. Gross EA, JA, Fields S, and Popp JA. Comp arative morphometry of the nasal cavity in Szczepanski M, and Szajnik phagocyt es: neutrophils and The Se min Thromb Hemost 1996;22:503-6. 280. dis ease. Galli SJ, Nakae S, and Mast cells in the adaptive immune responses. Nat Immunol 2005;6:135-42. 283. Kalesnikoff functions of mast cells. Methods Mol Biol 2011;677:207-20. 284. Steinman RM, and Cohn ZA. Identific ation of a novel cell type immune reseponse in the pathophysiology of experimental asthma 168 285. de Souza AW, Mesquita Junior D, Araujo JA, Catelan TT, Cruvinel Wde M, Andrade LE et al. Immune system: part III. The delic ate balance of the immune system between toleran ce and autoimmunity. Rev 2005;60:271- 82. 288. L, D'Amico A, Hochrein H, O'Keeffe M, S hortman K, and Lucas K. De velopment of thymic WW. A mechanism of cell trogocytosis. Immunity Robbins SH, and Brossay L. NK cell receptors: emerging roles 1983;302:575-81. 293. Grawunder U, BH, gene rearrangement steps are in early human precursor Fanning LJ, Connor AM, esis and immune memory Gen TJ, Mackall bench to clinic. Blood 2002;99:3892-904. 298. Akashi K, Traver D, Kondo M, and Weissman IL. Lymphoid development from hematopoietic Int J 1999;69:217-26. 299. Tydell CC, David-Fung ES, Rothenberg EV. Molecular J Immunol 2007;179:421-38. . Rev Haughn L, Aifantis I, Grassi F et al factors in the organized chaos of early T cell development. Nat Immunol 2007;8:137-44. Doyle C, and Doan Erma n B, Feigenbaum L, and selection. J Exp Med 2006;203:165-75. 307. Singer A, Adoro S, and Park JH. Lineage fate a nd Rev Immunol 2008;8:788-801. 308. Brugnera E, Bhandoola A, Cibotti R, Guinter TI, Singer A, and Bosselut CD4/CD8 coreceptors thymocyte development, Erman B, Bhandoola A, Sha rrow SO, and Singer A. In vitro evidence that cytokine receptor signals are 311. Yucel R, Karsunky H, Moro y T. transcriptional Kishimoto H, and selection the incl Exp Med 1997;185:263-71. Griesemer AD, Sorenson EC, and Hardy The thymus in tolerance. Transplantation 2010;90:465-74. Kisielow P, Bluthmann Staerz JI et al. Self-tolerance in B lymphocyte development. Adv Immunol 1995;59:279-368. 317. Taniguchi RT, and Anderson MS. The role of Aire in clonal selection. Imm unol Cell Biol 318. Garbe Exp MD, and Lake RJ. Notch signaling: cell fate control and signal integration in 1999;284:770-6. 320. Robey EA, and development by Notch signaling. Nat Immunol 2007;8:451-6. 322. Van de Walle I, De Smet G, De Smedt M, Vandekerckhove B, Leclercq G, Plum J et al. An early decrease in activation is required for TCR- gammadelta T cells. 2009;113:2988-98. 323. DI, and Berzins SP. Control points in NKT-cell development. Nat Rev Immunol 325. Gapin L, Matsuda JL, Surh NKT derive double-positive thymocytes that are se lected by CD1d. Nat Immunol 2001;2:971-8. 326. Bendelac Garcia C, Koezuka Y et al. A subset cells Nieda M, Koezuka Y, Nicol A, Porcel li SA, Ishikawa Y et al. An alysis of human V alpha 24+ CD4+ NKT Gapin L. The unconventional lifestyle of NKT cells. Nat Rev Immunol 2002;2:557- 68. 330. Apostolopoulos V, and McKenzie IF. e response. Curr Mol Med 2001;1:469-74. 331. Gough role view of Immunol (MBL): on cons tant alert in a hostile environment. Ups J Med Sci 2011;116:90-9. 335. Fearon Locksley immune reseponse Wells and Turka LA. Dynamics and requirements of T cell clonal expansion in vivo at roles for domain 4 of VCAM-1 in the regulation of cell ad A, Chiang SC, Re nsing-Ehl A, Jessen B, Fauriat C, Wood SM et al. ORAI1-mediated calcium influx is Smyth MJ, Kelly JM, Sutton VR, Davis JE, Browne KA, et al . IL-4 inhibits TGF-beta-induced Veldhoen M, Uyttenhove C, van Sn ick J, Helmby H, West endorf A, Buer J et al. Transforming growth factor-beta 'reprograms' the differentiation of T 9-producing subset. Immunology 350. Frey er J, Floess S, Garbe A, Baron U et al. DNA methylation controls Foxp3 gene expression. Eur J Immunol SL, Jeke r LT, Penaranda C, Martinez-Llordella M, Ashby et al. Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T ce lls in vivo. Nat Immunol 2009;10:1000-7. 352. Mosmann TR, 1986;136:2348-57. Ansel KM, Lee DU, and Rao A. An epigenetic view of helper T cell Placek E, Shafiani S, Negash A, Urdahl KB, Wilson CB et al. Fidelity of pathogen-specific CD4+ T cells Li S, Robinson SN, Yang H, St einer D et al. Th-1 polarization is regulated by dendritic-cell comparison of MHC CS, Macatonia SE, Tripp CS, Wolf SF, rra A, and Murphy KM. Development of TH1 CD4+ T cells through Flavell RA. Transforming growth factor-beta controls T helper type 1 development J Exp Med 2006;203:755-66. 362. Szabo SJ, Kim Costa GL, Zhang X, Fathman CG, and Glimcher A, al. 13 a B cell stimulating factor. J Exp Med 1994;179:135-43. 364. Emson CL, Bell SE, Jones A, Wisd en W, and McKenzie AN. Interle ukin Tomoe S, R, 1992;146:374-7. 366. Ansel KM, Djuretic Y, different in T- helper-cell differentiation. Nat Rev Immunol 2009;9:116-24. RA. The is Ferreira cell in vivo. Immunol 2001;167:724-32. Usui T, K itani W. GATA-3 suppresses development of on IL-12Rbeta2 2003;18:415- JM, Glimcher LH, Critic factor GATA-3 in thymocyte development. Immunity 2003;19:863-75. 375. Zhu J, Min B, Hu-Li J, Watson CJ, Grinberg A, Wang Q et Yamane H, L, and Paul WE. GATA-3 promotes responses through 2003;170:2956-61. 378. Kishikawa H, Sun J, Choi A, Miaw SC, and Ho IC . The cell type-specific expression of the murine regulated GAT A-3. J Immunol 2001;167:4414-20. 379. Zhu J, Cote-Sierra J, Guo L, an d Paul WE. Stat5 immune reseponse in pathophysiology of experimental asthma 172 381. Cote-Sierra J, Foucras G, Guo L, Chiodetti L, Young HA, Hu-Li J et al. Interleukin a central role in Th2 differentiation. Proc Natl Acad Sci U S A 2004;101:3880-5. 382. Zhu J, Guo L, Min B, Watson CJ, Hu-Li J, Young HA et al. CJ, Hu-Li J, and Paul WE. Stat6 2001;166:7276-81. 384. Bettelli E, Carrier Y, Gao W, Ko rn T, Strom TB, Oukka M et al. of Z, Seldin MF, Rousseau AM, inter SL, Herpesvirus Saimiri encodes a new novel cytokine receptor. Immunity 1995;3:811-21. 387. Yao Z, Painter SL, Fanslow WC, Ulrich D, M acduff BM, Spriggs MK et al. Human IL-17: a novel cytokine derived T cells. J Immunol 1995;155:5483-6. 388. Yang XO, Panopoulos AD, Nurieva R, Chang Wang D, Watowich et al. STAT3 regulates cytokine-mediated 389. R, Martinez GJ, Kang HS, C hung Y, Pappu BP et al. Molecular antagonism Tadokoro CE, Lepe lley A, Lafaille JJ et al. The orphan nuclear receptor directs program of 2006;126:1121-33. 391. Yang XO, Chang SH, Park H, Nurieva R, Shah B, A cero L et al. Regulation of inflammatory responses by P, on S, Bagby G, Summer WR et al. Interleukin-17 and lung C, Horton HF, Byrne MC, and Kamrad t T. Microbial lipopeptides induce the production of IL-17 in Th cells. J 2000;165:6107-15. 394. MC, Southard TL, JF, persistent interleukin O, Chomarat P, Flores-Romo L, C et al. cell thymic lymphocytes. Immunology 1970;18:723-37. 400. Kilshaw PJ, Brent L, and Pinto M. Suppressor T ce lls in mice made unresponsive to skin allografts. Nature 1975;255:489-91. 401. Cohen P, Hencin R, Liebhaber 1972;108:586-90. 402. MJ. of suppressor T population of 'educated' T cells. Nature 1974;248:236-8. 403. Eardley DD, and Gershon RK. Induction T cells in vitro. Immunol 1976;117:313- 8. 404. Bach MA, Phan-Dinh-Tuy F, Tournier E, Chatenoud L, Bach JF, Martin C et al. Deficit of suppressor T cells in active multiple scle rosis. Lancet 1980;2:1221-3. 405. Dorf ME, answers but more questions. Immunol Today 1992;13:241-3. 406. Green DR, and Webb DR. Saying the 'S' word in public. Immunol Today 1993;14:523-5. 407. Sakaguchi S, Sakaguchi M, Asano M, Itoh M, Morse SS, and Sakaguchi N. T cell-mediated maintenance of natural self-tolerance: its breakdown as a possible cause of various autoimmune diseases. J Autoimmun cells . Nat Immunol 2003;4:330-6. 411. Hori S, Nomura T, and i S. Control of regulatory T cell deve the transcription Khattri R, Cox T, SA, Ramsdell An essential role CD4+CD25+ T regulatory cells. Nat 2003;4:337-42. 413. Bennett CL, Christie J, Ramsdell F, Brunkow ME , Ferguson PJ, enteropathy, (IP FOXP3. Nat Genet 2001;27:20-1. 414. van der Vliet HJ, and Nieuwenhui s EE. B, Clark LB, Yasayko SA Disruption of a new forkhead/winged-helix protein, results in the lymphoproliferative Whitters MJ, Piccir illo CA, CD4(+)CD25(+) immunoregulatory al regulatory CD4+ T cell subset Crellin NK, Passerini Stei ner TS, Bacchetta R et al. Activation-induced FOXP3 in human T effector cells does not cytokine production. of expression in naive is confer Blood 421. Morgan ME, JH, Bakker AM, Heemskerk B, Schilham MW, Hartgers Expression mRNA not Hum Immunol Pagerols-Raluy erg HH, Ammerpohl O, Gr S, Sipos B et al. Foxp3 expression in pancreatic carcinoma cells as a novel immune evasi on in cancer. Cancer Res 2007;67:8344- 50. 423. Zuo T, Wang L, Morrison C, Ch ang X, Zhang H, Li W et al. FOXP3 is an X-linked breast cancer Putnam AL, Xu-Yu Z, Sz ot GL, Lee correlates with FoxP3 and T reg cells. Exp Med 2006;203:1701-11. 426. Chen X, Subleski JJ, Hamano R, Howard OM, W iltrout JJ. Co-expression of OXP3+ human peripheral blood. J Immunol 2010;40:1099-106. 427. Kleinewietfeld M, Puentes F, Borsellino immune reseponse in the pathophysiology of experimental asthma 174 428. Baecher-Allan C, Wolf E, and Hafler DA. cla ss II expression and Nat N, Malissen Waldmann H, and Hori Acad Sci G, and Bromberg JS. Relland LM, Truong N, Ca rlson MR, Williams CB et al. Regulatory T cell development the Nat le varieties of T regulatory protective to viral AL, Collison LW, Pillai Vignali The development and function of regulatory T cells. Cell Mol Life Sci 2009;66:2603-22. 436. Peng Y, Laouar Y, Li MO, Green EA, and Flavell RA. TGF-beta regulates in vivo expansion of diabetes. Proc Natl Acad Sci U S 2004;101:4572-7. 437. Wan YY, and Flavell RA. Identifying a reporter. Proc Natl Acad Sci U S A 2005;102:5126-31. Winkler B, Hufnagl K, Spittler A, Ploder M, Kallay E, Vrtala S et al. The role of Foxp3+ T cells in long- term efficacy 80. 439. Jin H, Xiao C, Geng S, Hu Y, She R, Yu Y al. Protein/DNA vaccine-induced 440. Su L, Creusot RJ, Gallo EM, Chan SM, Utz PJ, Fathman CG et al. Murine and function for interleukin 2 in Foxp3- expressing regulatory T cel ls. Nat Immunol 2005;6:1142-51. 443. Salomon B, Lenschow DJ, Rhee L, Ashourian N, Singh B, Sharpe A et al. B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ i mmunoregulatory T cells that control autoimmune diabetes. Immunity 2000;12:431-40. 444. Brunner MC, Chambers CA, Chan FK, Hanke J, Wi noto A, and Allison JP. C TLA-4-Mediated inhibition of early events of T cell pro liferation. J Immunol 1999;162:5813-20. 445. Perkins D, Wang Z, Donovan C, He H, Mark D, Guan G et 446. Jain N, Nguyen H, Chambers C, and Kang J. Dual function of CTLA-4 in regulatory T cells multiorgan mmunity. Proc Natl Acad Sci U S 2010;107:1524-8. 447. Wu Y, Borde M, Heissmeyer V, Feuerer M, Lapan AD, Str oud JC that control intestinal inflammation. J Exp Med 2000;192:295-302. 449. Wing K, Onishi Y, Prieto-Marti n P, Yamaguchi T, Miya ra M, Fehervari Z et al. CTLA-4 control over 2005;22:329-41. 451. Siebenlist U, Brown K, and Claudio E. Control of lymphocyte development by nuc lear factor-kappaB. Nat Rev Immunol 2005;5:435-45. REFERENCES 175 452. cells. S, Grumont RJ, Bunting K, Hoyn e G, Wilkinson N et al. c-Rel is required for the development of thymic Foxp3+ CD4 gulatory cells. 454. Deenick EK, Elford AR, Pellegrin i M, Hall H, Mak TW, and Ohashi PS. c-Rel but Hellhund A, Bothur E, Reinhard K, Bollig N et al. c-Rel is crucial for the induction of Foxp3(+) regulatory CD4(+) T cell s but not T(H)17 cells. J Immunol 2010;40:671-6. 456. Ono M, Yaguchi H, Ohkura N, Kitabayashi I, Naga mura et al. Foxp3 regulation key target genes dur ing T-cell stimulation. Nature 2007;445:931-5. 458. Zheng Y, Josefowicz SZ, Chu TT, Gavin MA, and Rudensky AY. Genome-wide analysis of Foxp3 target genes in developing and mature regulatory T cells. Nature 2007;445:936-40. 459. Gavin MA, Rasmussen JP, Fonte not JD, Vasta V, Manganiello Beavo TT, Leung BP, McInnes IB therapeutic en-induced arthritis through of regulatory T cells and suppression of Th17 cells. Eur J Immunol 2007;37:3021-9. 462. Rubtsov YP, Rasmussen JP, Chi EY, Fontenot J, Castelli L, et 464. Bardel E, Larousserie F, A and B in human cytotoxic lymphocyt e subsets and T regulator y cells. Blood 2004;104:2840- 8. 466. Zhao DM, Thornton AM, DiPaolo RJ, and EM. 2007;110:1225-32. 470. Deaglio S, Dwyer KM, Gao W, Friedman D, Usheva A, Erat A et al. Adenosin e generation catalyzed Huang CT, Lutz ER, Kowalski J, Horton MR, J regulatory cells. Blood 2008;111:251-9. 472. Sarris M, Andersen KG, Randow F, Mayr L, and Betz AG. Neuropilin -1 expression regulatory Workman C, Lee J, Chew C, Dale BM, Colonna L et al. Regul atory cells inhibit II. J 2008;180:5916-26. 474. Fallarino F, Grohmann U, Hwang KW, Orabona C, Vacca C, Bianchi R et al. Modulation of tryptophan catabolism by regulatory T immune reseponse in the pathophysiology experimental A, Bigler M, Rouleau M, Antonenko S, de Vries subset Gregori S, MK. secreting Immunol Rev 479. Crain cytokines. Exp Med 2002;195:603-16. 480. Minaee S, EJ, Barrat FJ, Boonstra A et al. IL-10-secreting regulatory T cells not express Foxp3 latory and Gregori S. Is FOXP3 a bona fide marker for human regulatory T cells? Eur J Immunol 2008;38:925-7. 482. Chen W, Jin W, Hardegen N, Le i KJ, Li L, Marinos N et al. Conver sion of peripheral CD4+CD25- naive T cells to CD4+CD25+ T induction of transcription factor J Exp be L, Jung S, Gruber AD, Hansen W et al. CD4+Foxp3+ regulatory T induced by antigen-driven epithelial cells independent of local dendritic cells. Gut 2009;58:211-9. 485. MacDonald TT. 1998;10:620-7. 486. Weiner HL, da Cunha AP, Quintana F, and Wu H. Oral tolerance. Immunol Rev 2011;241:241-59. 487. Zhang ZX, Yang L, Young KJ, DuTemple B, and Zhang L. Identification of Med 2000;6:782-9. Voelkl S, and Mackensen A. J Immunol 2011;41:739-48. 489. Marra LE, Zhang ZX, Joe B, Campbell J, Levy GA, Penninger J et al. IL-10 induces TNF-alpha. J Immunol 2004;172:1028-35. 490. Zhang ZX, Ma Y, Wang H, Arp J, Jiang J, Hua ng X et al. Double-negative T cells, activated by xenoantigen, lyse autologous B ligand- independent pathway. J Immunol BP, and regulatory T cells: non -conventional regulators. Immunol Res 2006;35:163-78. 492. Ford MS, Zhang ZX, Chen W, and Zhang L. Doubl e-negative T regulatory cells can develop outside the thymus do not from CD8+ T ce ll precursors. J Immunol 2006;177:2803-9. 493. Wang R, Wang-Zhu Y, and Grey H. between double positive Proc Acad Sci U S A 2002;99:2181-6. 494. Young KJ, and Zhang L. The nature and mechanisms of DN regulator y Inhibition regulatory T cells . J Immunol 2003;171:134-41. 496. Lee BP, Chen W, Shi H, Der SD, Forster R, and Zhang L. 2003;171:2421-6. 498. Young KJ, Kay LS, Phillips MJ, and Zhang L. An titumor mediated by cell peripheral s uppressor cells. J Immunol 2001;167:6188-94. 500. Chen W, Ford MS, Young KJ, Cybulsky MI, and Zha ng L. Role of double-negative regulatory T cells. 2005;105:2828-35. 502. Chen W, Zhou D, Torrealba JR, Waddell TK, Grant D, Immunol 2005;175:3409-16. 503. Jiang H, Zhang SI, and Pernis B. Role of CD8+ T ce lls in allergic Science Invest Field Caccavelli L, Fillion J, Kuhn J, Mandet C, Druet P et al. Neonatal induction of tolerance to T(h)2-mediated autoimmunity in rats. Int Immunol 2000;12:1467-77. AC, L, Fillion J, Kuhn J, Mandet C, and Bellon B. Neonatal induction and maintenance and Bellon B. Re gulatory CD8+ cells a J Immunol 1998;10:775-83. Ciubotariu R, Liu Z, Colovai AI, Ho Itescu S, S Invest 1998;101:398-405. 511. Zhou J, Appleton SE, Stadnyk A, Lee TD, and Na 512. Tang XL, Smith TR, V. Specific control of R, Manavalan Yuan Colovai AI, Piazza et al. Tolerization of dendritic cells T(S) RP. CD8+ Tregs in lupus, autoimmunity, and beyond. Autoimmun Rev 2010;9:560-8. Suzuki H, Kundig TM, Furlonger C, Wakeham A, Timms E, Matsuyama T activation autoimmunity 516. M, Kawamoto Y, Nakashima I, and Suzuki H. Essential roles of CD8+ CD122+ regulatory T cells in the maintenance of T cell homeostasis. J Exp Med 2004;200:1123-34. 517. Shi Z, Okuno Y, Rifa'i M, Endharti AT, Akane K, Isobe K et al. Human CD8+CXCR3+ T cells have the same function as murine CD8+CD122+ Treg. Eur J F, Lazzeri E, Francalanci M, Angeli R, Mazzinghi B S, Bjornbeth BA, Torgersen KM, al. Generation of Eur J Immunol 2008;38:640-6. 520. Lu L, Yu Y, Li G, Pu L, Zhang F, Zheng S et al. CD8(+)CD103(+) regulat ory T cells in Immunopharmacol R. Parallel expansion of 2007;179:1039-48. M, Negrini S, Procopio Fenoglio D, specific CD8+ T lymphocytes immune reseponse in the pathophysiology of experimental asthma 178 523. Filaci G, Rizzi M, Se tti M, Fenoglio D, Fravega M, Basso M et al. Acad Sci 2005;1050:115-23. 524. Sharabi A, and Mozes E. The suppression and function of and Dekruyff RH. The regulatory role of natural killer T cells in the airways. Int J Biochem Cell Biol 2010;42:529-34. RH, Bake r J, Zeiser R et al. Low doses of natural killer T cells provide protection from acute graft-versus-host disease via an 528. Pillai AB, George TI, Dutt S, and Strober S. Host na tural killer T cells induce an interleukin-4-dependent expansion of donor T ainst Blood 2009;113:4458-67. 529. La Cava A, Van Kaer L, and Fu Dong S. CD4+CD25+ Oliv ares-Villagomez D, Du C, Stanic AK et al. 11. 531. Araujo L, Kerschen P, Diem S, Bour geois E, Van LP et al. In variant NKT cells inhibit development of the Th17 lineage. Proc Natl Acad Sci U S A M, Almeida CF, Caridade M, Ribot JC Loddenkemper C, Westermann J, and Hoffmann JC. Ro le of gamma delta T cells in Aggravation of intestinal inflammation by depletion/deficiency of gammadelta T cells in different types of IBD animal models. Leukoc Biol roles of TGF-beta and IL-10 the of experimental co litis. J Immunol 2002;168:900-8. 539. Mota-Pinto A, Todo A, Alves V, Santos A, and Santos M. Regulatory T cells in Clin Immunol 2011;21:199-206. 540. Kang N, Tang L, Li X, Wu D, Li W, Chen X et al. Identificati on and characterization of Foxp3(+) gammadelta T cells in mouse and human. Immunol Lett 2009;125:105-13. 541. Li X, Kang N, Zhang X, Dong X, Wei W, Cui L et al. Generation of human regulatory gammadelta T cells by TCRgammadelta stimulation in the pres ence of TGF-beta and their involvement in the pathogenesis of systemic K, JD, mice. Methods Mol Biol 2011;677:99-111. 544. Mauri C, and Ehrenstein MR. The 'short' histor y of regulatory and Tedder TF. B10 ce during inflammation, autoimmunity, K, Bouaziz JD, Akiba H, Yagita H et al. Regulatory B cells are identified by expression of TIM-1 and be A, Jamin C. Regulatory B cells in autoimmune diseases: how do they work? Ann N Y Acad Sci 2009;1173:260-7. 550. Edwards JC, Leandro MJ, and Cambridge Am 2004;30:393-403, viii. 551. CY, Rodriguez-Pinto D, Du W, Ahuja A, Hene gariu O, GM, 553. Voo KS, Wang YH, Santori FR, B oggiano cells in humans. Proc A Sci U S A 2009;106:4793-8. 554. Beriou G, Costantino CM, Ashley CW, Yang L, Baecher-Allan C et al. human cells reta in suppressive function. Blood 2009;113:4240-9. 555. Xu L, Kitani and St W. Cutting edge: regulatory T cells induce cells are self-induced to become 556. Tsuji N, Kawamoto S, Suzuki K, Kanagawa O, Honjo T et al. Preferential generation of follicular B helper T cells from Foxp3+ T cells in gut Peyer's patches. Science 2009;323:1488-92. A, MC, Becker down-regulation of Smad7. J Immunol 2004;172:5149-53. 559. Mucida D, Park Y, Kim G, Turo vskaya O, Scott I, Kronenberg M regulatory Seumois G, Pickard C, Powell RM, Angco G, Sammut D et al. Invariant natural killer T in asthma and chronic Brienza NS, Mont ero-Martinez C, Verea-Hern ando H, Olivenstein R et al. proliferating 562. McWilliam AS, Nelson Reuter S, Stassen M, and C. Mast in allergic asthma and beyond. Yonsei J 2010;51:797- 807. Raible D, GC, and Young IG. Molecular organization of the cytokine gene cluster, involving the human IL-3, IL-4, IL-5, and genes, 1989;73:1142-8. 567. Noguchi E, Shibasaki M, Arinami T, Takeda K, Ma ki T, Miyamoto T et al. Evidence for linkage between asthma/atopy in childhood and chromosome 5q31-q33 in a Med 1997;156:1390-3. Role of immune reseponse in the pathophysiology of experimental asthma 180 Wilson MS, and Choy Jia G, Abbas AR, Ellwanger al. type 2-driven Med 2009;180:388-95. 570. Doherty TA, Soroosh P, Khorram N, Fukuyama S, Rosenthal P, Cho JY et al. The tumor necrosis factor family member LIGHT is a target for asthma tic airway remodeling. Nat Med 2011;17:596-603. 571. de Boer WI, van Schadewijk A, Sont JK, Sharma HS, Stolk J, Hiemstra PS al. growth factor beta1 and recruitment of macrophages Luyimbazi J, Xu X, Schofield B, Neben TY, CL et al. Interleukin-13: central mediator of allergic asth ma. Science 1998;282:2258-61. 573. Ramalingam Shedding LI GHT severe 2006;7:135. Preisser E, MH, Santarlasci V, Capone M, Cardilicchia E, Frosa li F et al. Identification of a novel subset of human circulating memory CD4(+) T cells that and Chaplin DD. Modulation airway inflammation by passive transfer of allergen-specifi c Th1 and Th2 cells in a mouse model of asthma. J Immunol 1999;162:2375-83. 579. Huang 581. Vock C, Hauber HP, and Wegmann M. The other T help er cells in asthma pathoge nesis. J Allergy (Cairo) 2010;2010:519298. 582. Yoshimoto T, Bendelac A, Watson C, Hu-Li J, and Paul WE. Role of NK1.1+ T cells in a TH2 response and in immunoglobulin E production. Kaplan MH, Grusby secreting CD1-dependent cells. Science 1997;275:977-9. 584. Akbari O, Stock P, Meyer E, Kr onenberg M, Sidobre S, Nakayama T et al. Essential role of NKT cells producing IL-4 and IL-13 in development of al lergen-induced airway hyperreactivity. Nat Med 2003;9:582-8. 585. Sen Y, Yongyi B, Yuling H, Lu okun X, Li H, Jie X et al. V alpha 24-invariant NKT cells from patients with allergic asthma express CCR9 high freque ncy J Med 2006;354:1117-29. 587. Erpe nbeck VJ al. The development 588. Hartl D, Koller B, Mehlhorn AT, Reinhardt D, Nicolai T, Schendel DJ et al. Quantitative and functional 589. Sakaguchi S. Regulatory T cells in the past and for the future. Eur J Immunol 2008;38:901-37. 590. Boudousquie C, Pellaton C, Barbie F. T cell depletion Atzberger A, e8. REFERENCES 181 592. Kearley J, Barker JE, Robinson DS, and Ll oyd CM. Resolution of airway inflammation and hyperreactivity after in vivo transfer CD4+CD25+ T cells is inte rleukin D, Wegmann M, Huber S, Schmitt S, al. Coexpression of spir Care Med 2009;180:211-25. 595. Leigh R, Ellis R, Wattie J, Southam DS, De Hoogh M, Gauldie J et al. Dysfunction and remodeling of Pouladi MA, Alvarez D, Johnson JR, Wa lker TD, Goncharova S et al. 2000. James AL, Hogg JC, Dunn LA, and Pare PD. Dis L, Brienza NS, nteno-Cortes A, Lopez-Pelaez E, Verea H et [Development murine of Arch Bronconeumol 2009;45:422-8. 601. Cortijo Gimeno J. Modelos experimentales de asma. Aportaciones y limita ciones. Arch Bronconeumol 2003;39:54-6. 602. Torres R, Picado C, and de Mora F. Descubriendo el asma de origen aler gico a traves del raton. Un repaso a la patogenia de los modelos de asma alergica en el raton y su similitud con el asma alergica humana. Arch Bronconeumol 2005;41:141-52. 603. Tsitoura S, Bahceciler NN, and Transfer of A, Inman M, Dahlen SE et al. Comparison of aerosol and intranasal challenge in a mouse model of alle rgic and hype rresponsiveness. Int Arch Allergy Immunol 2010;153:249-58. 608. Torres R, Picado C, and de Mora F. [Again an asthma model. but a useful one]. Arch Bronconeumol 2009;45:419-21. 609. Swirski FK, D, Ritz SA, C undall MJ, Cates Croito ru tissues. J Immunol 2006;176:2568-80. 611. Murphy Walport M. Janeway's Im munobiology. 7th. New York: Taylor & Francis, Inc., 2008. 612. Galli SJ, Borregaard N, and Wynn TA. Phenotypic and f unctional plasticity and of adaptive immune reseponse in the pathophysiology of experimental asthma 182 614. James A, and Carroll N. Theoretic effects L, N, and Homer RJ. Cyto kine regulation of mucus production in 2002;248:201-13; discussion Foley S, Shannon J, Lemi ere C, Olivenstein R, Ernst P et al . between Biol 2003;29:19-27. 618. Schmidt M, Sun G, Stacey MA, Mori L, and Matto li S. Identification 619. Saunders R, Siddiqui S, Ka ur D, Doe C, Sutcliffe A, Hollins F et al. Fibrocyte localization to the airway Kony S, Guenegou A, Bousquet J, M between and rhinitis according Fa thman rare of T lymphocytes by therapy for autoimmune disease. J Immunol 2000;164:3581-90. 626. Wang CL. Activation of mast cells is essential for developm experimental tec hnique. London: Methuen & Co., 1959. 629. Singh J. The national centre for the replacement, re finement, and reduction of animals in research. J Pharmacol Pharmacother 2012;3:87-9. 630. Jacquet A. The role of activation in house Kim HY, Treuting P, en T, Zheng Y et al. Extrathymically generated regulatory T cells control mucosal TH 2 inflammation. Nature 2012;482:395-9. 632. Yang Y, Zhang HL, and Wu J. Role of T regul atory Inoue H, Fukuya ma S, Kan OK, Eguchi-T suda M, Matsumoto T et al. Frequency of Foxp3+CD4CD25+ T cells is 183 Immunol XD, Pridgeon C, Dallm an M, Arbery J 0.5% (weight-volume) periodic acid solution water. 2. Eosin We used a 7 eosin (Merck) solution in distilled water. 3. 4. Solution made of 3% FBS and 0.09% sodic azide in PBS. Solution is 0.22 m filter (Millipore) and store at 4\u00baC before use. 5. Luria-Bertani culture medium 5.1. LBA reaction 2 Primer forward 2 Primer reverse 0.5 Pol Taq 33.5 H 2O 50 Total Supplementary methods 188 Primer solutions were at 0.01 mM. We used one cycle of initial denaturing (95\u00baC for 5 30 cycles (\u00baC) Time 1 95 5 min 95 30 s Ta 30 s 30 72 Et 1 72 5 min Where Ta: annealing temperature (depending on primers); Et: elongation 1000 base length elongation. 7. Lipofectamine transfection protocol was diluted into 50 L DMEN and incubated at RT for 5 minutes. Lipofectamine solution was then mixed with 50 L of DMEN containing 0.8 g of lineal plasmidic DNA and incubated for 20 minutes at RT. Each well was incubated with this transfection so lution for 4 hours and then changed with fresh medium. Then after 24 plate (Gibco) with fresh medium. The following day, a transfected pool plates with DMEM 5% FBS for 48 hours. Representative wells were co unted for the average of cells in each well. Virus supernatant, 0.5 l, 5 l, 50 l and 500 l of were added to the wells in duplicate, using 6 g/ml polybrene in each well. Cells were incubated with virus suspen sion for 24 hours and then replaced by fresh DMEM 10% FBS 1% PSG. take the following: cells (% of GFP positive cells/100)/ mL of virus used, where TU is the transforming unit and thenumber of cells refers to the amount of cells at the beginning of the culture. 9. Western blot assay for at 37\u00baC ambient air, supplemented with 5% CO 2 as normal Cell cultures were lysed for 30 minutes in 0.3 mL of 1% Triton X-100 lysis buffer (20 mM Tris-HCl, pH 7.5; units for aprotinin. After centrifugation at 14000 g for 10 min, 50 g of the protein contained in the supernatant was resuspeneded in 10% polyacrilamide SDS-PAGE and running at 200V for 40 minutes. -mercaptoethanol and SDS give negative charge to proteins according to the mass, so they can migrate to Samples were Cruz Data tables Table S1. R L responsiveness to MCh. IP and IN OVA models. Data are mean \u00b1 standard error of the mean. IP D0 to BAL 1.264 Data the 3IN, OVA : versus CTRL. versus 3IN CTRL. : versus 0.05 IP OVA \u00b1 0.06 >0.05 0.05 \u00b1 0.05 0.05 \u00b1 0.03 >0.05 - Data are mean \u00b1 standard error of the mean. IP 1.36 * P<0.001 CTRL 0 \u00b1 0 30IN OVA 5.1 \u00b1 0.96 * P<0.001 Data are mean \u00b1 standard error of the mean. 3IN, Data are of the mean. 3IN, CTRL 0.45 \u00b1 4.78 P<0.019 Data are the 3IN, CTRL (dimensionless) 0 \u00b1 930 3IN OVA 391.97 P=0.004 Data are the 3IN, CTRL morphology in nasal mucosa. Model Group Goblet cells/mm2 CTRL 11.934 \u00b1 1.269 *P<0.001 Data are the 3IN, CTRL of the mean. 3IN, CTRL 3IN; : versus (dimensionless) CTRL 0.1043 \u00b1 0.02 IP OVA 0.1218 \u00b1 P=0.658 CTRL 0.0838 \u00b1 0.2075 \u00b1 0.03 * P=0.004 Data are mean \u00b1 standard error of the mean. 3IN, the 3IN, CTRL counted. to cell adoptive transfer model. Data standard error of the mean. Airway instilla Recipients of 1x105 naive T cells, OVA-challeng ed, are Total BAL are mean \u00b1 standard error of the mean. T ce ll transfer and i.n. instillations as indicated. *: versus Control 1 (recipients of activated T PBS-instilled); : versus Control (recipients naive T OVA-challenged). model . of the mean. challenged with vehicle (PBS) 30 times in the absence of adoptive transfer that were used as a control group. *: versus same dose on control group. : versus same dose on HDM challenge group that received \u00b1 standard of cell transfer and i.n. instillations as : challenge mice that received adoptive transfer of cell transfer and i.n. instillations are mean \u00b1 standard erro r of the mean.* vs control Summary 208 III. Summary Castellano El asma afecta aproximadamente a unos 300 millones de personas en todo el mundo. Su prevalencia se ha incrementado, especialmente en los pa\u00edses industrializados, habiendo llegado a doblarse en solamente una d\u00e9cada en la Uni\u00f3n Europea. A pesar de los desarrollos terap\u00e9uticos ya alcanzados, aproximadamente un 10% de los asm\u00e1tico s sufren enfermedad grave refractaria a la terapia m\u00e1xima disponible. El asma es una enfe rmedad compleja caracteri zada principalmente por la inflamaci\u00f3n cr\u00f3nica de la v\u00eda a\u00e9rea junto con cambios estructurales, conocidos mediante el t\u00e9rmino \"remodelaci\u00f3n\", que subyace n a las manifestaciones cl\u00ednicas y gravedad de la enfermedad, especialmente al deterioro irreversible de funci\u00f3n pulmonar que existe en algunos asm\u00e1ticos. La remodelaci\u00f3n de v\u00edas respiratorias en el asma ocur re en asociaci\u00f3n a la inflamaci\u00f3n cr\u00f3nica, resulta en anormalidades estructurales permanentes en su pared, y afecta v\u00edas respiratorias de todas las categor\u00edas en cuanto a localizaci\u00f3n y tama\u00f1o. Se entiende actualmente que la remodelaci\u00f3n de las v\u00edas respiratorias forma parte del sustrato fisiopatol\u00f3gico de la hiperreactividad bronquial y la obstrucci\u00f3n al flujo a\u00e9reo, y puede comenzar en una fase temprana de la enfermedad, previa a la aparici\u00f3n de s\u00edntomas. Los cambios estructurales descritos como parte de la remodelaci\u00f3n de v\u00edas respiratorias son: (i) engrosamiento del epitelio respiratorio, junto con hiperplasia e hipertrofia de c\u00e9lulas caliciformes; (ii) aumento del tama\u00f1o y n\u00famero de gl\u00e1ndulas mucosas que se traduce, junto con los cambios en las c\u00e9lulas caliciformes, en la hi persecreci\u00f3n de moco a la luz de la v\u00eda a\u00e9rea, participando de forma especial en la obstrucci\u00f3n al flujo a\u00e9reo de instauraci\u00f3n s\u00fabita en el contexto de crisis, y contribuyendo al desarrollo de atelect asias; (iii) hiperplasia de c\u00e9lulas caliciformes, asociada a la hipersecrecci\u00f3n de moco; (iv) fibros is subepitelial, debida a un dep\u00f3sito excesivo de matriz extracelular en la capa de tejido conjuntivo que subyace al epitelio bron quial; (v) angiog\u00e9nesis bronquial y permeabilidad vascular alterada, que facilita la formaci\u00f3n de edema; y (vi) aumento de la masa de m\u00fasculo liso bronquial y bronquiolar, debido a la combinaci\u00f3n de hiperplasia e hipertrofia de las c\u00e9lulas muscular es lisas, m\u00e1s una probable contribuci\u00f3n de c\u00e9lulas progenitoras circulantes que son reclutadas y se di ferencian a miofibroblasto y c\u00e9lula muscular lisa. De entre estos cambios, el m\u00e1s estudiado es la remodelaci\u00f3n del m\u00fasculo liso, que se considera de importancia central en el mecanismo de la hiperreactividad bronquial y obstrucci\u00f3n al flujo a\u00e9reo. Los modelos animales de enfermedad experi mental permiten el estudio de mecanismos biol\u00f3gicos de enfermedad con un detalle y profundidad no posible en sujetos humanos. Los modelos animales de asma experimental han contribuido a una mejor comprensi\u00f3n y tratamiento de la APPENDIX 209 enfermedad en humanos. La especie m\u00e1s ampliament e utilizada para modelar asma experimental es el rat\u00f3n, tanto por reproducir la mayor\u00eda de los rasgos patol\u00f3gicos de la enfermedad humana como por su bajo coste y f\u00e1cil manejo. La fisiopatolog\u00eda del asma ha sido ampliamente estudiada en modelos de asma experimental basados en sens ibilizaci\u00f3n intraperitoneal a ant\u00edgenos junto con coadyuvantes seguido de provocaci\u00f3n con el ant\u00edgen o en la v\u00eda a\u00e9rea. Este procedimiento reproduce con intensidad la mayor\u00eda de signos de la enfermedad asm\u00e1tica, tales como la hiperreactividad bronquial y remodelaci\u00f3n de v\u00edas respiratorias, a trav\u00e9s de una respuesta al\u00e9rgica tipo Th2 con elevados niveles de IgE. Sin embargo, esta estrateg ia experimental no represen ta el modo real en el que los humanos desarrollan asma y rinitis al\u00e9rgica por sensibilizaci\u00f3n y exposici\u00f3n a aeroal\u00e9rgenos, y puede haber diferencias relevantes en los mecanismos biol\u00f3gicos subyacentes. De hecho, el contacto di recto de la mucosa del tracto respiratorio con el ant\u00edgeno alerg\u00e9nico es con gran probabilidad esencial para la funci\u00f3n del sistema inmunitario innato, e interacciones a este nivel pueden determinar la subsiguiente respuesta inmunitaria, en t\u00e9rminos de ataque o tolerancia. Es altamente probable que los modelos de asma al\u00e9r gica experimental que se basan en sensibilizaci\u00f3n intraperitoneal se salten un paso crucial para entender la fisiopatolog\u00eda del asma. Por tanto, modelos animales basados en exposici\u00f3n primaria al ant\u00edgeno en la v\u00eda a\u00e9rea, sin sensibilizaci\u00f3n intraperitoneal tipo \"vacuna\", pueden tener el pote ncial de reflejar de un modo m\u00e1s integral el desarrollo del asma al\u00e9rgica, por involucrar las v\u00edas inmunorreguladoras que los modelos basados en sensibilizaci\u00f3n intraperitoneal pueden fallan en reflejar. En dichas v\u00edas inmunorreguladoras, pueden estar implicadas c\u00e9lulas T con funci\u00f3n reguladora (c\u00e9lulas Treg). Desde la descripci\u00f3n en 2003 del factor de transcripci\u00f3n FOXP3 como responsable del fenotipo regulador de c\u00e9lulas T CD4+, han sido descritos diversos tipos de c\u00e9lulas T con fenotipo regulador. Auque en la actualidad es generalmente aceptado que no todas las c\u00e9lul as con fenotipo regulador expresan FOXP3, la detecci\u00f3n de este marcador contin\u00faa siendo un in strumento de gran utilidad en el estudio de la funci\u00f3n inmunoreguladora vehiculada por c\u00e9lulas T CD4+. A todo esto hay que a\u00f1adir que la v\u00eda a\u00e9rea superior ha sido extensamente ignorada en los modelos animales de asma experimental. Recientemente, se ha desarrollado la teor\u00eda de la \"v\u00eda a\u00e9rea \u00fanica\", que postula que el asma y la rinitis son dos manifestaciones diferentes de una misma enfermedad, en dos partes de una v\u00eda a\u00e9rea com \u00fan. Aunque esta teor\u00eda es criticada de ser excesivamente simplista, existe evidencia de una asociaci\u00f3n entre rinitis al\u00e9rgica y asma, y de una relaci\u00f3n biol\u00f3gica e inmunol\u00f3gica entre la mucosa de la v\u00eda a\u00e9rea superior, y la de las v\u00edas respiratorias intrapulmonares. Summary 210 Por todo ello, en el presente trabajo de tesis doctoral nos propusimos desarrollar un modelo integrado de rinitis al\u00e9rgica y asma basado en exposici\u00f3n primaria antig\u00e9nica en v\u00eda respiratoria, y estudiar en este modelo la existencia de mecanismos de inmunorregulaci\u00f3n acoplados a la respuesta efectora generadora del asma, y la posible implicaci\u00f3n de las c\u00e9lulas Treg en el desarrollo de la enfermedad. Adicionalmente, para a\u00f1adir valor tras lacional b\u00e1sico-cl\u00ednico a los datos obtenidos en los modelos animales, realizamos an\u00e1lisis en biopsias bronquiales humanas. Para explorar la respuesta a la sensibilizaci\u00f3n al \u00e9rgica en la v\u00eda a\u00e9rea, desarrollamos modelos de exposici\u00f3n primaria a OVA en v\u00eda a\u00e9rea mediante instilaci\u00f3n intranasal repetida en r\u00e9gimen lunes- mi\u00e9rcoles-viernes, en ausencia de adyuvantes inmunol\u00f3gicos, con recogida de datos y estudio en tres puntos de tiempo diferentes: (i) un punto temprano exploratorio de enfermedad m\u00ednima o incipiente (tres instilaciones, denominado modelo 3IN); (ii) un punto de intervalo de tiempo desde la primera exposici\u00f3n an tig\u00e9nica equivalente a un modelo cl\u00e1s ico de sensibilizaci\u00f3n intraperitoneal (10 instilaciones, denominado modelo 10IN, que fue comparado con el modelo de sensibilizaci\u00f3n intraperitoneal -IP-); y (iii) un modelo prolongado pa ra explorar si el grado de enfermedad reflejado en el modelo 10IN se reforzar\u00eda, alcanzar\u00eda un plateau o se atenuar\u00eda si la exposici\u00f3n antig\u00e9nica intranasal se extendiese (30 instilaciones, modelo 30IN). En el modelo de sensibilizaci\u00f3n intraperitoneal, los imales tras infiltraci\u00f3n inflamatoria as imismo eosin\u00f3fila de v\u00edas respirator ias mostrada en secciones de tejido pulmonar y nasal, incremento de la presencia de sustancias mucosas en v\u00edas a\u00e9reas superior en inferiores, incremento de la masa de m\u00fasculo liso en v\u00edas respiratorias intrapulmonares; y un aumento notable de c\u00e9lulas con expresi\u00f3n de mRNA de Foxp3 con aumento limitado de c\u00e9lulas con expresi\u00f3n de mRNA de Il10 y Tgfb. En los modelos de exposici\u00f3n antig\u00e9nica primaria en v\u00eda respiratoria, la reactividad de v\u00edas respiratorias a metacolina result\u00f3 atenuada en el m odelo 10IN respecto al modelo IP, y declin\u00f3 en el modelo 30IN. Los tres modelos de exposici\u00f3n antig\u00e9nica primaria en v\u00eda a\u00e9rea presentan un aumento de c\u00e9lulas totales en lavado broncoalveolar con predominancia de linfocitos. Los modelos 10IN y 30IN mostraron infiltraci\u00f3n inflamatoria pulmonar con presencia de eosin\u00f3filos, pero atenuada respecto al modelo IP, y con un viraje del recuento diferencial hacia predominio linfocitario. Sin embargo el infiltrado inflamatorio en la mucosa nasal fue comparable al modelo IP, excepto en el modelo de 3IN, en el que no se apr eci\u00f3 un aumento respecto al grupo control. En lo que respecta a la producci\u00f3n de sustancias muco sas, los intranasales mostraron un aumento progresivo de la respuesta mucoide en el epitelio nasal, desde las 3 instilaciones hasta las 30, siendo APPENDIX 211 este \u00faltimo modelo comparable a lo obtenido en el modelo IP. Por el contrario, la respuesta mucoide en pulm\u00f3n, aunque aumentada respecto a los grupos control tras 3, 10 y 30 instilaciones, result\u00f3 atenuada respecto al modelo IP. En lo que concie rne a la deposici\u00f3n de ma triz extracelular, tras 3 instilaciones intranasales no se apr eciaron diferencias significativas respecto al grupo control ni al modelo IP; sin embargo, s\u00ed se apreci\u00f3 fibrosis s ubepitelial tras 10 y 30 instilaciones intranasales, lo que sugiere que la fibrosis subepitelial es un fen\u00f3meno progresivo con la duraci\u00f3n de la enfermedad. La masa de m\u00fasculo liso solo result\u00f3 incrementada pero de forma atenuada en el modelo 30IN, de forma concomitante a la atenuaci \u00f3n observada en la hipe rreactividad bronquial. La obtenci\u00f3n de una respuesta al\u00e9rgica con m\u00e1ximo atenuado y subsiguiente declive en los modelos intranasales, en comparaci\u00f3n con el modelo de se nsibilizaci\u00f3n intraperitoneal como comparador de capacidad de respuesta m\u00e1xima, sugiere que la exposi ci\u00f3n primaria antig\u00e9nica en v\u00eda respiratoria, tal como ocurre en la adquisici\u00f3n natural de enfermedad humana, activan mecanismos inmunoreguladores. La evidencia de este brazo inmunoregulador, reflejado en la atenuaci\u00f3n de la inflamaci\u00f3n e hiperreactividad de v\u00edas respiratorias, nos condujo a explorar un posible papel de c\u00e9lulas Treg. Debido a dificultades t\u00e9cnicas para la detecci\u00f3n de prote\u00edna FO XP3 en tejido de rat\u00f3n fijado con formalina, analizamos la expresi\u00f3n de mRNA de Foxp3 en estos modelos, junto con la expresi\u00f3n de mRNA de Il10 y Tgfb, dos citoquinas directamente rel acionadas con la funci\u00f3n de las c\u00e9lulas T reguladoras. Estos an\u00e1lisis , realizados mediante hibridaci\u00f3n in situ sobre secciones de tejido pulmonar, condujeron a la detecci\u00f3n en los infiltrados inflamatorios de un aumento progresivo de la cantidad de c\u00e9lulas que expresaban Foxp3 , Il10 y Tgfb hasta alcanzar sus m\u00e1ximos niveles en el modelo 30IN. La cantidad de c\u00e9lulas con expresi\u00f3n de Il10 y Tgfb fue comparable a lo observado en el modelo de sensibilizaci\u00f3n intraper itoneal. Sin embargo, la cantidad de c\u00e9lulas con expresi\u00f3n de Foxp3 en el modelo IP fue desproporcionadamente elevada, sugiriendo la presencia de c\u00e9lulas Foxp3+ sin funcionalidad inmunoreguladora. Estos datos mostraron que la exposici\u00f3n primaria a ant\u00edgeno en la v\u00eda a\u00e9rea y en ausencia de sensibilizaci\u00f3n intraperitoneal o adyuvantes induce ri nitis al\u00e9rgica que progre sa durante el per\u00edodo de exposici\u00f3n al ant\u00edgeno, y asma experimental atenuada que se modula como resultado de la exposici\u00f3n continuada. Esta modulaci\u00f3n est\u00e1 asociada con un aumento de los n\u00fameros de c\u00e9lulas linfoides que expresan Foxp3, Il10 y Tgfb en los infiltrados inflamatorios pulmonares, lo que sugiere mecanismos de inmunorregulaci\u00f3n activa que los modelos basados en sensibilizaci\u00f3n intraperitoneal fallan en reflejar. Los resultados obtenidos en esta primera parte del trabajo de investigaci\u00f3n doctoral mostraron que la exposici\u00f3n primaria y continuada a ant\u00edgeno en las v\u00edas respiratorias induce la activaci\u00f3n de un brazo inmunoregulador que resulta en la atenuaci\u00f3n de los Summary 212 rasgos del asma al\u00e9rgica experimental, pero no de la rinitis al\u00e9rgica, sugiriendo adem\u00e1s un papel importante de c\u00e9lulas Treg productoras de IL10 y TGFB. Este conjunto de datos fue asimismo consistente con la hip\u00f3tesis de que la interacci\u00f3n del al\u00e9rgeno con la mucosa de la v\u00eda respiratoria en el momento de la exposici\u00f3n antig \u00e9nica primaria es crucial, median te la probable participaci\u00f3n del sistema inmunitario innato, para definir el perfil de respuesta subsiguiente a cargo del sistema inmunitario adaptativo. As\u00ed pues, en la siguiente parte del trabajo nos propusimos demostrar el papel de c\u00e9lulas T efectoras CD4+ y c\u00e9lulas T reguladoras CD4+ en el asma experimental. Para estudiar el papel de las c\u00e9lulas T CD4+ efectoras y reguladoras, realizamos experimentos de transferencia adoptiva en dos modelos de exposi ci\u00f3n antig\u00e9nica en v\u00eda a\u00e9rea. Con la finalidad de realizar seguimiento in vivo de las c\u00e9lulas transferidas, proced imos a su modificaci\u00f3n gen\u00e9tica para inducir la expresi\u00f3n permanente de una variante de prote\u00edna verde fluorescente (GFP). La expansi\u00f3n clonal de c\u00e9lulas T activadas representa el cicl o celular m\u00e1s r\u00e1pido conocido entre las c\u00e9lulas de organismos pluricelulares . Dada la necesidad de conseguir la modificaci\u00f3n gen\u00e9tica permanente de las c\u00e9lulas diana y su progenie, nos decantamos por la transducci\u00f3n retroviral empleando vectores de tipo onco-retroviral que, tras su retrotranscripci\u00f3n, se integran de forma permanente en el genoma de las c\u00e9lulas transducidas, y con ello el cDNA de inter\u00e9s subclonado en el vector. Para ello, estos vectores aprovechan la ausencia de envoltura nuclear durante la mitosis (metafase y anafase) para integrarse en el genoma celular y originar expresi\u00f3 n constitutiva. Esta caracter\u00edstica, combinada con la estimulaci\u00f3n in vitro de c\u00e9lulas T efectoras ant\u00edgeno-espec\u00edficas obtenidas de donantes sensibilizados a un dete rminado ant\u00edgeno, resulta en un m\u00e9todo eficaz para la transducci\u00f3n de c\u00e9lulas T efectoras ant\u00edgeno-es pec\u00edficas, dado que el tipo de vector de transferencia g\u00e9nica empleado solamente transduce c\u00e9lulas en ciclo cel ular activo, y \u00fanicamente las c\u00e9lulas T CD4+ ant\u00edgeno-espec\u00edficas entran en ci clo celular cuando una poblaci\u00f3n de esplenocitos de un animal sensibilizado se expone al ant\u00edgeno in vitro . Tras el dise\u00f1o y construcci\u00f3n del vector retr oviral de transferencia g\u00e9nica para inducir expresi\u00f3n permanente de GFP, al que hemos denominado pMSCV-GFP por derivarse de un Murine Stem Cell Virus , procedimos a generar mediante transducci\u00f3n y separar por citometr\u00eda de flujo c\u00e9lulas T CD4+GFP+ efectoras, con las cuales realizamos un modelo de asma experimental basado en transferencia ad optiva de estas c\u00e9lulas a animales recep tores sing\u00e9nicos no sensibilizados, y posterior instilaci\u00f3n intranasal del ant\u00edgeno (OVA) en los animales receptores. En este modelo, nos propusimos titular el n\u00famero m\u00ednimo de c\u00e9lulas T CD4+ ant\u00edgeno-espec\u00edficas efectoras necesario para inducir hiperreactividad e inflamaci\u00f3n de v\u00edas respiratorias, bajo la hip\u00f3tesis de que muy peque\u00f1as cantidades de estas c\u00e9lulas ser\u00edan sufici entes. Los ratones recepto res fueron instilados dos APPENDIX 213 veces con OVA antes de la transfer encia adoptiva y tres veces despu\u00e9 s (5 instilaciones intranasales), en forma de un modelo breve para prevenir posible solapamiento con una respuesta inmunitaria adaptativa que el hu\u00e9sped podr\u00eda desarrollar. Realizamos series de titulaci\u00f3n, que mostraron que la transferencia adoptiva de 105 c\u00e9lulas T efectoras CD4+ OVA-espec\u00edficas es su ficiente para inducir hiperreactividad a metacolina, incremento de c\u00e9lulas totales en el lavado broncoalveolar e inflamaci\u00f3n de la v\u00eda a\u00e9rea evidente en el an\u00e1lisis histopatol\u00f3gico del tejido pulmonar, donde se detectaron c\u00e9lulas GFP+. Estos datos indicaron que peque\u00f1os n\u00fameros de c\u00e9lulas T CD4+ efectoras ant\u00edgeno-espec\u00edficas tienen la capacidad de migrar a las v\u00edas respiratorias y dirigir la inflamaci\u00f3n en una respuesta inmunitaria adaptativa al\u00e9rgica. En el segundo modelo de transferencia adoptiva, nos propusimos comprobar el efecto de la transferencia de c\u00e9lulas Treg en un modelo de asma experimental con enfermedad establecida, inducido en este caso por exposici\u00f3n primaria en v\u00eda a\u00e9rea a extracto estandarizado de \u00e1caros del polvo ( house dust mite , en adelante HDM). Para las finalida des de este experimento se generaron c\u00e9lulas T CD4+ reguladoras in vitro mediante transducci\u00f3n retrovir al de una manera similar a la obtenci\u00f3n de c\u00e9lulas T CD4+ efectoras descrita anteriormente, pero a partir de donantes sensibilizados a HDM. En este caso se construy\u00f3 un vector retroviral bicistr\u00f3nico que contiene las secuencias de Foxp3 y gfp separadas por una secuencia in terna de entrada ribosomal (un internal ribosome entry site , en adelante IRES), vector al que de nominamos pRetroFOXP3-IRES-GFP. Este vector induce la expresi\u00f3n simult \u00e1nea de FOXP3 y GFP en las c\u00e9lulas transducidas, de forma que la detecci\u00f3n de GFP permite la identificaci\u00f3n de c\u00e9lulas FOXP3+. La expresi\u00f3n forzada de FOXP3 generada de este modo en c\u00e9lulas T CD4+ activadas induce funci\u00f3n re guladora en estas c\u00e9lulas, es decir, genera c\u00e9lulas Treg. Adem\u00e1s, las c\u00e9lulas Treg as\u00ed generadas son ant\u00edgeno-espec\u00edficas. Los animales receptores fueron instilados con HDM un total de 28 veces a lo largo de 40 d\u00edas de duraci\u00f3n del modelo. En el grupo receptor de tr ansferencia adoptiva, 75.0 00 c\u00e9lulas Treg fueron inyectadas en la vena de la cola antes de la finalizaci\u00f3n de las instilaciones intranasales (en la instilaci\u00f3n 24, d\u00eda 31). En este experimento piloto (n=4 por grupo), la transferencia adoptiva de solamente estas 75.000 c\u00e9lulas Treg generadas in vitro provoc\u00f3 una modesta reducci\u00f3n en los infiltrados inflamatorios en tejido pulmonar, sin modificar significativamente los recuentos de c\u00e9lulas totales en lavado broncoalveolar, y se observ\u00f3 asimismo una atenuaci\u00f3n de la hiperreactividad de v\u00edas respirat orias, demostr\u00e1ndose mediante de tecci\u00f3n de GFP que las c\u00e9lulas transferidas estaban presentes en los infiltrados inflamatorios en las v\u00edas respiratorias intrapulmonares. Summary 214 Como \u00faltimo objetivo y con un enfoque traslacional, nos propusimos explorar la aplicabilidad de los datos obtenidos en los modelos animales a la enfermedad humana. Los datos sobre c\u00e9lulas Treg en el asma humana est\u00e1n en una fase muy in cipiente y los resultados en este sentido son limitados e inconsistentes. La totalidad de los escas os trabajos realizados so bre c\u00e9lulas Treg en el asma humana se han centrado en la detecci\u00f3n de dichas c\u00e9lulas en sangre perif\u00e9rica o lavado broncoalveolar, pero hasta la fecha no existen estudios sobre tejido pulmonar. Teniendo en cuenta esta carencia, nos propusimos estudi ar la presencia de c\u00e9lulas FOXP3+ mediante inmunohistoqu\u00edmica en biopsias bronquiales de pacientes con asma grave y compararlos con sujetos control. Hemos hallado que las c\u00e9lulas FOXP3 + est\u00e1n pr\u00e1cticamente ausentes en biopsias de sujetos control. Por el contrario, las biopsias de pacientes con asma grave mostraron una presencia significativa de c\u00e9lulas FOXP3+ infiltrando principalmente zonas de tejido conectivo laxo subepitelial. Este aumento de c\u00e9lulas FOXP3+ en biopsias bronquiales de pacientes con asma grave sugiere un papel de la inmunorregulaci\u00f3n mediada por c\u00e9lulas Treg, y es adem\u00e1s consistente con los datos derivados de modelos animales. Nuestro conjunto de datos generados a partir de asma experimental e investigaci\u00f3n cl\u00ednica sugiere que las c\u00e9lulas Treg est\u00e1n aumentadas en la pared de las v\u00edas respiratorias en el asma, pr obablemente de forma reactiva a la inflamaci\u00f3n cr\u00f3ni ca que subyace a la enfermedad. Si las c\u00e9lulas FOXP3+ observadas en las biopsias bronquiales humanas son funcionalmente competentes como c\u00e9lulas Treg o no, es desconocido en este punto y, por tanto, se necesitan nuevos estudios que las caractericen de fo rma m\u00e1s extensa en sujetos asm\u00e1ticos. El fallo en resolver la inflamaci\u00f3n cr\u00f3nica de las v\u00edas respiratorias en el asma tiene con toda probabilidad una causa compleja multifactorial, y no necesaria mente implica una deficiencia en la funci\u00f3n o reclutamiento de c\u00e9lulas Treg. De los resultados obtenidos en el presente trabajo de tesis doctoral se puede concluir que: - La exposici\u00f3n primaria en la v\u00eda a\u00e9rea y la provocaci\u00f3n continuada con ant\u00edgeno, a diferencia de la sensibilizaci\u00f3n intraperitoneal seguida de provocaci\u00f3n intranasal, induce asma experimental atenuada con disminuci\u00f3n de la hiperreacitividad de v\u00edas respiratorias, la hipersecreci\u00f3n de moco y ligero aumento de la masa de m\u00fasculo liso. Por el contrario, la fibrosis subepitelial aumenta progresivamente y los infiltrados inflamatorios giran hacia un predominio linfocitario. - Tras la exposici\u00f3n primaria a ant\u00edgeno en la v\u00ed a a\u00e9rea, se produce una hipertrofia e hiperplasia de c\u00e9lulas caliciformes, tanto en v\u00eda a\u00e9rea superior como v\u00edas respiratorias inferiores, en un espacio de tiempo insuficiente para el desarrollo de una respuesta inmunitaria adaptativa. Esta respuesta mucosa temprana podr\u00eda ser el resultado de la acci \u00f3n de mecanismos del sistema inmunitario innato. APPENDIX 215 - En la mucosa nasal, tanto la exposici \u00f3n primaria a ant\u00edgeno en v\u00eda a\u00e9rea como la sensibilizaci\u00f3n intraperitoneal previa, inducen ri nitis al\u00e9rgica con infiltraci\u00f3n eosinof\u00edlica, hiperplasia de c\u00e9lulas caliciformes y aumento de la producci\u00f3n de moco. Al contrario de las manifestaciones del asma experimental, la exposici\u00f3n primaria a ant\u00edgeno en la v\u00eda a\u00e9rea seguida de provocaci\u00f3n continuada provoca un aume nto progresivo de la intensidad de la rinitis al\u00e9rgica con el tiempo. - Tras la exposici\u00f3n primaria a ant\u00edgeno en la v\u00eda a\u00e9rea seguida de provocaci\u00f3n intranasal continuada, la atenuaci\u00f3n de la mayor parte de las caracter\u00edsticas del asma experimental, la progresi\u00f3n de la fibrosis subepitelial y el viraje hacia infiltrados predominantemente linfocitarios est\u00e1n asociados con una progresiva presencia en el infiltrado inflamatorio de c\u00e9lulas que expresan mRNA de Foxp3 , Il10 y Tgfb. La sensibilizaci\u00f3n intraperitoneal tiene como consecuencia un aumento anormal de c\u00e9lulas que expresan mRNA de Foxp3 en el infiltrado inflamatorio, pero que no se correlaciona con un aumento concordante en la transcripci\u00f3n de Tgfb. - C\u00e9lulas T CD4+ efectoras ant\u00edgeno-espec\u00edficas diri gen el reclutamiento de c\u00e9lulas inflamatorias y la hiperreactividad de v\u00edas respirat orias tras la provocaci\u00f3n antig\u00e9nica. Estas c\u00e9lulas, en escasa cantidad, son capaces de migrar a las v\u00edas respiratorias y provocar los efectos mencionados. - C\u00e9lulas T efectoras CD4+ ant\u00edgeno-espec\u00edficas con expresi\u00f3 n forzada de FOXP3 act\u00faan como c\u00e9lulas Treg in vivo y modulan la hiperreactividad e inflamaci \u00f3n de las v\u00edas respiratorias en modelos animales con asma experimental establecida. Estas c\u00e9lulas, en escaso n\u00famero, son capaces de migrar a las v\u00edas respiratorias y provocar los efectos mencionados. - Existe un aumento significativo en la presencia de linfocitos FOXP3+ en biopsias bronquiales de pacientes con asma grave en comparaci\u00f3n con sujetos control. Dicho aumento puede reflejar un incremento de c\u00e9lulas Treg re activo a la inflamaci\u00f3n cr\u00f3nica. Summary 216 Galego A asma afecta a uns 300 mill\u00f3ns de persoas en to do o mundo. A sua prev alencia incrementouse, especialmente nos pa\u00edses industria lizados, chegando a duplicarse en tan s\u00f3 unha d\u00e9cada Europea. A pesares dos caracteri xunto con cambios e gravidade da enfermidad e, especialmente \u00f3 deterioro irreversible da funci\u00f3n pulmonar que se encontra nalg\u00fans asm\u00e1ticos . A remodelaci\u00f3n das v\u00edas respiratorias na asma ocorre en asociaci\u00f3n \u00e1 in flamaci\u00f3n cr\u00f3nica, resulta en anormalid ades estructurais permanentes na s\u00faa parede, e afecta v\u00edas respiratorias de t\u00f3da las categor\u00edas en canto a localizaci\u00f3n e tama\u00f1o. Ent\u00e9ndese actualmente que a remodelaci\u00f3n das v\u00edas respiratorias forma parte do sustrato fisiopatol\u00f3xico da hiperreactivid ade bronquial e a obstruci\u00f3n \u00f3 fluxo a\u00e9reo, e pode empezar cedo na enfermidade, previo \u00e1 aparici\u00f3n de s\u00edntomas. Os cambios estructur\u00e1is descritos como parte da remodelaci\u00f3n de v\u00edas respiratorias son: (i) engrosamento do epitelio respiratorio, xunto con hiperplasia e hipertrofia de c\u00e9lulas caliciformes; (ii) aumento do tama\u00f1o e n\u00famero das gl\u00e1ndulas mucosas que se traduce, xunto cos cambios nas c\u00e9l ulas caliciformes, na hipersecreci\u00f3n de moco \u00e1 luz da v\u00eda a\u00e9rea, participando de xeito especial na obstrucci\u00f3n \u00f3 fluxo a\u00e9reo de instauraci\u00f3n s\u00fabita no contexto de crise, e contribu\u00edndo \u00f3 desarroio de atelectasias; (iii) hiperplasia de c\u00e9lulas caliciformes, asociada \u00e1 hipersecrecci\u00f3n de moco (i v) fibrose subepitelial, debida a un dep\u00f3sito excesivo de matriz extracelular na capa de teci do conxuntivo que subxace \u00f3 epitelio bronquial; (v) anxiox\u00e9nese bronquial e permeabilidade vascular alterada, que facilita a formaci\u00f3n de edema; e (vi) aumento da masa de m\u00fasculo liso bronquial e bronquiolar, por mor da combinaci\u00f3n de hiperplasia e hipertrofia das c\u00e9lulas musculares lisas, m\u00e1is unha probable contribuci\u00f3n de c\u00e9lulas proxenitoras circulantes que son reclutadas e que se diferencian a miofibroblasto e c\u00e9lula muscular lisa. De entre estes cambios, o m\u00e1is estudado \u00e9 a remodelaci\u00f3n do m\u00fasculo liso, que se considera de importancia central no mecanismo da hiperreactividade bronquial e a obstruci\u00f3n \u00f3 fluxo a\u00e9reo. Os modelos anim\u00e1is de enfermidade experiment al permiten o estudo de mecanismos biol\u00f3xicos de enfermidade cun detalle e profundidade non posible en suxeitos humanos. Os modelos anim\u00e1is de asma experimental contribu\u00edron a unha mellor comprensi\u00f3n e tratamento da enfermidade en humanos. A especie m\u00e1is amplamente usada para modela-la asma experimental \u00e9 o rato, tanto por reproducires a maior\u00eda dos rasgos patol\u00f3xicos da enfermidade humana como polo seu baixo coste e f\u00e1cil manexo. A fisiopatolox\u00eda da asma foi amplamen te estudada en modelos de experimental basadosen sensibilizaci\u00f3n intraperitoneal a ant\u00edxenos xunto con adxuvantes seguido de provocaci\u00f3n co ant\u00edxeno na v\u00eda a\u00e9rea. Este procedemento re produce con intensidade a maior\u00eda dos signos da enfermidade asm\u00e1tica, tales como a hiperreact ividade bronquial e remodelaci\u00f3n v\u00edas respiratorias, a trav\u00e9s dunha resposta al\u00e9rxica tipo Th2 con elevados niveis de IgE. Sen embargo, esta estratexia experimental non representa o xeito real no que os humanos desarroian asma e rinitis por subxacentes. De feito, o cont acto directo da mucosa do tracto respiratorio co ant\u00edxeno alerx\u00e9nico \u00e9, cunha grande posibilidade, esencial para a funci\u00f3n do sistema inmunitario innato, e interacci\u00f3ns a este nivel poden determinar a conseguinte re sposta inmunitaria, en termos de ataque ou tolerancia. \u00c9 altamente probable que os modelos de asma al\u00e9rxica experimental basados en sensibilizaci\u00f3n intraperitoneal salten un pa so crucial para entende res a fisiopatolox\u00eda da asma. Polo tanto, modelos anim\u00e1is basados en exposici\u00f3n primaria a ant\u00edxeno na v\u00eda a\u00e9rea, sen sensibilizaci\u00f3n intraperitoneal tipo \"vacina\", poden te-lo potencial de reflexar dun modo m\u00e1is integral o desarroio da asma al\u00e9rxica, por mor de involucra-las v\u00edas inmunorreguladoras que os modelos basados en sensibilizaci\u00f3n intraperitoneal errar en refl exar. En ditas v\u00edas inmunorreguladoras, poden estar implicadas c\u00e9lulas T con funci\u00f3n reguladora (c\u00e9lulas Treg). Dende a descrici\u00f3n no 2003 do factor de transcrici\u00f3n FOXP3 como respons\u00e1bel do fenotipo regulador de c\u00e9lulas T CD4 +, te\u00f1en sido descritos diversos tipos de c\u00e9lulas T con fenotipo regulador. A\u00ednda que na actualidade \u00e9 xeralmente aceptado que non t \u00f3dalas c\u00e9lulas con fenotipo regulador expresan FOXP3, a detecci\u00f3n deste marcador contin\u00faa sendo un instrumento de gran utilidade no estudo da funci\u00f3n inmunorreguladora levada a cabo por c\u00e9lulas T CD4+. A todo isto hai que engadir que a v\u00eda a\u00e9rea superior foi extensamente ignorada nos modelos anim\u00e1is de asma experimental. Recentemente, de senvolveuse a teor\u00eda da \"v\u00eda a\u00e9rea \u00fanica\", que postula que a asma e a rinitis son d\u00faas manifestaci\u00f3ns diferentes dunha misma enfermidade, en a\u00e9rea com\u00fan. A\u00ednda que esta teor \u00eda \u00e9 criticada por seres excesivamente simplista, existe evidencia dunha asociaci\u00f3n entre rinitis al\u00e9rxica e asma, e dunha relaci\u00f3n biol\u00f3xica e inmunol\u00f3xica entre a mucosa da v\u00eda a\u00e9rea superior, e a de v\u00edas respiratorias intrapulmonares. Por todo elo, no presente traballo de tese doutoral propux\u00e9monos desenvolver un modelo integrado de rinitis al\u00e9rxica e asma basado en exposici\u00f3n primaria antix\u00e9nica en v\u00eda respiratoria, e estudar neste modelo a existencia de mecanismos de inmunorregulaci\u00f3n acoplados \u00e1 resposta efectora xeradora da asma, e \u00e1 impli caci\u00f3n c\u00e9lulas Treg no desenvolvemento \u00e1 sensibilizaci\u00f3n al \u00e9rxica na v\u00eda a\u00e9rea, desenvolvemos modelos de exposici\u00f3n primaria a OVA na v\u00eda a\u00e9rea mediante instilaci\u00f3n intranasal repetida en r\u00e9xime lunes- m\u00e9rcores-venres, en ausencia inm unol\u00f3xicos, con recollida e datos e estudo en tres puntos de tempo diferentes: (i) un punto temper\u00e1n exploratorio de enfermidade m\u00ednima ou incipiente (tres instilaci\u00f3ns, denominado modelo 3IN) ; (ii) un punto de intervalo de tempo dende a primeira exposici\u00f3n antix\u00e9nica equivalente a un modelo cl\u00e1sico de sensibilizaci\u00f3n intraperitoneal (10 instilaci\u00f3ns, denominado modelo 10 IN, que foi comparado co modelo de sensibilizaci\u00f3n intraperitoneal -IP-); e (iii) un modelo prolong ado para explorar se o grado de enfermidade reflectido no modelo 10IN reforzar\u00edase, extendese instilaci lavado bronco- alveolar, infiltraci\u00f3n inflamatoria eosin\u00f3fila de v\u00edas respiratorias detectada en secci\u00f3ns de tecido pulmonar e nasal, incremento da presenza de su stancias mucosas en v\u00edas a\u00e9reas superiores e inferiores, incremento da masa de m\u00fasculo liso en v\u00edas respiratorias intrapulmonares; e un aumento not\u00e1bel de c\u00e9lulas con expresi\u00f3n de mRNA de Foxp3 con aumento limitado de c\u00e9lulas con expresi\u00f3n de mRNA de Il10 e Tfgb. Nos modelos de exposici\u00f3n antix \u00e9nica primaria en v\u00eda respirat oria, a reactividade de v\u00edas respiratorias a metacolina resultou atenuada no modelo 10IN respecto do modelo IP, e disminu\u00edu do modelo 30IN. Os tres modelos de exposici\u00f3n antix\u00e9nimca primaria na v\u00eda a\u00e9rea presentan un aumento de c\u00e9lulas totais en lavado bronco-alveolar con predominancia de linfocitos. respecto do modelo IP, e cunha viraxe do recont o diferencial a predominio linfocitario. Sen embargo, o infiltrado inflamatorio na mucosa nasal foi comparable \u00f3 do modelo IP, excepto no modelo 3IN, no que non se apreciou un aumento respecto do grupo control. No que respecta \u00e1 producci\u00f3n de sustancias mucosas, os intranas\u00e1is amosaron un aumento progresivo da resposta mucoide no epitelio nasal, dende as 3 instilaci\u00f3ns ate as 30, sendo neste \u00faltimo modelo comparable \u00f3 obtido no modelo IP. Pola contra, a resposta mucoide no pulm\u00f3n, a\u00ednd a que aumentada respecto dos gruops control tras 3, 10 e 30 instilaci\u00f3ns, resultou atenuada respecto do modelo IP. No concernete \u00e1 deposici\u00f3n de matriz extracelular, tr as 3 instilaci\u00f3ns intranas \u00e1is non se apreciaron diferenzas significativas respecto do grupo control nin do modelo IP; sen embargo, s\u00ed se apreciou fibrose subepitelial tras 10 e 30 instilaci\u00f3ns intranas\u00e1is, o que suxire que a fibrose subepitelial \u00e9 un fen\u00f3meno progresivo coa duraci\u00f3n da enfermidade. A masa de m\u00fasculo liso resultou incrementada, APPENDIX 219 pero de forma atenuada, no modelo 30IN, de forma concomitante \u00e1 atenuaci\u00f3n observada na m\u00e1ximo atenuado e subseguinte declive nos modelos intranas\u00e1is, en comparaci\u00f3n co modelo de sensibilizaci\u00f3n intraperitoneal como comparador de capacidade de resposta m\u00e1xima, suxire que a exposici\u00f3n primaria antix\u00e9nica en v\u00eda respir atoria, tal e coma ocorre na adquisici\u00f3n natural de enfermidade humana, activan mecanismos inmunorreguladores. A evidencia deste brazo inmunorregulador, reflectido na atenuaci\u00f3n da inflamaci\u00f3n e da hiperreactividade de v\u00edas respiratorias, conduciunos a explorar un posible papel de c\u00e9lulas Treg. Debi do a dificultades t\u00e9cnicas para a detecci\u00f3n de prote\u00edna FOXP3 en tecido de rato fixado con d\u00faas citocinas directamente relacionadas coa funci\u00f3n das c\u00e9lulas Treg. Esta s an\u00e1lises, realizadas mediante hibridaci\u00f3n in situ sobre de tecido lev\u00e1ronnos nos infilitrados no modelo 30IN. A cantidade de c\u00e9lulas con expresi\u00f3n de Il10 e Tgfb foi comparable \u00f3 observado no modelo de sensibili zaci\u00f3n intraperitoneal. Sen embargo, a cantidade de c\u00e9lulas con expresi\u00f3n de Foxp3 no modelo IP foi desproporcin adamente inmunorreguladora. Estes datos amosaron que a expo sici\u00f3n primaria a ant\u00edxeno na v\u00eda a\u00e9rea en ausencia de sensibilizaci\u00f3n intraperitoneal ou ad xuvantes induce rinitis al\u00e9rxica qu e progresa durante o periodo de exposici\u00f3n \u00f3 ant\u00edxeno, e asma experimental atenuada que se modula como resultado da exposici\u00f3n continuada. Esta modulaci\u00f3n est\u00e1 asociada cun aumento dos n\u00fameros de c\u00e9lulas linfoides qeu expresan Foxp3 , Il10 o que suxire mecansimos de inmunorregulaci\u00f3n activa que os mode los basados en sensibilizaci\u00f3n intraperitoneal erran en reflectir. Os resultados traballo de investigaci\u00f3n doutoral amosaron que a exposici\u00f3n primaria e continua da a ant\u00edxeno nas v\u00edas respiratorias induce a activaci\u00f3n dun brazo inmunorregulador que resulta na atenuaci\u00f3n dos rasgos da asma al\u00e9rxica experimental, pero non da rinitis al\u00e9rxica, suxerindo adem\u00e1is un papel importante de c\u00e9lulas Treg IL10 e TGFB. Este conxunto de datos foi tam\u00e9n consistente coa hip\u00f3tese de que a interacci\u00f3n do al\u00e9rxeno coa mucosa da v\u00eda resp iratoria no momento da exposici\u00f3n antix\u00e9nica primaria \u00e9 crucial, mediante a probable participaci\u00f3n do sistema inmunitario innato, para defini-lo perfil de resposta subseguinte a cargo do sistema inmunitario adaptativo. As\u00ed pois, na seguinte parte do traballo propux\u00e9monos demostra-lo papel de c\u00e9lulas T efectoras CD4+ e c\u00e9lulas T reguladoras CD4+ na asma experimental. Summary 220 Para estuda-lo papel das c\u00e9lulas T CD4+ efectoras e reguladoras, realizamos experimentos de transferencia adoptiva nos modelos de exposici\u00f3n an tix\u00e9nica na v\u00eda a\u00e9rea. Coa finalidade de realizar seguimento in vivo das c\u00e9lulas transferidas, procedemos \u00e1 s\u00faa modificaci\u00f3n xen\u00e9ti ca para introducir a expresi\u00f3n permantente dunha variante de prote\u00edna verde fluorescente (GFP). A expansi\u00f3n clonal de c\u00e9lulas T activadas representa o ciclo celul ar m\u00e1is r\u00e1pido co\u00f1ecido entre as c\u00e9lulas de organismos pluricelular es. Dada a necesidade de conseguire s a modificaci\u00f3n xen\u00e9tica permantente das c\u00e9lulas diana e da s\u00faa proxenie, decant\u00e1monos po la transducci\u00f3n retroviral usando vectores de tipo retroviral que, trala s\u00faa retrotranscripci\u00f3n, int\u00e9granse de modo permanente no xenoma das c\u00e9lulas transducidas, e con elo o cDNA de interese subclonado no vector. Para elo, estes vectores aproveitan a ausencia de envoltura nuclear durante a mitose (metafase e anafase) para integrarse no xenoma celular e orixinar expresi\u00f3n constitutiva. Esta caracter\u00edstica, combinada coa estimulaci\u00f3n in vitro de c\u00e9lulas T efectoras ant\u00edxeno-espec\u00edficas obtidas de donantes sensibilizados a un determinado ant\u00edxeno, resulta nun m\u00e9todo efi caz para a transducci\u00f3n de c\u00e9lulas T efectoras ant\u00edxeno-espec\u00edficas, dado que o tipo de vector de transferencia x\u00e9nica usado soamente transduce c\u00e9lulas en ciclo celular activo, e \u00fanicamente as c\u00e9lulas T CD4 + ant\u00edxeno-espec\u00edficas entran en ciclo celular cando a poboaci\u00f3n de esplenocitos . dese\u00f1o e construcci\u00f3n vector de transferencia x\u00e9nica para inducir expresi\u00f3n permantente de GFP, \u00f3 que denominamos como pMSCV-GFP por Cell Virus procedemos xerar mediante fluxo c\u00e9lulas T CD4+GFP+ efectoras, coas que realizamos un modelo de asma experimental basado en transferencia adoptiva destas c\u00e9lulas a anim\u00e1is receptores sinx\u00e9 nicos non sensibilizados, no s anim\u00e1is receptores. Neste modelo, propux\u00e9monos titular o n\u00famero m\u00ednimo de c\u00e9lulas T CD4+ ant\u00edxeno espec\u00edficas efectoras necesario para inducir hiperreactividade e inflamaci\u00f3n de v\u00edas respiratorias, baixo a hip\u00f3tese de que cantidades moi pequenas destas c\u00e9lulas ser\u00eda sufi cientes. Os ratos receptores fo ron instilados d\u00faas veces con OVA antes da transferencia adoptiva e tres veces tras el a (5 instilaci\u00f3ns intranas\u00e1is), en forma dun modelo curto para previr un solapamento coa desposta inmunitaria adaptativa que o h\u00f3spede poder\u00eda desenvolver. Realizamos series de titulaci\u00f3n, que amosaron que a transferencia adoptiva de 105 c\u00e9lulas T efectoras CD4+ OVA-espec\u00edficas \u00e9 abondo para incremento de c\u00e9lulas totais no la vado bronco-alveolar e inflamaci\u00f3n da v\u00eda a\u00e9rea evidente na an\u00e1lise histopatol\u00f3xica do teci do pulmonar, onde se detectaron c\u00e9lulas GFP+. Estes datos indicaron que pequenos n\u00fameros de c\u00e9lulas efectoras T CD4+ ant\u00edxeno-espec\u00edficas te\u00f1en a 221 capacidade dirixir a inflamaci\u00f3n nunha resposta inmunitaria adaptativa al\u00e9rxica. No segundo modelo de transferencia adoptiva, propux\u00e9monos comproba-lo efecto da transferencia de c\u00e9lulas Treg nun modelo de asma experimental con enfermidade establecida, inducido neste caso por exposici\u00f3n primaria na v\u00ed a a\u00e9rea a extracto estandarizado de \u00e1caros de po (house dust mite , en adiante HDM). Para as finalidades deste CD4+ in vitro mediante transducci\u00f3n retroviral dun xeito similar \u00e1 obtenci\u00f3n de c\u00e9lulas T CD4+ descrita pero que as secuencias de Foxp3 e gfp separadas por unha secuencia interna de ribosomal \u00f3 que nomeamos pRetroFOXP3-IRES-GFP. Este vector induce a ex presi\u00f3n simult\u00e1nea de FOXP3 e GFP nas c\u00e9lulas tr ansducidas, de xeito que a detecci\u00f3n de GFP permite a identificaci\u00f3n de c\u00e9lulas FOXP3+. A expresi\u00f3n forzada de FOXP3 xerada deste modo en c\u00e9lulas T CD4+ activadas induce reguladora nestas c\u00e9lulas, \u00e9 instilados con HDM un totla de 28 veces \u00f3 largo de 40 d\u00edas de duraci\u00f3n do modelo. No grupo receptor de transferencia adoptiva, 75.000 c\u00e9lulas Treg foron inxectadas na vena da cola antes da finalizaci\u00f3n das instilaci\u00f3ns intranas\u00e1is (na instilaci\u00f3n 24, d\u00eda 31). Neste experimento piloto (n =4 por grupo), a transferencia adoptiva de tan s\u00f3 estas 75.000 c\u00e9lulas Treg xeradas in reduci\u00f3n nos en tecido pulmonar, sen modificar significativamente os recontos de tot\u00e1is lavado bronco-alveolar, e atenuaci\u00f3n da de v\u00edas respiratorias, prob\u00e1ndos e mediante detecci\u00f3n de GFP que as c\u00e9lulas transferidas estaban presentes nos infiltrados inflamatorios na s v\u00edas respiratorias intrapulmonares. \u00e1 enfermidad e humana. Os datos sobre c\u00e9lulas Treg na asma humana est\u00e1n nunha fase moi inicial e os resultados neste sentido son limitados e inconsistentes. A totalidade dos escasos traballos realizados sobre c\u00e9lulas Treg na asma humana centr\u00e1ronse na detecci\u00f3n destas c\u00e9lulas en sang ue perif\u00e9rica ou lavado bronco-alveolar, pero ata o de agora non existen estudos sobre pulmonar. Tendo inmunohistoqu\u00edmica de doentes con asma grave e comparalos con suxeitos control. Atopamos que as c\u00e9lulas reguladoras CD4+ est\u00e1n pr\u00e1cticamente ausentes en biopsias de suxeitos cont rol. Pola contra, as biopsias de doentes con asma grave amosaron una presenza significativa de c\u00e9lulas FOXP3+ infiltrando principalmente pacientes con asma grave suxire un papel da inmunorregulaci\u00f3n mediada pro c\u00e9lulas Treg, e \u00e9 adem\u00e1is consistente cos datos derivados de modelos anim\u00e1is. O noso conxunto de datos xerados a partires de asma experimental e investigaci\u00f3n cl\u00edn ica suxire que as c\u00e9lulas Treg est\u00e1n aumentadas na parede das v\u00edas respiratorias na asma, proba blemente de forma reactiva \u00e1 inflamaci\u00f3n cr\u00f3nica que subxace \u00e1 enfermidade. Se as c\u00e9lulas FOXP3+ observadas nas biopsias bronquiais humanas son funcionalmente competentes como c\u00e9lulas Treg ou non, \u00e9 desconocido neste punto e, polo tanto, son necesarios novos estudos que as car actericen de suxeitos asm\u00e1ticos. O erro en resolve-la inflamaci\u00f3n cr\u00f3nica das v\u00edas respirator ias na asma ten con toda probabilidade una causa complexa multifactorial, en non implica necesariamente unha diferenc ia na funci\u00f3n ou reclutamento de c\u00e9lulas Terg. tese doutora p\u00f3dese conclu\u00edr que: - A exposici\u00f3n primaria na v\u00eda a\u00e9rea e a provo caci\u00f3n continuada con ant\u00edxeno, a diferenza da sensibilizaci\u00f3n intraperitoneal seguida de provo caci\u00f3n intranasal, induce asma experimental atenuada con disminuci\u00f3n da hiperreactividade das v\u00edas respiratorias, hipersecreci\u00f3n de moco e lixeiro aumento da masa de m\u00fasculo liso. Pola contra, a fibrose subepitelial aumenta progresivamente e os infiltrados inflamatorios xiran cara un predominio linfocitario. - Trala exposici\u00f3n primaria ant\u00edxeno na v\u00eda a\u00e9rea, prod\u00facese unha hipertrofia e hiperplasia de c\u00e9lulas caliciformes, tanto en v\u00eda a\u00e9rea superior coma v\u00edas a\u00e9reas respiratorias inferiores, nun estpacio de tempo insuficiente para o Esta resposta mucosa temper\u00e1 poder\u00eda se-lo resultado da acci\u00f3n de mecanismos do sistema inmune innato. - Na mucosa nasal, tanto a exposici\u00f3n primaria a ant\u00edxeno na v\u00eda a\u00e9rea coma a sensibilizaci\u00f3n intraperitoneal previa, inducen rinitis al\u00e9rxica c on infiltraci\u00f3n eosinof\u00edlica, hiperplasia de c\u00e9lulas caliciformes e aumento da produci\u00f3n de moco. \u00d3 contrario das manifestaci\u00f3ns da asma experimental, a exposici\u00f3n primaria a ant\u00edxeno na v\u00eda a\u00e9rea seguido de provocaci\u00f3n continuada provoca un aumento progresivo da intensidade da rinitis al\u00e9rxica co tempo. - Trala exposici\u00f3n primara a ant\u00edxenon na v\u00ed a a\u00e9rea seguida de provocaci\u00f3n intranasal continuada, a atenuaci\u00f3n da maior parte das caracter \u00edsticas da asma experimental, a progresi\u00f3n da fibrose subepitelial e a viraxe cara infiltrados predominantemente linfocitarios est\u00e1n asociados cunha progresiva presenza no infiltrado inflam atorio de c\u00e9lulas que expresan Foxp3 , e Tgfb. A sensibilizaci\u00f3n intraperitoneal ten coma c onsecuencia un aumento a n\u00f3malo de c\u00e9lulas que APPENDIX 223 expresan mRNA de Foxp3 no infiltrado inflamatorio, pero que non se correlaciona cun aumento concordante na transcripci\u00f3n de reclutamento c\u00e9lulas inflamatorias hiperreactividade de v\u00edas respiratorias tral a provocaci\u00f3n antix\u00e9nica. Estas c\u00e9lulas, nesta cantidade, son capaces de migrar \u00e1s efectos mencionados. CD4+ con expresi\u00f3n forzada de FOXP3 act\u00faan como c\u00e9lulas Treg in vivo e modulan a hiperreactividade e inflamaci \u00f3n de v\u00edas respiratorias en modelos anim\u00e1is con asma experimental establecida. Estas c\u00e9lulas, en escaso n\u00famero, son capaces de migrar \u00e1s v\u00edas respiratorias e provoca-los efectos mencionados. - Existe un aumento significativo na presenza de linfocitos FOXP3+ en biopsias bronquiais de pacientes con asma grave en comparaci\u00f3n con suxeitos control. Este aumento pode reflectir un incremento de c\u00e9lulas Treg reacivo \u00e1 inflamaci\u00f3n cr\u00f3nica. "}